Volcano (VOLC) 10-K 28 Feb 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Feb. 14, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'Volcano Corp	'	'
Entity Central Index Key	'0001354217	'	'
Trading Symbol	'volc	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	51,926,493	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Public Float	'	'	$981.50

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$107,159	$330,635
Short-term available-for-sale investments	231,864	140,960
Accounts receivable, net	81,962	76,348
Inventories	60,970	52,811
Prepaid expenses and other current assets	27,299	21,773
Total current assets	509,254	622,527
Long-term available-for-sale investments	34,887	44,385
Property and equipment, net of accumulated depreciation of $96,651 and $80,652, respectively	118,094	104,385
Intangible assets, net	58,108	50,657
Goodwill	55,087	51,577
Other non-current assets	56,489	28,813
Total assets	831,919	902,344
Liabilities and Stockholders’ Equity	'	'
Accounts payable	19,137	16,284
Accrued compensation	26,918	23,227
Accrued expenses and other current liabilities	28,453	23,529
Deferred revenues	10,652	9,789
Contingent consideration	3,750	2,908
Total current liabilities	88,910	75,737
Convertible senior notes	401,012	382,300
Other long-term debt	1,268	1,119
Deferred revenues	5,079	4,661
Contingent consideration, non-current portion	29,888	27,323
Other non-current liabilities	5,960	2,859
Total liabilities	532,117	493,999
Commitments and Contingencies	'	'
Stockholders’ equity:	'	'
Preferred stock, par value of $0.001; 10,000 shares authorized; no shares issued and outstanding at December 31, 2013 and December 31, 2012	0	0
Common stock, par value of $0.001; 250,000 shares authorized at December 31, 2013 and December 31, 2012; 51,530 and 53,944 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	52	54
Additional paid-in capital	420,234	494,276
Accumulated other comprehensive loss	-4,088	-4,083
Accumulated deficit	-116,396	-81,902
Total stockholders’ equity	299,802	408,345
Total liabilities and stockholders’ equity	$831,919	$902,344

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Property and equipment, accumulated depreciation	$96,651	$80,652
Preferred stock, par value (dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	51,530,000	53,944,000
Common stock, shares outstanding	51,530,000	53,944,000

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'		'	'
Revenues	$393,678	[1]	$381,866	$343,546
Cost of revenues, excluding amortization of intangibles	143,302		128,915	114,533
Gross profit	250,376	[1]	252,951	229,013
Operating expenses:	'		'	'
Selling, general and administrative	182,950		172,794	147,057
Research and development	69,159		55,469	53,098
Amortization of intangibles	3,832		3,240	3,447
Acquisition-related items	4,964		1,858	0
Restructuring charges	19,374		0	0
Total operating expenses	280,279		233,361	203,602
Operating (loss) income	-29,903	[1]	19,590	25,411
Interest income	1,287		902	908
Interest expense	-26,908		-7,975	-7,107
Exchange rate loss	-1,156		-576	-997
Loss from debt extinguishment	0		-4,969	0
Other, net	5,856		2,717	-112
(Loss) income before income tax	-50,824		9,689	18,103
Income tax (benefit) expense	-16,330		1,667	-19,990
Net (loss) income	($34,494)	[1]	$8,022	$38,093
Net (loss) income per share:	'		'	'
Basic (dollars per share)	($0.63)	[1]	$0.15	$0.73
Diluted (dollars per share)	($0.63)	[1]	$0.15	$0.70
Shares used in calculating net (loss) income per share:	'		'	'
Basic (shares)	54,341		53,475	52,300
Diluted (shares)	54,341		55,195	54,596
[1]	)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'		'	'
Net (loss) income	($34,494)	[1]	$8,022	$38,093
Other comprehensive income (loss)	'		'	'
Foreign currency translation adjustments	-522		-2,732	-819
Changes in unrealized gain on available-for-sale investments, net of tax	16		31	30
Changes in unrealized gains on foreign currency forward exchange contracts, net of tax	501		0	0
Other comprehensive loss	-5		-2,701	-789
Comprehensive (loss) income	($34,499)		$5,321	$37,304
[1]	)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (USD $)	Total		Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands
Beginning Balance, value at Dec. 31, 2010	$274,336		$51	$402,895	($593)	($128,017)
Beginning Balance, shares at Dec. 31, 2010	'		51,366	'	'	'
Issuance of common stock under equity compensation plans	13,026		2	13,024	'	'
Issuance of common stock under equity compensation plans, shares	'		1,285	'	'	'
Employee stock-based compensation cost	12,855		'	12,855	'	'
Non-employee stock-based compensation cost	115		'	115	'	'
Reversal of valuation allowance related to Convertible Senior Notes and tax benefit related to stock-based compensation	1,601		'	1,601	'	'
Net (loss) income	38,093		'	'	'	38,093
Other comprehensive income (loss)	-789		'	'	-789	'
Ending Balance, value at Dec. 31, 2011	339,237		53	430,490	-1,382	-89,924
Ending Balance, shares at Dec. 31, 2011	'		52,651	'	'	'
Issuance of common stock under equity compensation plans	13,813		1	13,812	'	'
Issuance of common stock under equity compensation plans, shares	'		1,293	'	'	'
Employee stock-based compensation cost	15,135		'	15,135	'	'
Equity component of convertible senior notes due 2017	89,415		'	89,415	'	'
Portion of convertible bond issuance costs attributed to equity component	-2,840		'	-2,840	'	'
Net deferred tax recognized in connection with issuance of convertible senior notes due 2017 and retirement of convertible senior notes due 2015	2,599		'	2,599	'	'
Call options purchased in connection with convertible senior notes due 2017	-89,798		'	-89,798	'	'
Issuance of warrants in connection with convertible senior notes due 2017	53,686		'	53,686	'	'
Portion of retirement of convertible senior notes due 2015 attributed to equity	-21,811		'	-21,811	'	'
Retirement of call options in connection with retirement of a portion of senior convertible notes due 2015	15,156		'	15,156	'	'
Retirement of warrants in connection with the retirement of a portion of senior convertible notes due 2015	-11,603		'	-11,603	'	'
Reversal of valuation allowance related to Convertible Senior Notes and tax benefit related to stock-based compensation	35		'	35	'	'
Net (loss) income	8,022		'	'	'	8,022
Other comprehensive income (loss)	-2,701		'	'	-2,701	'
Ending Balance, value at Dec. 31, 2012	408,345		54	494,276	-4,083	-81,902
Ending Balance, shares at Dec. 31, 2012	'		53,944	'	'	'
Issuance of common stock under equity compensation plans	9,959		1	9,958	'	'
Issuance of common stock under equity compensation plans, shares	'		1,143	'	'	'
Employee stock-based compensation cost	16,045		'	16,045	'	'
Common stock repurchase/retirement	-100,048		-3	-100,045	'	'
Common stock repurchase/retirement, shares	'		-3,557	'	'	'
Net (loss) income	-34,494	[1]	'	'	'	-34,494
Other comprehensive income (loss)	-5		'	'	-5	'
Ending Balance, value at Dec. 31, 2013	$299,802		$52	$420,234	($4,088)	($116,396)
Ending Balance, shares at Dec. 31, 2013	'		51,530	'	'	'
[1]	)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Operating activities	'		'	'
Net (loss) income	($34,494)	[1]	$8,022	$38,093
Adjustments to reconcile net income to net cash provided by operating activities:	'		'	'
Depreciation and amortization	26,363		23,503	23,214
Amortization (accretion) of investment premium (discount), net	3,294		3,256	3,805
Accretion of debt discount on convertible senior notes and other long-term debt	19,026		5,743	4,668
Loss on debt extinguishment	0		4,969	0
Accretion of contingent consideration	3,607		231	0
Non-cash stock compensation expense	16,084		15,079	12,991
Asset impairment related to restructuring	11,402		0	0
Gain on sale of other long-term investment	-5,832		0	0
Effect of exchange rate changes and others	-13,360		593	2,350
Deferred income taxes	-18,558		-1,009	-22,771
Changes in operating assets and liabilities, net of acquisitions:	'		'	'
Accounts receivable	-10,398		-9,971	-9,337
Inventories	-14,385		-13,270	831
Prepaid expenses and other assets	-3,865		-658	-540
Accounts payable	-40		157	-2,362
Accrued compensation	2,691		3,386	1,976
Accrued expenses and other liabilities	3,988		6,756	-6,541
Deferred revenues	1,271		4,217	1,919
Net cash provided by operating activities	13,514		49,818	43,596
Investing activities	'		'	'
Purchase of short-term and long-term available-for-sale securities	-374,954		-298,260	-310,573
Sale or maturity of short-term and long-term available-for-sale securities	290,304		252,937	365,639
Capital expenditures	-31,926		-43,842	-43,248
Cash paid for acquisitions, net of cash acquired	-14,975		-54,462	0
Cash paid for intangible assets	-3,537		-4,823	-1,222
Cash paid for other long-term investments	-17,936		-1,001	-2,260
Proceeds from sale of other long-term investments	7,333		1,500	0
Proceeds from foreign currency exchange contracts	0		1,260	2,355
Payment for foreign currency exchange contracts	0		-525	-3,962
Net cash (used in) provided by investing activities	-145,691		-147,216	6,729
Financing activities	'		'	'
Common stock repurchase	-100,048		0	0
Proceeds from issuance of convertible senior notes	0		460,000	0
Payment of debt issuance costs in connection with the convertible senior notes	0		-14,611	0
Purchase of call options in connection with the convertible senior notes	0		-89,798	0
Proceeds from warrants issuance in connection with the convertible senior notes	0		53,686	0
Repurchase of a portion of 2.875% convertible senior notes due 2015	0		-104,832	0
Retirement of call options in connection with the retirement of a portion of 2.875% convertible senior notes due 2015	0		15,156	0
Retirement of warrants in connection with the retirement of a portion of 2.875% convertible senior notes due 2015	0		-11,603	0
Proceeds from sale of common stock under employee stock purchase plan	3,576		3,880	3,554
Proceeds from exercise of common stock options	6,383		9,933	9,472
Tax benefit related to stock-based compensation	0		35	165
Repayment of capital lease liability	-37		-90	-51
Net cash (used in) provided by financing activities	-90,126		321,756	13,140
Effect of exchange rate changes on cash and cash equivalents	-1,173		-739	122
Net (decrease) increase in cash and cash equivalents	-223,476		223,619	63,587
Cash and cash equivalents, beginning of year	330,635		107,016	43,429
Cash and cash equivalents, end of year	107,159		330,635	107,016
Supplemental disclosures of cash flow information:	'		'	'
Cash paid for interest	8,567		3,334	3,395
Cash paid for income taxes	$3,309		$2,399	$2,387
[1]	)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

Organization_And_Summary_Of_Si

Organization And Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	Organization and Summary of Significant Accounting Policies
	Our Company
	We design, develop, manufacture and commercialize a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. We believe that these products enhance the diagnosis and treatment of coronary and peripheral vascular disease by improving the efficiency and efficacy of existing diagnostic angiograms and percutaneous coronary interventional, or PCI, and endovascular procedures in the coronary arteries or peripheral arteries and veins. We are facilitating the adoption of functional PCI, in which our FFR technology is used to help determine whether or not a stent is necessary, and IVUS is used as an adjunct to angiography to guide stent placement and optimization. We market our products to physicians, nurses and technicians who perform a variety of endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals.
	Our products consist of consoles that are marketed as stand-alone units or as units that can be integrated into a variety of hospital-based interventional surgical suites called catheterization laboratories, or cath labs. We have developed customized cath lab versions of these consoles and are developing additional functionality options as part of our cath lab integration initiative. Our consoles have been designed to serve as a multi-modality platform for our phased array and rotational IVUS catheters, FFR pressure and flow wires and image-guided therapy catheters, such as the Pioneer Plus reentry device acquired from Medtronic, Inc., or Medtronic, on August 30, 2013.
	Our IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters, and additional functionality options such as ChromaFlo® stent apposition analysis. Our FFR offerings can be accessed through our multi-modality platforms, and we also provide FFR-only consoles. Our FFR disposables are single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque's physiological impact on blood flow and pressure. We have developed additional offerings for integration into the platform, including adenosine-free Instant Wave-Free Ratio FFR, or iFR®. We are currently developing high resolution Focal Acoustic Computed Tomography, or FACT, catheters, co-registration with IVUS and an IVUS-guided Crux VCF system featuring our inferior vena cava, or IVC, filter. Our Valet microcatheter, Visions® PV .035 catheter and Eagle Eye® Platinum ST short tip catheter, or EEP, products received 510(k) clearance and CE Mark approval in 2012 and their commercial launch occurred in 2013. In addition, we initiated the commercial launch of our Verrata pressure guide wire, our fifth new pressure wire in five years, during 2013.
	Through Axsun Technologies, Inc., or Axsun, one of our wholly-owned subsidiaries, we also develop and manufacture optical monitors for the telecommunications industry, laser and non-laser light sources, optical engines used in medical optical coherence topography, or OCT, imaging systems and advanced photonic components and sub-systems used in spectroscopy and other industrial applications. We believe Axsun's proprietary OCT technology will provide us competitive advantages in the invasive imaging sector, as well as for applications in ophthalmology and dental.
	Basis of Presentation and Principles of Consolidation
	Our consolidated financial statements include the accounts of Volcano Corporation and its wholly–owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain amounts have been reclassified to conform to the current year presentation.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, the allowance for doubtful accounts, inventory reserves, depreciation and amortization, intangible assets, sales returns, deferred revenues, business combinations, warranty costs, certain accruals, long-lived asset impairment calculations, deferred tax assets and liabilities, contingent consideration and other contingencies. Actual results could differ materially from the estimates and assumptions we use in the preparation of our consolidated financial statements.
	Foreign Currency Translation
	The Company's reporting currency is the U.S. dollar. The yen and the euro are the functional currencies of our subsidiaries, Volcano Japan and Volcano Europe, respectively, as they are the primary currencies within the economic environments in which Volcano Japan and Volcano Europe operate. Assets and liabilities of their operations are translated into U.S. dollars at period-end exchange rates, and revenues and expenses are translated into U.S. dollars at average exchange rates in effect during each reporting period. Adjustments resulting from the translation are reported in other comprehensive income or loss.
	Exchange rate fluctuations resulting from the remeasurement of the inter-company balances between Volcano Corporation, our U.S. entity, and Volcano Japan, and Volcano Corporation and Volcano Europe, and other non-U.S. dollar denominated balances into U.S. dollars are recorded as foreign currency transaction gains or losses and are included in exchange rate gain (loss) in the consolidated statements of operations.
	The functional currency of our other foreign subsidiaries is the U.S. dollar since they operate as an extension of the Company’s U.S. operations.
	Cash and Cash Equivalents
	Cash primarily consisted of cash in bank deposits. Cash equivalents consist of money market funds and other highly liquid investments with an original maturity of three months or less on the date of acquisition.
	Available-for-Sale Investments
	Our short-term available-for-sale investments consist of highly liquid financial investments with maturities of one year or less that were not previously classified as cash equivalents. Our long-term available-for-sale investments consist of investments with maturities over one year. All investments are classified as available-for-sale and are recorded at market value using the specific identification method. Unrealized gains or losses are reflected in other comprehensive income or loss.
	Financial Instruments
	Financial instruments included in our financial statements are comprised of cash and cash equivalents, short-term and long-term available-for-sale investments, accounts receivable, derivative financial instruments, accounts payable, certain accrued liabilities, convertible senior notes, contingent consideration and other contingent liabilities. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term nature of those instruments. Our available-for-sale investments are carried at quoted fair market value with unrealized gains and losses reported in stockholders' equity as a component of accumulated other comprehensive income (loss). The fair value of our convertible senior notes is influenced by interest rates, our stock price, and stock price volatility, which is determined by market trading.
	We record derivative financial instruments as either assets or liabilities in our consolidated balance sheets and measure them at fair value in accordance with ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes.
	Certain of the derivative instruments we use to mitigate our exchange rate exposure are not designated for hedge accounting treatment, and as a result, changes in their fair values are recorded in exchange rate gain (loss) in the consolidated statement of operations. Changes in the fair value of cash flow hedges, excluding time value of the hedges which is recorded as interest expense, are reported as a component of accumulated other comprehensive income (loss), or AOCI, within stockholders' equity. Once the underlying hedged transaction occurs, we de-designate the derivative, cease to apply hedge accounting treatment to the transaction, reclassify the gain or loss recorded to date from AOCI into cost of goods sold, and record any further gains or losses to exchange rate gain (loss). We evaluate hedge effectiveness at the inception of the hedge and on an ongoing basis. To the extent we experience ineffectiveness in our hedges, the gains or losses accumulated in other comprehensive income associated with the ineffective portion of the hedge are reclassified immediately into exchange rate gain (loss). We adjust the level and use of derivatives as soon as practicable after learning that an exposure has changed. We review all exposures on derivative positions on a regular basis. See "Note 3 – Financial Statement Details - Derivative Financial Instruments" for additional information.
	We recognize contingent purchase price consideration at fair value at acquisition date. The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period. Therefore, any changes in the fair value will impact our earnings in such reporting period, thereby resulting in potential variability in our earnings until such contingencies are resolved.
	Concentration of Credit Risk
	Financial instruments which subject us to potential credit risk consist of our cash and cash equivalents, short-term and long-term available-for-sale investments, derivative financial instruments, and trade accounts receivable.
	We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and holding investments with maturities that maintain safety and liquidity. We place our cash and cash equivalents with high credit quality financial institutions. Deposits with these financial institutions may exceed the amount of insurance provided; however, these deposits typically are redeemable upon demand. Therefore we believe the financial risks associated with these financial instruments are minimal.
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms. We perform ongoing credit evaluations of our customers, and generally we do not require collateral on our accounts receivable. We estimate the need for allowances for potential credit losses based on historical collection activity and the facts and circumstances relevant to specific customers and we record a provision for uncollectible accounts when collection is uncertain. To date, we have not experienced significant credit related losses.
	No single customer accounted for more than 10% of our revenues for 2013, 2012 and 2011. No single customer accounted for more than 10% of our trade receivables at December 31, 2013, 2012 and 2011.
	We are exposed to credit losses in the event of nonperformance by the banks with which we transact foreign currency contracts. We currently hold foreign exchange forward contracts with two counterparties. Our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We manage this credit risk by executing foreign currency contracts with counterparties that meet our minimum requirements, and monitoring the credit ratings of our counterparties on a periodic basis. As of December 31, 2013, we had a total credit exposure of $1.6 million from nonperformance of foreign exchange hedging counterparties.
	In connection with the issuance of our 2.875% Convertible Senior Notes due 2015, or the 2015 Notes, and our 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, we purchased call options from counterparties. Non-performance by the counterparties under these call options would potentially expose us to dilution of our common stock to the extent our stock price exceeds the conversion price (in the case of the 2015 Notes and the 2017 Notes). See Note 3 “Financial Statement Details—Debt” for additional information.
	We purchase integrated circuits and other key components for use in our products. For certain components, which are currently single sourced, there are relatively few sources of supply. Although we believe that other suppliers could provide similar components on comparable terms, establishment of additional or replacement suppliers cannot be accomplished quickly. Any significant supply interruption could have a material adverse effect on our business, financial condition and results of operations. For further discussion, see “Risk Factors—Our manufacturing operations are dependent upon third party suppliers, some of which are sole-sourced, which makes us vulnerable to supply problems, price fluctuations and manufacturing delays.”
	Inventories
	Inventories are valued at the lower of first-in, first-out cost or market value. Inventory provisions are recorded for materials that have become obsolete or are no longer used in current production and for inventory that has a market value less than the carrying value in inventory. We regularly monitor potential inventory excess, obsolescence and lower market values compared to standard costs and, when necessary, reduce the carrying amount of our inventory to its market value. Specific reserves are maintained to reduce the carrying value of inventory items on hand that we know may not be used in finished goods. If our estimates for potential inventory losses prove to be too low, then our future earnings will be affected when the related additional inventory losses are recorded.
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Equipment and capitalized software are depreciated over the estimated useful lives of the assets, which range generally from three to ten years. Leasehold improvements are amortized over the lesser of the lease term including renewal periods that are reasonably assured or the estimated useful lives of the improvements, which are between three and ten years. The straight-line method is used for depreciation and amortization. Land is stated at cost and is not depreciated. Significant improvements which substantially extend the useful lives of assets are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred.
	Assets held under capital leases are recorded at the net present value of the minimum lease payments of the leased asset at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the assets or the period of the related lease and is included in our depreciation expense.
	Our long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. We recorded $2.0 million in long-lived assets impairment charges as part of the restructuring charges during 2013. See Note 3 “Financial Statement Details—Restructuring Activity” for additional information. No significant impairment of long-lived assets was identified or recorded during the years ended December 31, 2012 and 2011.
	Goodwill
	We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired in a business combination to goodwill. The impairment evaluation for goodwill is conducted annually as of October 1, or more frequently if events or changes in circumstances indicate the carrying value of the goodwill may not be recoverable. We test for goodwill impairment at the reporting unit level, which is the same as our operating segment level. Our goodwill at December 31, 2013 and 2012 is allocated entirely to our medical segment.
	We first assess qualitative factors to determine whether it is necessary to perform the two-step impairment test. If we believe, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of our reporting unit is less than its carrying amount, the quantitative two-step impairment test is required; otherwise, no further testing is required. In the first step, we compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of our reporting unit's goodwill. If the carrying value of our reporting unit's goodwill exceeds its implied fair value, then we record an impairment loss equal to the difference. There was no impairment of goodwill during the years ended December 31, 2013, 2012 and 2011.
	Intangible Assets
	Intangible assets are recorded at historical cost and amortized over their estimated useful lives. Intangible assets consist of acquired developed technology, licenses, customer relationships, patents and trademarks and covenants-not-to-compete as well as acquired in-process research and development technology. Intangible assets with a definite life are amortized using the straight-line method over their estimated useful lives of up to 20 years.
	When we acquire another entity, the purchase price is allocated, as applicable, between acquired in-process research and development, or IPR&D, other identifiable intangible assets, and net tangible assets, with the remainder recognized as goodwill. IPR&D has an indefinite life and is not amortized until completion and development of the project, at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner or the project is terminated or abandoned, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. Determining the allocation of the purchase price, including the portion of the purchase price allocated to IPR&D requires us to make significant estimates. The amount of the purchase price allocated to IPR&D is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. These methodologies include consideration of the risk of the project not achieving commercial feasibility.
	Intangible assets with definite lives are tested for impairment annually or whenever events or circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. We recorded $6.3 million in intangible asset impairment charges, including $4.1 million of IPR&D impairment, as part of our restructuring charges during 2013. See Note 3 “Financial Statement Details—Restructuring Activity” for additional information. No impairment of intangible assets was identified or recorded during the years ended December 31, 2012 and 2011.
	Other Non-Current Assets
	At December 31, 2013 and 2012, other non-current assets include $18.4 million and $2.0 million, respectively, of investments we have made in various privately held entities engaged in emerging product development activities.
	We account for our investments in privately held entities, for which fair value is not readily determinable, in accordance with ASC Topic 323, Investments – Equity Method and Joint Ventures. For all of our investments in privately held entities, we do not have the ability to exercise significant influence over the investee, thus we accounted for these investments under the cost method of accounting.
	Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. If the fair value of the investment is less than its carrying value, the investment is impaired and we make a determination as to whether the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless we have the ability and intent to hold an investment for a period sufficient for a market recovery up to the carrying value of the investment. Further, evidence must indicate that the carrying value of the investment is recoverable within a reasonable period. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. There was no impairment of investment in privately held entities during the years ended December 31, 2013, 2012 and 2011.
	At December 31, 2013 and 2012, other non-current assets include $749,000 and $711,000, respectively, of restricted cash, which was restricted as collateral for our performance obligations to customers in foreign jurisdictions. The certificates of deposit and cash in the bank will remain restricted until such time as the current obligation is terminated.
	Revenue Recognition
	We recognize revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of our products is generally recognized when title and risk of loss transfer to the customer. We recognize revenue from consignment arrangements based on product usage, which indicates that the sale is complete. Installation and training are generally not required elements of our sales transactions as most of our products do not require these services. In instances where installation and training are required elements of the sales transaction, revenue is recognized upon completion.
	For an arrangement containing multiple deliverables that are considered separate units of accounting, we allocate arrangement consideration based on the relative selling prices of the separate units of accounting. Selling prices are determined using fair value, when available, or our estimate of selling price when fair value is not available.
	We evaluate lease agreements entered into with customers to determine whether they are sales-type leases or operating leases. Agreements classified as operating leases result in rental revenue reported on a straight-line basis as income over the lease term as it becomes receivable according to the provisions of the lease. For leases qualifying as sales-type leases, we recognize the present value of the lease payments as revenue at the time the lease is recorded and the associated unearned interest is amortized over the term of the lease. Our sales-type lease and operating lease revenue and receivables relating to sales-type leases are not significant for the years ended 2013, 2012 and 2011.
	All costs associated with the provision of service are recognized in cost of revenues as incurred. Amounts billed in excess of revenue recognized are included as deferred revenue in the consolidated balance sheets.
	We sell our products through direct sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in international markets. Sales to distributors are recorded when title and risk of loss transfer upon shipment (generally FOB shipping point). No direct sales customers or distributors have price protection. Estimated returns, which are historically nominal, are recorded as an allowance for sales return and as a reduction in revenues.
	Shipping and Handling Costs
	Shipping and handling costs billed to customers are included in revenues. Shipping and handling costs we incur associated with shipping products to our customers are included in cost of revenues.
	Product Warranty Costs
	We typically offer a one-year warranty for parts and labor on our products commencing upon the transfer of title and risk of loss to the customer. We accrue the estimated cost of product warranties when we invoice our customers, based on historical results. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Our product warranty costs are not significant for the years ended 2013, 2012 and 2011.
	Research and Development
	Company-sponsored research and development expenses include the costs of technical activities that are useful in developing new products, services, processes or techniques, as well as expenses for technical activities that may significantly improve existing products or processes, and are expensed as incurred.
	Clinical Studies
	We recognize research and development costs for activities associated with clinical studies performed by third parties as incurred. All other costs relative to setting up clinical study sites are recognized as research and development expense as incurred. Clinical study site costs related to patient enrollment are accrued as patients are entered into the studies. Equipment that has alternative future use and is used at clinical study sites for participation in the studies is capitalized and expensed over the estimated life of the equipment.
Acquisition-related Items
Acquisition-related items include acquisition transaction costs, subsequent accretion of and revision, if any, to the fair value of the contingent consideration related to acquisitions and other expenses directly associated with acquisitions.
Restructuring Charges
Restructuring charges include employee termination benefits, contract termination costs, asset impairments and other related charges associated with restructuring activities.
Stock-Based Compensation
We account for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, or ASC 718, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option pricing model, or Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. We estimate forfeitures at the time of grant and revise our estimate in subsequent periods if actual forfeitures differ from those estimates. See Note 5 “Stockholders’ Equity” for a complete discussion of our equity compensation programs and the fair value assumptions used to determine our stock-based compensation expense.
We account for stock-based compensation awards and warrants granted to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees, or ASC 505-50. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.
Income Taxes
We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent a deferred tax asset cannot be recognized under the preceding criteria, allowances are established.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.
In 2013, the Company incurred a net loss, and is not projecting a return to profitability in 2014. As of December 31, 2013, management has evaluated the recoverability of its Federal deferred tax assets, including factors such as a consideration of forecasted operating results, in-process changes in its manufacturing processes, potential tax planning strategies, as well as the period of time that will transpire before the underlying deferred tax assets will expire. Based on this evaluation, management has concluded that it is more likely than not that the underlying deferred tax assets will be utilized prior to their expiration, and therefore continues to believe that the Federal deferred tax assets will be recovered.
During the fourth quarter of 2013, we concluded that it was more likely than not that we would not be able to realize a $3.8 million benefit related to our state and select foreign deferred tax assets. Further, in 2013, we completed our purchase accounting analysis and concluded that it was more likely than not that $1.4 million of foreign deferred tax assets related to the Sync-Rx, Ltd. acquisition and $1.1 million of state deferred tax assets related to the Crux Biomedical, Inc. acquisition are not realizable. This resulted in an increase in valuation allowance against these deferred tax assets, which was recorded as a reduction to goodwill.
During the fourth quarter of 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. We released $4.9 million of the valuation allowance on our foreign deferred tax assets as we expect our foreign operations in the respective jurisdictions will generate sufficient taxable income in future periods to realize the tax benefit associated with the related deferred tax assets. We believe that it was more likely than not that the benefit from certain international net operating losses and a portion of our state deferred tax assets will not be realized. In recognition of this risk, we will continue to provide a valuation allowance on the deferred tax assets relating to these items.
We will continue to assess the need for a valuation allowance on the deferred tax assets by evaluating both positive and negative evidence that may exist. To the extent we establish or change the valuation allowance in a period, the tax effect will generally flow through the statement of operations. In the case of an acquired or merged entity, we will record valuation allowance on a deferred tax asset through purchase accounting procedures as an adjustment to goodwill at the acquisition date, if it is more likely than not that all or a portion of the acquired deferred tax assets will not be realized in the future. Any subsequent change to a valuation allowance established during purchase accounting within the measurement period of the acquisition (not to exceed twelve months) will also be recorded as an adjustment to goodwill, provided that such change relates to new information about the facts and circumstances that existed on the acquisition date.
FASB ASC Topic 740, Income Taxes, or ASC 740, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
We accrue interest and penalties on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in our consolidated statements of operations. The amounts recognized for interest and penalties during the years ended December 31, 2013, 2012 and 2011 were $53,000, $46,000, and $34,000, respectively.
Net Income (Loss) Per Share
Basic and diluted net income (loss) per share is presented in accordance with FASB ASC Topic 260, Earnings per Share. Basic net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period.
On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received 3,557,137 shares of our common stock (See Note 5 “Stockholders' Equity”). The annual weighted average number of the initial delivered shares was removed from the denominator of the basic and diluted net income (loss) per share calculation at the share delivery date.
Our potentially dilutive shares include outstanding common stock options, restricted stock units, including those with performance conditions, incremental shares issuable upon the conversion of the Notes or exercise of the warrants relating to the Notes (See Note 3 “Financial Statement Details — Debt”) and the incremental shares receivable under the forward contract portion of the ASR. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income (loss) per share as discussed in the following paragraph. For the years ended December 31, 2013, 2012 and 2011, potentially dilutive shares totaling 20.8 million, 9.0 million, and 1.7 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive.
Diluted net income (loss) per common share includes zero, zero and 12,000 incremental shares related to the Notes for the years ended December 31, 2013, 2012 and 2011, respectively. Because the principal amount of the Notes will be settled in cash upon conversion, only the conversion spread relating to the Notes may be included in our calculation of diluted net income (loss) per common share. As such, the Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2015 Notes and $32.83 for the 2017 Notes, subject to adjustments) of the Notes. During the year ended December 31, 2011, 12,000 shares related to the 2015 Notes were included in the computation of the diluted net income (loss) per common share because the average market price of our common stock during the three months ended September 30, 2011 exceeded the conversion price of the 2015 Notes. The average price of our common stock did not exceed the conversion price of the Notes during any quarter of the years ended December 31, 2013 and 2012 or the other three quarters of 2011.
The diluted net income (loss) per common share does not include any incremental shares related to the exercise of the warrants for the years ended December 31, 2013, 2012 and 2011. The warrants will not have an impact on diluted net income (loss) per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes (see Note 3 “Financial Statement Details — Debt”), are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
The basic and diluted net income (loss) per common share calculations for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands, except per share data):
	Years Ended December 31,
	2013			2012		2011
Net (loss) income	$	(34,494	)	$	8,022	$	38,093
Weighted average common shares outstanding for basic	54,341			53,475		52,300
Dilutive potential common stock outstanding:
Stock options	—			1,404		1,896
Restricted stock units	—			309		377
Employee stock purchase plan	—			7		11
Convertible senior notes	—			—		12
Weighted average common shares outstanding for diluted	54,341			55,195		54,596
Net (loss) income per share:
Basic	$	(0.63	)	$	0.15	$	0.73
Diluted	$	(0.63	)	$	0.15	$	0.7
Comprehensive Income (Loss)
Comprehensive income (loss) represents the net income (loss) for the period plus the results of certain changes to stockholders’ equity that are not reflected in the consolidated statements of operations. Our comprehensive income (loss) consists of net income (loss), foreign currency translation adjustments, and changes in unrealized net gains and losses on available-for-sale investments and foreign currency forward exchange contracts, net of income taxes. Foreign currency translation adjustments were not adjusted for income taxes as they relate to cumulative losses in foreign subsidiaries which provide no corresponding tax benefit or investments in foreign subsidiaries with earnings which the foreign subsidiaries does not plan on remitting to the parent company.
Recent Accounting Pronouncements
In December 2011, the FASB amended the accounting standards to increase the prominence of other comprehensive income (“OCI”) by eliminating the option to present components of OCI as part of the statement of changes in shareholders’ equity and requiring the components of OCI to be presented either in a single continuous statement of comprehensive income or in two consecutive statements. We adopted the amended accounting standards in 2013 by electing to present consolidated statements of comprehensive income separate from the consolidated statements of income.
In February 2013, the FASB further amended the above accounting standards to improve the presentation of amounts reclassified out of accumulated other comprehensive income in its entirety and by component by presenting the reclassification adjustments on either the face of the statement where net income is presented or in a separate disclosure in the notes to the financial statements. Amounts that are not required to be reclassified in their entirety to net income are required to be cross referenced to related footnote disclosures that provide additional detail. The amended accounting standards only impact the financial statement presentation of OCI and do not change the components that are recognized in net income or OCI. The adoption had no impact on the Company’s financial position or results of operations.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	Pioneer Acquisition
	On August 30, 2013, we completed the acquisition of the Pioneer Plus re-entry catheter product line, or Pioneer, from Medtronic. The product is an interventional medical device designed to enable the crossing of sub-total, total and chronic total occlusions within the peripheral vasculature, potentially eliminating the need for surgery. The primary reason for the acquisition was to diversify our product offerings, allow us the opportunity to better position ourselves in the peripheral vascular market and to increase our IVUS product sales.
	This transaction was structured as an asset purchase and was accounted for as a business combination with an aggregate purchase price of $15.0 million. The assets acquired, primarily $12.7 million of intangible assets, were recorded at their estimated fair values as of the acquisition date. The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed is $1.5 million, which represents the goodwill amount resulting from the acquisition and was allocated to our medical segment and is not deductible for income tax purposes. As of the date of this Annual Report on Form 10-K, the Company is still finalizing the allocation of the purchase price. Changes to the current allocation may occur as additional information becomes available related to the valuation of inventory, fixed assets and intangible assets and deferred taxes, with such changes recorded as an adjustment to goodwill.
	The acquisition was not individually or collectively considered material to the overall consolidated financial statements and the results of the Company’s operations. We have included the operating results associated with the Pioneer acquisition in our consolidated financial statements from the date of acquisition.
	Crux Acquisition
	On December 12, 2012 we completed the acquisition of all outstanding equity interests in Crux Biomedical, Inc., or Crux, a privately-held company engaged in the development of filter technology for the vascular, cardiovascular and interventional radiology markets. The primary reason for the acquisition was to diversify our product offerings, allow us the opportunity to better position ourselves in the peripheral vascular market and to increase our IVUS product sales. The transaction was accounted for as a business combination. The operating results of Crux from the date of acquisition were included in our consolidated financial statements.
	Consideration
	We made up-front cash payments totaling $39.1 million in exchange for 100% of Crux's capital stock. We also have a receivable for a working capital shortfall to target which is expected to be settled in 2014. The fair value of the working capital receivable represents the amount by which the working capital acquired in the transaction was less than the target working capital as stated in the Merger Agreement. The receivable will be accreted to its fair value with accretion recorded in acquisition-related items within operating expense. The receivable has a legal right of offset against milestone payments, which are expected to be paid beginning in 2014, and therefore is reflected as a contra liability in our consolidated financial statements. The working capital receivable was estimated to be approximately $1.2 million and the fair value of this receivable was estimated to be $900,000 at acquisition. According to the working capital audit completed in the second quarter of 2013, the working capital receivable was adjusted to be approximately $1.4 million and the fair value of this receivable was estimated to be $1.1 million at acquisition. The $200,000 adjustment is a result of additional information about facts that existed at the acquisition date that we obtained after that date, therefore this adjustment resulted in an increase in the working capital receivable and a reduction to goodwill. At December 31, 2013, the present value of the working capital adjustment was estimated to be $1.2 million.
	In addition, under the Merger Agreement, we agreed to pay a cash milestone payment of $3.0 million following the achievement of written clearance by the U.S. Food and Drug Administration, or FDA, of a 510(k) notification for the commercial sale in the United States of an inferior vena cava filter retrieval device currently being developed by Crux, provided such 510(k) notification was submitted on or before June 30, 2013. On July 1, 2013, we entered into an amendment to the Merger Agreement to extend the date by which the 510(k) notification must be submitted from June 30, 2013 to November 30, 2013 for the $3.0 million milestone payment to remain eligible to be paid upon the written clearance by the FDA. The fair value of this contingent consideration was previously estimated to be $2.9 million at acquisition. The 510(k) notification was submitted to the FDA on November 30, 2013 and we received written clearance from the FDA on February 3, 2014. The $3.0 million milestone payment is expected to be made on or before March 1, 2014.
	Furthermore, subject to the terms of the Merger Agreement, we may be required to make payments upon reaching various sales milestones. We estimated the contingent milestone payments to be approximately $46.6 million and the fair value of this contingent consideration was estimated to be $28.0 million at acquisition. We determined the fair value of the contingent consideration relative to the milestone payments based on commercial sales of Crux products using various estimates, including revenue projections, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At December 31, 2013, we estimated the contingent milestone payment to be approximately $48.6 million and the present value of this contingent consideration to be $31.9 million. At December 31, 2013, for the fair value relative to the milestone payments based on the commercial sales of Crux products, the key assumptions in applying the income approach include a 14% discount rate and probability-weighted expected milestone payment ranges from $32.8 million to $70.1 million based on estimated commercial sales of Crux products ranging from $124.9 million to $279.8 million from December 2013 to 2019.
	Using different valuation assumptions could result in significant differences in the fair value of the contingent consideration and accretion expense in the current or future periods.
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net with working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
	Fair value measurement at acquisition December 12, 2012	$	30,000
	Change in fair value measurement included in operating expenses	231
	Contingent consideration settled	—
	Fair value measurement at December 31, 2012	30,231
	Change in fair value measurement included in operating expenses	3,607
	Working capital adjustment	(200		)
	Contingent consideration settled	—
	Fair value measurement at December 31, 2013	$	33,638
	A reconciliation of upfront payments in accordance with the Merger Agreement to the total purchase price is presented below (in thousands):
	Base payment per agreement	$	36,000
	Reimbursement of transaction expenses incurred by Crux	3,100
	Total up-front payments	39,100
	Estimated fair value of receivable for working capital adjustment	(1,100		)
	Estimated fair value of contingent consideration at acquisition	30,900
	Total purchase price	$	68,900
	Purchase Price Allocation
	During 2013, we recorded adjustments to net assets acquired (total purchase price), deferred tax asset and goodwill, as a result of finalizing the purchase accounting.
	The adjustment to the total purchase price is related to the $200,000 working capital receivable adjustment as a result of additional information about facts that existed at the acquisition date, therefore this adjustment resulted in an increase in the working capital receivable (component of total purchase price) and a reduction to goodwill.
	In addition, we established a valuation allowance of $1.0 million against the deferred tax asset as realization of a portion of such assets do not meet the more likely than not threshold. This adjustment resulted in an increase to goodwill.
	We recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
		12-Dec-12
	Current assets:
	Cash and cash equivalents	$	1,474
	Deferred tax asset - current	108
	Other current assets	253
	Property and equipment	39
	In-process research and development	28,400
	Covenants-not-to-compete	200
	Deferred tax asset	11,861
	Total assets acquired	42,335
	Current liabilities:
	Accounts payable	(223		)
	Accrued expenses	(302		)
	Other long term payable	(97		)
	Deferred tax liability	(10,307		)
	Total liabilities assumed	(10,929		)
	Goodwill	37,494
	Net assets acquired	$	68,900
	The IPR&D asset we recorded in the amount of $28.4 million represents an estimate of the fair value of in-process technology related to Crux's filter technology and retrieval device programs. The estimated fair value was determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after tax cash flows attributable to that intangible asset. The fair value using the multi-period excess earnings method was dependent on an estimated weighted average cost of capital for Crux of 14%, which represents a rate of return that a market participant would expect for these assets.
	The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed, $37.5 million, represents the goodwill amount resulting from the acquisition, which was allocated to our medical segment and is not deductible for income tax purposes. We expect to benefit from the acquisition by expanding our product offerings to physicians thereby contributing to an expanded revenue base. Further, we expect to realize synergies by offering the products developed from the acquisition utilizing our existing sales force.
	Pro forma financial information (unaudited)
	The following unaudited pro forma information presents the combined results of operations for the years ended December 31, 2012 and 2011 as if the acquisition of Crux had been completed as of the beginning of 2011 (in thousands, except per share data):
		Years Ended December 31,
		2012			2011
	Revenues	$	381,866		$	343,546
	Net (loss) income	$	(515	)	$	31,035
	Net (loss) income per share, basic and diluted:
	Basic	$	(0.01	)	$	0.59
	Diluted	$	(0.01	)	$	0.57
	Shares used in computing basic and diluted net (loss) income per share:
Basic	53,475			52,300
Diluted	53,475			54,596
The pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations. Included in the pro forma net loss for the year ended December 31, 2012 are approximately $943,000 of acquisition-related costs, which are not expected to have an ongoing impact.
Sync-Rx Acquisition
On November 26, 2012, we acquired all of the outstanding equity interests in Sync-Rx Ltd., or Sync-Rx, a privately-held company, which is engaged in the development of advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. The Sync-Rx technology will provide us with a platform on which to build a range of advanced software features that will aid clinical decision-making by providing angiography and intra-body image enhancement, measurement and non-invasive imaging and intravascular co-registration capabilities, and future opportunities in physiology and peripheral therapy guidance.
The aggregate purchase price was $17.3 million, of which $3.3 million is being held in escrow to satisfy claims for indemnification for certain matters made within 18 months following the closing. The transaction was accounted for as a business combination. We have included the operating results associated with the Sync-Rx acquisition in our consolidated financial statements from the date of acquisition.
In connection with the acquisition, we recorded a contingent liability of $1.1 million related to a government grant received to develop the underlying technology. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technology for which grant proceeds were received. We expect to generate revenues sufficient to repay the liability in its entirety. The grant was recorded as other long term debt at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. At acquisition, for the fair value relative to this liability, the key assumptions in applying the income approach included an 8% discount rate and estimated commercial sales derived from the underlying technology ranging from $256.1 million to $298.3 million over the expected period of re-payment of 10 to 16 years. The long term liability will be accreted to the re-payment amount of $1.9 million plus interest, with such accretion recorded as interest expense over the expected period of re-payment. As of December 31, 2013, there were no significant changes in the range of outcomes for the contingent liability recognized as a result of the acquisition.
During 2013, we recorded adjustments to deferred tax assets, deferred tax liabilities and goodwill, as a result of finalizing the purchase accounting. We established a valuation allowance of $1.2 million against the net deferred tax asset as it is expected that the net operating loss carryforward initially recorded as a deferred tax asset will not be utilized. This adjustment resulted in an increase to goodwill.
We recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
	26-Nov-12
Current assets:
Cash and cash equivalents	$	423
Receivable and other current assets	72
Property and equipment	37
Developed technology	3,200
In-process research and development	1,300
Covenants not-to-compete	100
Other non-current assets	8
Total assets acquired	5,140
Current liabilities:
Accounts payable	(56		)
Accrued expenses	(375		)
Other long-term debt	(1,100		)
Total liabilities acquired	(1,531		)
Goodwill	13,650
Net assets acquired	$	17,259
The $3.2 million developed technology represents an estimate of the fair value of Sync-Rx's image enhancement technology, which is subject to an estimated useful life of ten years. The $1.3 million IPR&D asset represents an estimate of the fair value of in-process technology related to Sync-Rx's co-registration technology, which is still under development. The estimated fair values of the developed technology and the IPR&D asset were determined using the multi-period excess earnings method, a variation of the income approach. The multi-period excess earnings method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset. The rate used to discount net future after-tax cash flows to their present values was based on a discount rate of 19% for developed technology and 20% for the IPR&D. Significant factors considered in the calculation of the discount rates include the weighted average cost of capital, the internal rate of return and the weighted average return on assets, as well as the risks inherent in the development process for the technology.
The excess of purchase price over the fair value amounts of the assets acquired and liabilities assumed, $13.7 million, represents the goodwill amount resulting from the acquisition, which was allocated to our medical segment and is not deductible for income tax purposes. We expect to benefit from the acquisition by expanding our product offerings to physicians thereby contributing to an expanded revenue base. Additionally, we expect to realize synergies by offering the products developed from the acquisition utilizing our existing sales force.
Acquisition-Related Items
During 2013, we recorded $5.0 million in acquisition-related items, including charges of $3.6 million related to the change in fair value of the contingent consideration associated with the Crux acquisition, which is primarily due to the passage of time, and $860,000 in transaction costs associated with the Pioneer, Crux and Sync-Rx acquisition.
During 2012, we recorded $1.9 million in acquisition-related items, including charges of $231,000 related to the change in fair value of the contingent consideration associated with the Crux acquisition, which is primarily due to the passage of time, and $1.6 million in transaction costs primarily associated with the Crux and Sync-Rx acquisitions.

Financial_Statement_Details

Financial Statement Details	12 Months Ended
	Dec. 31, 2013
Financial Statement Details [Abstract]	'
Financial Statement Details	'
	Financial Statement Details
	Cash and Cash Equivalents and Available-for-Sale Investments
	We invest our excess funds in U.S. government securities, corporate fixed income securities, commercial paper, certificates of deposit and money market funds. As of December 31, 2013, all of our investments were classified as available-for-sale and will mature within 18 months. These investments are recorded at their estimated fair value including accrued interest receivable, with unrealized gains or losses reported as a separate component of accumulated other comprehensive income or loss.
	At December 31, 2013 and 2012, available-for-sale investments are detailed as follows (in thousands):
	At December 31, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	165,598			$	72			$	4			$	165,666
	U.S. Treasury and agency debt securities		66,214				2				18				66,198
	Short-term available-for-sale investments		$	231,812			$	74			$	22			$	231,864
	Long-term:
	Corporate debt securities		$	11,814			$	30			$	—			$	11,844
	U.S. Treasury and agency debt securities		23,028				15				—				23,043
	Long-term available for sale investments		$	34,842			$	45			$	—			$	34,887
	At December 31, 2012
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	121,883			$	52			$	5			$	121,930
	U.S. Treasury and agency debt securities		19,020				10				—				19,030
	Short-term available-for-sale investments		$	140,903			$	62			$	5			$	140,960
	Long-term:
	Corporate debt securities		$	33,384			$	6			$	17			$	33,373
	U.S. Treasury and agency debt securities		11,010				2				—				11,012
	Long-term available for sale investments		$	44,394			$	8			$	17			$	44,385
	Available-for-sale investments that are in an unrealized loss position at December 31, 2013 and 2012 are detailed as follows (in thousands):
			At December 31, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	21,464			$	4
	U.S. Treasury and agency debt securities		41,034				18
			$	62,498			$	22
	At December 31, 2013, eight of our corporate debt securities and two of our U.S. Treasury and agency debt securities are in an unrealized loss position. We fully expect to receive par value with full principal and interest when these securities mature. These investments have been in an unrealized loss position for less than 12 months. We do not consider these investments to be other-than-temporarily impaired at December 31, 2013.
			At December 31, 2012
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	46,987			$	22
	U.S. Treasury and agency debt securities		—				—
			$	46,987			$	22
	Derivative Financial Instruments
	Foreign Currency Forward Contracts
	We are exposed to foreign currency risks through our global operations, primarily in Japan and Europe, and when we enter into transactions in non-functional currencies. Exchange rate fluctuations between the U.S. dollar and foreign currencies, primarily Japanese yen and euro, could adversely affect our financial results. We use derivative financial instruments to mitigate our foreign currency exposures. We do not enter into derivative instruments for speculative purposes.
	We enter into derivative financial instruments, principally forward contracts, to manage a portion of the foreign currency risk related to transactions in non-functional currencies. We record derivative financial instruments as either assets or liabilities in our consolidated balance sheets and measure them at fair value. Certain of the derivative instruments we use to mitigate this exposure are not designated for hedge accounting treatment, and as a result, changes in their fair values are recorded in exchange rate gain (loss) in the consolidated statement of operations.
	Commencing April 2013, we broadened our currency hedging program to hedge certain forecasted intercompany inventory transactions that are denominated in yen and euro. These forward contracts are designated as cash flow hedges and have maturity dates of up to 13 months. Changes in the fair value of cash flow hedges, excluding time value of the hedges which is recorded as interest expense, are reported as a component of accumulated other comprehensive income (loss), or AOCI, within stockholders' equity. Once the underlying hedged transaction occurs, we de-designate the derivative, cease to apply hedge accounting treatment to the transaction, reclassify the gain or loss recorded to date from AOCI into cost of goods sold, and record any further gains or losses to exchange rate gain (loss). We evaluate hedge effectiveness at the inception of the hedge and on an ongoing basis. To the extent we experience ineffectiveness in our hedges, the gains or losses accumulated in other comprehensive income associated with the ineffective portion of the hedge are reclassified immediately into exchange rate gain (loss). We adjust the level and use of derivatives as soon as practicable after learning that an exposure has changed. We review all exposures on derivative positions on a regular basis.
	At December 31, 2013 and December 31, 2012, the notional amount of our outstanding forward contracts was $97.3 million and $64.4 million, respectively, of which $40.3 million and $0, respectively, were designated as cash flow hedges. At December 31, 2013, our outstanding forward contracts mature through January 2015.
	As of December 31, 2013, the deferred gain, net of tax, for those derivative contracts that qualified for hedge accounting treatment was $501,000, all of which will be reclassified from accumulated other comprehensive loss into cost of sales at the then-current values over the next twelve months as the underlying hedged transactions are recognized.
	The following tables summarize the location and fair values of derivative instruments on our consolidated balance sheets (in thousands) at December 31, 2013 and December 31, 2012. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		As of December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	954			Other current liabilities		$	251
	Foreign exchange forward contracts	Other long-term assets		81				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			1,035						251
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		1,953				Other current liabilities		1,164
	Total Derivatives Not Designated as Hedging Instruments			1,953						1,164
	Total Derivatives			$	2,988					$	1,415
		As of December 31, 2012
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
Foreign exchange forward contracts	Other current assets		$	—			Other current liabilities		$	—
Foreign exchange forward contracts	Other long-term assets		—				Other long-term liabilities		—
Total Derivatives Designated as Hedging Instruments			—						—
Derivatives Not Designated as Hedging Instruments
Foreign exchange forward contracts	Other current assets		3,886				Other current liabilities		425
Total Derivatives Not Designated as Hedging Instruments			3,886						425
Total Derivatives			$	3,886					$	425
The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information (in thousands) as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.
	As of December 31, 2013
					Gross Amount Not Offset on the Balance Sheet
	Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged				Net Amount
Derivative Assets
Foreign exchange forward contracts	$	2,988			$	(1,415	)		$	—			$	1,573
Derivative Liabilities
Foreign exchange forward contracts	(1,415		)		1,415				—				—
Total	$	1,573			$	—			$	—			$	1,573
	As of December 31, 2012
					Gross Amount Not Offset on the Balance Sheet
	Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged				Net Amount
Derivative Assets
Foreign exchange forward contracts	$	3,886			$	—			$	—			$	3,886
Derivative Liabilities
Foreign exchange forward contracts	(425		)		—				—				(425		)
Total	$	3,461			$	—			$	—			$	3,461
The following table summarizes the effect of our foreign exchange forward contracts on our consolidated statements of operations (in thousands).
		Year Ended
		December 31,
		2013				2012			2011
Derivatives Designated as Hedging Instruments
Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)		$	449			$	—		$	—
Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)		(319		)		—			—
Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)		49				—			—
Derivatives Not Designated as Hedging Instruments
Gain (loss) recognized in exchange rate gain (loss), net		$	6,413			$	4,786		$	(2,772	)
Options and Warrants Related to Our Convertible Notes
In connection with our convertible debt offering in December 2012, we purchased call options on our common stock. The call options give us the right to purchase up to approximately 14.0 million shares of our common stock at $32.8286 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the underlying debt. Additionally, we sold warrants, which gave the purchasers of the warrants the right to purchase up to approximately 14.0 million shares of our common stock at $37.59 per share, subject to certain adjustments. In accordance with the authoritative guidance, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2017 Notes occur.
In connection with our convertible debt offering in September 2010, we purchased call options on our common stock. The call options give us the right to purchase up to approximately 3.9 million shares of our common stock at $29.64 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the underlying debt. Additionally, we sold warrants, which gave the purchaser of the warrants the right to purchase up to approximately 3.9 million shares of our common stock at $34.875 per share, subject to certain adjustments. In accordance with the authoritative guidance, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2015 Notes occur. In December 2012, $90.0 million of the $115 million in aggregate principal amount of 2015 Notes were repurchased by the Company and the proportionate call option and warrant related to the convertible notes were also retired. The remaining call options give us the right to purchase up to approximately 850,000 shares of our common stock at $29.64 per share, subject to certain adjustments, and the remaining warrants give the counterparty the right to purchase up to approximately 850,000 shares of our common stock at $34.875 per share, subject to certain adjustments. The remaining call options and warrants continue to be classified as equity instruments and are not being marked to market prospectively unless certain conditions as described in the 2015 Notes occur.
Fair Value Measurements
Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities.
•	Level 1—Valuations based on quoted prices for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Our Level 1 assets consist of money market funds and U.S. Treasury and agency debt securities.
•	Level 2—Valuations based on quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data, such as alternative pricing sources with reasonable levels of price transparency. Our Level 2 assets consist of corporate debt securities including commercial paper, corporate bonds, certificates of deposit and foreign currency forward contracts.
•	Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Our Level 3 liability includes the contingent consideration related to the Crux acquisition and the other long-term debt related to the Sync-Rx acquisition.
We utilize a third-party pricing service to assist us in obtaining fair value pricing for our investments. Pricing for certain securities is based on proprietary models. Inputs are documented in accordance with the fair value disclosure hierarchy. We also utilize third-party financial institutions to assist us in obtaining fair value pricing for our foreign currency forward contracts.
Contingent consideration arrangements obligate us to pay former shareholders of an acquired entity if specified future events occur or conditions are met such as the achievement of certain technological milestones or the achievement of targeted revenue milestones. We measure such liabilities using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. We used various key assumptions, such as the probability of achievement of the agreed milestones and the discount rate, in our determination of the fair value of contingent consideration. We monitor the fair value of the contingent consideration and the subsequent revisions are reflected in our consolidated statements of operations. For a further discussion on the key assumptions used in determining the fair value and the change in the estimated fair value of the contingent consideration during the year ended December 31, 2013 and 2012, refer to Note 2, "Acquisitions - Crux Acquisition".
In connection with the Sync-Rx acquisition, we recorded a contingent liability related to a government grant received to develop an underlying technology. The timing of repayment of the grant is contingent upon the generation of revenues derived from the technology for which grant proceeds were received. We measure such liability using Level 3 unobservable inputs, applying the income approach, such as the discounted cash flow technique, or the probability-weighted scenario method. The grant was recorded as other long term debt at its present value using various estimates, including revenue projections, discount rate and estimated years of re-payment. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. We monitor the fair value of the contingent liability and the subsequent revisions are reflected in our consolidated statements of operations. For a further discussion on the key assumptions used in determining the fair value, refer to Note 2, "Acquisitions - Sync-Rx Acquisition".
During the years ended December 31, 2013 and 2012, no transfers were made into or out of the Level 1, 2, or 3 categories. We will continue to review our fair value inputs on a quarterly basis.
Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December 31, 2013 and 2012 (in thousands):
		Fair Value Measurements at December 31, 2013
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	98,436			$	98,436			$	—			$	—
Money market funds		8,723				8,723				—				—
Corporate debt securities		165,666				—				165,666				—
U.S. Treasury and agency debt securities		66,198				66,198				—				—
Foreign currency forward contracts		2,907				—				2,907				—
Non-current:
Corporate debt securities		11,844				—				11,844				—
U.S. Treasury and agency debt securities		23,043				23,043				—				—
Foreign currency forward contracts		81				—				81				—
Total assets measured at fair value		$	376,898			$	196,400			$	180,498			$	—
Liabilities:
Current:
Foreign currency forward contracts		$	1,415			$	—			$	1,415			$	—
Contingent consideration, current portion (1)		3,750				—				—				3,750
Non-current:
Other long-term debt		1,268				—				—				1,268
Contingent consideration		29,888				—				—				29,888
Total liabilities measured at fair value		$	36,321			$	—			$	1,415			$	34,906
(1) This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.
		Fair Value Measurements at December 31, 2012
		Total				Level 1				Level 2				Level 3
Assets:
Current:
Cash		$	41,636			$	41,636			$	—			$	—
Money market funds		288,999				288,999				—				—
Corporate debt securities		121,930				—				121,930				—
U.S. Treasury and agency debt securities		19,030				19,030				—				—
Foreign currency forward contracts		3,886				—				3,886				—
Non-current:
Corporate debt securities		33,373				—				33,373				—
U.S. Treasury and agency debt securities		11,012				11,012				—				—
Total assets measured at fair value		$	519,866			$	360,677			$	159,189			$	—
Liabilities:
Current:
Foreign currency forward contracts		$	425			$	—			$	425			$	—
Contingent consideration, current portion		2,908				—				—				2,908
Non-current:
Other long-term debt		1,088				—				—				1,088
Contingent consideration (1)		27,323				—				—				27,323
Total liabilities measured at fair value		$	31,319			$	—			$	—			$	31,319
(1) This amount is reflected net of the fair value of the working capital receivable in the amount of $907,000 at December 31, 2012.
Accounts Receivable, Net
Accounts receivable, net consists of the following (in thousands):
		December 31,
		2013				2012
Trade accounts receivable		$	82,409			$	76,717
Less: allowance for doubtful accounts		447				369
		$	81,962			$	76,348
The change in the allowance for doubtful accounts for the years ended December 31, 2013, 2012 and 2011 is summarized in the following table (in thousands):
		Years Ended December 31,
		2013				2012				2011
Balance at beginning of year		$	369			$	84			$	29
Additions charged to selling, general and administrative expense		78				285				55
Balance at end of year		$	447			$	369			$	84
Inventories
Inventories consist of the following (in thousands):
		December 31,
		2013				2012
Finished goods (1)		$	27,237			$	19,002
Work-in-process		12,051				15,780
Raw materials		21,682				18,029
		$	60,970			$	52,811
(1) Finished goods inventory includes consigned inventory of $5.6 million and $5.3 million at December 31, 2013 and 2012, respectively.
Property and Equipment
Property and equipment consists of the following (in thousands):
		December 31,
		2013				2012
Medical diagnostic equipment		$	68,923			$	65,548
Other equipment		52,523				44,879
Leasehold improvements		12,641				9,289
Software		34,392				5,447
Land		3,046				3,046
Building		33,245				29,098
Construction-in-progress (1)		9,975				27,730
		214,745				185,037
Less: Accumulated depreciation and amortization		(96,651		)		(80,652		)
		$	118,094			$	104,385
-1	At December 31, 2012, construction-in-process includes $1.0 million of capitalized interest related to the implementation of ERP systems worldwide. The implementation was completed during 2013.
Property and equipment includes certain medical diagnostic equipment that is located at customer premises. We retain the ownership of the equipment and have the right to remove the equipment if it is not being utilized according to expectations. Depreciation expense relating to the equipment of $8.3 million, $9.6 million and $10.9 million is recorded in cost of revenues during the years ended December 31, 2013, 2012 and 2011, respectively. The net book value of this equipment was $16.5 million and $21.7 million at December 31, 2013 and December 31, 2012, respectively. Also included in medical diagnostic equipment is property and equipment used for demonstration and evaluation purposes. Depreciation expense for equipment used for demonstration and evaluation purposes recorded in selling, general and administrative expenses totaled $416,000, $816,000 and $1.2 million during the years ended December 31, 2013, 2012 and 2011, respectively. The net book value of this equipment was $939,000 and $869,000 at December 31, 2013 and December 31, 2012, respectively. Medical diagnostic equipment is recorded at our cost to acquire or manufacture the equipment and is depreciated over its estimated useful life (generally three to five years).
Depreciation and amortization expense for the years ended December 31, 2013, 2012 and 2011 was $22.0 million, $19.9 million, and $19.8 million, respectively.
Intangible Assets
Intangible assets consisted of acquired developed technology, licenses, customer relationships, patents and trademarks, and covenants-not-to-compete, as well as acquired in-process research and development technology. Intangible assets, except for acquired in-process research and development technology, are amortized using the straight-line method over their estimated useful lives of up to 20 years. Amortization of acquired in-process research and development technology will not commence until the technology reaches market feasibility. If the related project is terminated or abandoned, we may have an impairment related to the in-process research and development technology, calculated as the excess of the asset’s carrying value over its fair value.
During the year ended December 31, 2013, we recorded developed technology additions of $35.7 million, including $11.6 million from the Pioneer acquisition in August 2013 and $24.1 million IPR&D associated with the Crux IVC filter that was transferred to developed technology when the product launched in the fourth quarter of 2013. Other additions in intangible assets include a $5.6 million addition in patents and trademark, including a $4.7 million addition to internally developed patents and a $0.9 million addition in trademark and trade names from the Pioneer acquisition in August 2013.
We also recorded $6.3 million of net intangible asset impairments due to the restructuring plan we executed in 2013, including a $4.1 million impairment for the IPR&D assets associated with the Forward-Looking IVUS project we acquired from Novelis in 2008, a $1.7 million impairment (cost of $3.2 million and accumulated amortization of $1.6 million) for the developed technology associated with the Optical Coherence Tomography project we acquired from CardioSpectra, Inc. in 2007, and a $566,000 impairment (cost of $2.1 million and accumulated amortization of $1.5 million) for the developed technology associated with the discontinuation of our ReFLOW Aspiration Catheter product line. Refer to "Note 3 - Financial Statement Details - Restructuring Activity" for details.
During the year ended December 31, 2012, we recorded intangible asset additions of $4.4 million related to developed technology, $150,000 related to licenses, $4.0 million related to internally developed patents and trademarks, $300,000 related to covenants-not-to-compete, and $29.7 million related to in-process research and development technology acquired from acquisitions.
Intangible assets subject to amortization, by major class, consist of the following (in thousands):
		December 31, 2013
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	57,507			$	16,393			$	41,114			8.6
Licenses		7,441				7,102				339				8.8
Customer relationships		4,441				4,312				129				6.1
Patents and trademarks		13,668				2,894				10,774				13.2
Covenants-not-to-compete		300				108				192				3
		83,357				30,809				52,548				9.2
Intangible assets not yet subject to amortization
In-process research and development		5,560				—				5,560				n/a
		$	88,917			$	30,809			$	58,108
		December 31, 2012
Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
						Amortization								Average Life
														(in years) (1)
Developed technology		$	27,051			$	17,408			$	9,643			8.8
Licenses		7,345				6,709				636				10
Customer relationships		4,177				3,756				421				6
Patents and trademarks		8,029				2,114				5,915				13.2
Covenants-not-to-compete		300				8				292				3
		46,902				29,995				16,907				9.4
Intangible assets not yet subject to amortization
In-process research and development		33,750				—				33,750				n/a
		$	80,652			$	29,995			$	50,657
-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
We recorded amortization of intangible assets totaling $3.8 million, $3.2 million and $3.4 million for the years ended December 31, 2013, 2012 and 2011, respectively.
At December 31, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
2014	$	7,187
2015	7,027
2016	6,821
2017	6,309
2018	6,182
Thereafter	19,022
	$	52,548
Goodwill
The change in goodwill for the years ended December 31, 2013 and 2012 is summarized in the following table (in thousands):
		Years Ended December 31,
		2013				2012
Balance at beginning of year		$	51,577			$	2,487
Additions		3,510				49,090
Balance at end of year		$	55,087			$	51,577
In 2013, goodwill of $817,000 was recorded in connection with finalizing the purchase price allocation for the Crux acquisition, goodwill of $1.2 million was recorded in connection with finalizing the purchase price allocation for the Sync-Rx acquisition, and goodwill of $1.5 million was recorded in connection with the Pioneer acquisition.
In 2012, goodwill of $12.4 million was recorded in connection with the Sync-Rx acquisition, and goodwill of $36.7 million was recorded in connection with the Crux acquisition.
Accrued Warranty
Accrued warranty liability is included in accrued expenses and other current liabilities in the consolidated balance sheets. The change in the accrued warranty liability for the years ended December 31, 2013, 2012 and 2011 is summarized in the following table (in thousands):
		Years Ended December 31,
		2013				2012				2011
Balance at beginning of year		$	1,176			$	1,077			$	852
Warranties issued		2,135				1,898				1,864
Settlements		(2,159		)		(1,799		)		(1,639		)
Balance at end of year		$	1,152			$	1,176			$	1,077
Capital Lease Obligations
We lease certain equipment under capital lease arrangements. See Note 4 “Commitments and Contingencies - Leases” for more information.
Restructuring Activity
Disposables Manufacturing Transition to Costa Rica Initiative
During the second quarter of 2013, our management approved plans to consolidate and transition our manufacturing resources related to the manufacture of disposables to Costa Rica. Activities under this restructuring plan were initiated in the second quarter of 2013 and are expected to be substantially completed by the end of 2014. We estimate that this restructuring plan will result in total pre-tax charges of approximately $2.8 million, all of which are one-time termination benefits, including severance payments and continuing medical benefits.
A summary of the activities related to this initiative during 2013 is presented below (in thousands):
		Employee Termination Cost
Balance at beginning of year		$	—
Restructuring charges		333
Payments		(333		)
Balance at end of year		$	—
All charges were recorded in the restructuring charges line item within our consolidated statement of operations.
Strategic Reorganization Initiative
During the third quarter of 2013, our management evaluated various development projects, product lines and functional areas in an effort to reprioritize and reallocate our resources within our distribution, research and development, and clinical programs to focus on development and commercial efforts that we believe better advance our key strategies. The key elements under this restructuring plan include the discontinuation of development programs for our FL.IVUS, FL.ICE and OCT intravascular coronary imaging development programs, the termination of the commercial sale of the ReFLOW product line, and a modest reorganization of several functional areas and business units within the Company.
Activities under this restructuring plan were initiated in the third quarter of 2013 and are expected to be substantially completed by mid-year 2014. We estimate that this restructuring plan will result in total pre-tax charges of approximately $19.2 million, of which $19.0 million incurred during 2013. Approximately $7.8 million of these charges resulted or will result in cash outlay. The following provides a summary of our expected total costs associated with the plan by major type of costs (in thousands):
Type of Cost		Total Estimated Amount
Employee termination cost		$	2,812
Asset write-off		11,402
Other associated cost		4,983
Total		$	19,197
A summary of the restructuring charges related to this initiative during 2013 is presented below (in thousands):
		Employee Termination Cost				Asset Write-Off				Other Associated Cost				Total
Balance at beginning of year		$	—			$	—			$	—			$	—
Restructuring charges		2,867				11,402				4,772				19,041
Payments/write-off		(797		)		(11,402		)		—				(12,199		)
Balance at end of year		$	2,070			$	—			$	4,772			$	6,842
The employee termination cost includes severance payments and continuing medical and other benefits. The asset write-off is related to the discontinued programs and includes impairment of properties, plant and equipments of $2.0 million, impairment of intangible assets of $6.3 million and other tangible asset impairment of $3.1 million. The other associated costs include our estimate of the probable contract termination costs related to our purchase and lease commitments, and other costs directly related to the restructuring activities.
All charges were recorded in the restructuring charges line item within our consolidated statement of operations.
Both restructuring initiatives are related to our medical segment.
Debt
1.75% Convertible Note Due December 1, 2017
In December 2012, we issued $460 million aggregate principal amount of 1.75% Convertible Senior Notes due 2017 ("2017 Notes"), in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on June 1 and December 1, commencing on June 1, 2013.
The 2017 Notes are general unsecured obligations that rank the same with our other existing and future unsecured obligations. Prior to August 7, 2017, the 2017 Notes are convertible only upon certain specified events. The initial conversion rate for the 2017 Notes is 30.4612 shares of common stock per $1,000 principal amount of the 2017 Notes, representing an initial effective conversion price of approximately $32.83 per share of common stock. The conversion rate is subject to adjustment for certain events as outlined in the indenture governing the 2017 Notes but will not be adjusted for accrued and unpaid interest.
We received net proceeds of $409.3 million from issuance of the 2017 Notes, net of $14.6 million debt issuance costs and net payments of $36.1 million related to our hedge transactions. We recorded total debt issuance costs (including broker fees) of approximately $14.6 million, which have been allocated on a pro-rata basis to the debt ($11.8 million) and equity ($2.8 million) components of the transaction. The long-term debt component is included in non-current liabilities and is being accreted to interest expense over 5 years, the term of the 2017 Notes. The equity component was netted against the proceeds and included in additional paid-in capital.
We may not redeem the 2017 Notes prior to maturity. However, in the event of a fundamental change, as defined in the indenture, the holders of the 2017 Notes may require us to purchase all or a portion of their 2017 Notes at a purchase price equal to 100% of the principal amount of the 2017 Notes, plus accrued and unpaid interest, if any, to the repurchase date. Holders, who convert their 2017 Notes in connection with a make-whole fundamental change, as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate.
Prior to August 7, 2017, the 2017 Notes are convertible only under the following circumstances: (1) during any fiscal quarter commencing after March 31, 2013 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “ 2017 Notes Measurement Period”) in which, for each trading day of such 2017 Notes Measurement Period, the trading price per $1,000 principal amount of 2017 Notes on such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; or (3) upon the occurrence of specified distributions and corporate events. As of December 31, 2013, none of the conditions allowing holders of the 2017 Notes to convert had been met.
We determined that the embedded conversion option in the 2017 Notes is not required to be separately accounted for as a derivative under ASC 815, Derivatives and Hedging. However, since the 2017 Notes are within the scope of ASC 470, Topic 20, Debt with Conversion and Other Options, we are required to separate the 2017 Notes into a liability component and equity component. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability (including any embedded features other than the conversion option) that does not have an associated equity component. The carrying amount of the equity component representing the embedded conversion option is determined by deducting the fair value of the liability component from the initial proceeds ascribed to the 2017 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount is amortized to interest cost over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in ASC 815, Topic 40, Contracts in an Entity’s Own Equity, or ASC 815.
We are using an effective interest rate of 7.00% to calculate the accretion of the bond discount, which is being recorded as interest expense over the expected remaining term of the 2017 Notes. (The amount by which interest expense calculated using the effective interest rate of 7.00% exceeds the interest expense related to the coupon rate of 1.75%, is non-cash interest expense.) The effective rate is based on the interest rate for a similar instrument that does not have a conversion feature. We may be required to pay additional interest upon occurrence of certain events as outlined in the indenture governing the 2017 Notes. As of December 31, 2013, the remaining term of the 2017 Notes is 3.92 years.
Upon conversion of a note, holders of the 2017 Notes will receive up to the principal amount of the converted note in cash and any excess conversion value (conversion spread) in shares of our common stock. The amount of cash and the number of shares of our common stock, if any, will be based on an 80 trading day observation period as described in the indenture. As described in Note 1 - “Organization and Summary of Significant Accounting Policies”, the conversion spread will be included in the denominator for the computation of diluted net income (loss) per common share, using the treasury stock method, if the effect is dilutive.
As discussed above, to hedge against potential dilution upon conversion of the 2017 Notes, we also purchased call options on our common stock from counterparties. The call options give us the right to purchase up to approximately 14.0 million shares of our common stock at $32.83 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the 2017 Notes. We paid an aggregate of $89.8 million to purchase these call options. The call options will expire on December 1, 2017, unless earlier terminated or exercised. To reduce the cost of the hedge, in a separate transaction we sold warrants to counterparties. These warrants give the counterparties the right to purchase up to approximately 14.0 million shares of our common stock at $37.59 per share, subject to certain adjustments. These warrants will be exercisable and will expire in equal installments for a period of 120 trading days beginning on March 15, 2018. We received an aggregate of $53.7 million from the sale of these warrants. In accordance with ASC 815, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and will not be marked to market prospectively unless certain conditions as described in the 2017 Notes occur. The net amount of $36.1 million was recorded as a reduction to additional paid-in capital. The settlement terms of the call options provide for net share settlement and the settlement terms of the warrants provide for net share or cash settlement at our option.
2.875 Convertible Note Due September 1, 2015
In September 2010, we issued $115 million aggregate principal amount of 2.875% Convertible Senior Notes due 2015 ("2015 Notes"), in an offering registered under the Securities Act of 1933, as amended. Interest is payable semiannually in arrears on March 1 and September 1, commencing on March 1, 2011.
The 2015 Notes are general unsecured obligations that rank the same with our other existing and future unsecured obligations. Prior to June 1, 2015, the 2015 Notes are convertible only upon certain specified events. The initial conversion rate for the 2015 Notes is 33.7339 shares of common stock per $1,000 principal amount of the 2015 Notes, representing an initial effective conversion price of approximately $29.64 per share of common stock. The conversion rate is subject to adjustment for certain events as outlined in the indenture governing the 2015 Notes but will not be adjusted for accrued and unpaid interest.
We received proceeds of $100.5 million from issuance of the 2015 Notes, net of debt issuance costs of $4.4 million and net payments related to our hedge transactions of $10.0 million which are described in more detail below. We recorded total debt issuance costs (including broker fees) of approximately $4.4 million, which have been allocated on a pro-rata basis to the debt ($3.5 million) and equity ($866,000) components of the transaction. The debt component is primarily included in non-current liabilities and is being accreted to interest expense over 5 years, the term of the 2015 Notes. The equity component was netted against the proceeds and included in additional paid-in capital.
We may not redeem the 2015 Notes prior to maturity. However, in the event of a fundamental change, as defined in the indenture, the holders of the 2015 Notes may require us to purchase all or a portion of their 2015 Notes at a purchase price equal to 100% of the principal amount of the 2015 Notes, plus accrued and unpaid interest, if any, to the repurchase date. Holders, who convert their 2015 Notes in connection with a make-whole fundamental change, as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate.
Prior to June 1, 2015, the 2015 Notes are convertible only under the following circumstances: (1) during any fiscal quarter commencing after December 31, 2010 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “2015 Notes Measurement Period”) in which, for each trading day of such 2015 Notes Measurement Period, the trading price per $1,000 principal amount of 2015 Notes on such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; or (3) upon the occurrence of specified distributions and corporate events. As of December 31, 2013, the “if-converted” value of the 2015 Notes did not exceed its principal amount and none of the conditions allowing holders of the 2015 Notes to convert had been met.
We determined that the embedded conversion option in the 2015 Notes is not required to be separately accounted for as a derivative under ASC 815, Derivatives and Hedging. However, since the 2015 Notes are within the scope of ASC 470, Topic 20, Debt with Conversion and Other Options, we are required to separate the 2015 Notes into a liability component and equity components. The carrying amount of the liability component is calculated by measuring the fair value of a similar liability (including any embedded features other than the conversion option) that does not have an associated equity component. The carrying amount of the equity component representing the embedded conversion option is determined by deducting the fair value of the liability component from the initial proceeds ascribed to the 2015 Notes as a whole. The excess of the principal amount of the liability component over its carrying amount is amortized to interest cost over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in ASC 815, Topic 40, Contracts in an Entity’s Own Equity, or ASC 815.
We are using an effective interest rate of 7.65% to calculate the accretion of the bond discount, which is being recorded as interest expense over the expected remaining term of the 2015 Notes. (The amount by which interest expense calculated using the effective interest rate of 7.65% exceeds the interest expense related to the coupon rate of 2.875%, is non-cash interest expense.) The effective rate is based on the interest rate for a similar instrument that does not have a conversion feature. We may be required to pay additional interest upon occurrence of certain events as outlined in the indenture governing the 2015 Notes. As of December 31, 2013, the remaining term of the 2015 Notes is 1.67 years.
Upon conversion of a note, holders of the 2015 Notes will receive up to the principal amount of the converted note in cash and any excess conversion value (conversion spread) in shares of our common stock. The amount of cash and the number of shares of our common stock, if any, will be based on a 25 trading day observation period as described in the indenture. As described in Note 1 - “Organization and Summary of Significant Accounting Policies”, the conversion spread will be included in the denominator for the computation of diluted net income (loss) per common share, using the treasury stock method.
As discussed above, to hedge against potential dilution upon conversion of the 2015 Notes, we also purchased call options on our common stock from a counterparty. The call options give us the right to purchase up to approximately 3.9 million shares of our common stock at $29.64 per share subject to certain adjustments that generally correspond to the adjustments to the conversion rate for the 2015 Notes. We paid an aggregate of $27.2 million to purchase these call options. The call options will expire on September 1, 2015, unless earlier terminated or exercised. To reduce the cost of the hedge, in a separate transaction we sold warrants to a counterparty. These warrants give the counterparty the right to purchase up to approximately 3.9 million shares of our common stock at $34.875 per share, subject to certain adjustments. These warrants will be exercisable and will expire in equal installments for a period of 50 trading days beginning on December 1, 2015. We received an aggregate of $17.1 million from the sale of these warrants. In accordance with ASC 815, we concluded that the call options and warrants were indexed to our stock. Therefore, the call options and warrants were classified as equity instruments and will not be marked to market prospectively unless certain conditions as described in the 2015 Notes occur. The net amount of $10.0 million paid to the counterparty was recorded as a reduction to additional paid-in capital. The settlement terms of the call options provide for net share settlement and the settlement terms of the warrants provide for net share or cash settlement at our option.
Concurrently with the issuance of the 2017 Notes in December 2012, the Company repurchased $90.0 million of its 2015 Notes with a $104.9 million cash payment, including $711,000 of accrued interest. Since the 2015 Notes are within the scope of ASC 470, we allocated the consideration to the extinguishment of the liability component and the reacquisition of the equity component. We recognized a $5.0 million loss on repurchasing the 2015 Notes, which is the difference between the carrying value of the liability component, including any unamortized debt issuance costs, and the consideration attributed to the liability component as loss from debt extinguishment in other expenses in December 2012. The consideration attributed to the liability component of $83.0 million is calculated by measuring the fair value of a similar liability that does not have an associated equity component. The consideration attributable to the equity component of $21.8 million was recorded as a reduction of additional paid-in capital. In addition, the proportionate call options and warrants related to the 2015 Notes were also retired in December 2012. We received an aggregate of $15.2 million for the proportionate call option retirement and paid an aggregate of $11.6 million for buying back the proportionate portion of the warrants. The net amount of $3.6 million was recorded as an addition to additional paid-in capital.
Carrying value, fair value and interest expense
The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes, together the "Notes", are reflected in our consolidated balance sheets as follows (in thousands):
		As of December 31,
		2013				2012
Long-term debt:
2.875% Convertible Senior Notes due 2015:
Principal amount		$	25,000			$	25,000
Unamortized discount of liability component		(1,818		)		(2,830		)
Unamortized debt issuance costs		(204		)		(326		)
Carrying value of liability component		$	22,978			$	21,844
1.75% Convertible Senior Notes due 2017:
Principal amount		$	460,000			$	460,000
Unamortized discount of liability component		(72,902		)		(88,536		)
Unamortized debt issuance costs		(9,064		)		(11,008		)
Carrying value of liability component		$	378,034			$	360,456
Total long-term debt		$	401,012			$	382,300
Equity—net carrying value
2.875% Convertible Senior Notes due 2015		$	452			$	452
1.75% Convertible Senior Notes due 2017		$	89,415			$	89,415
The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
	As of December 31,
	2013				2012
2.875% Convertible Senior Notes due 2015	$	25,950			$	26,950
1.75% Convertible Senior Notes due 2017	456,320				462,850
Total	$	482,270			$	489,800
Interest expense related to the Notes was included in interest expense on the consolidated statements of operations as follows (in thousands):
	Year Ended December 31,
	2013				2012
Contractual coupon interest	$	8,769			$	3,625
Amortization of debt issuance costs	2,217				811
Accretion of debt discount	16,646				4,932
Capitalized interest	(939		)		(1,638		)
	$	26,693			$	7,730

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Loss Contingency [Abstract]	'
Commitments And Contingencies	'
	Commitments and Contingencies
	Litigation-LightLab
	On January 7, 2009, LightLab Imaging, Inc., or LightLab, which was acquired by St. Jude Medical, Inc., or St. Jude, in 2010, filed a complaint against us and our wholly owned subsidiary, Axsun, in the Superior Court of Massachusetts, Suffolk County, seeking injunctive relief and unspecified damages (the Massachusetts Action). The complaint included allegations that Volcano interfered with an agreement between Axsun and Lightlab and with LightLab's advantageous business relationship with Axsun, breach of contract by Axsun, that Axsun and Volcano misappropriated LightLab's confidential information and trade secrets, and violated Chapter 93A, a Massachusetts statute that provides for recovery of up to three times damages plus attorney's fees (93A).
	On April 7, 2011, the Court entered an Amended Final Judgment in the Massachusetts Action: a) in favor of Volcano and Axsun on LightLab's claims for trade secret misappropriation on items 1-30 on LightLab's list of alleged trade secrets, b) ordered Volcano and Axsun to collectively pay $600,000 in damages and $4.5 million in attorneys' fees, c) in favor of LightLab on its claims against Axsun for breach of contract, breach of implied covenant of good faith and fair dealing, for violation of 93A, and misappropriation of trade secrets for disclosing three particular items to Volcano in December 2008 - the specifications for the two lasers provided by Axsun to LightLab and one Axsun laser prototype made in 2008, d) in favor of LightLab on its claims against Volcano for intentional interference with a contract and advantageous business relationship, unjust enrichment, violation of 93A, and misappropriation of trade secrets for the same three trade secrets described above. In addition, the Court denied a majority of LightLab's requested injunctions, and entered limited injunctive relief, none of which management believes have a material effect upon Volcano.
	LightLab appealed various decisions of the Court including, a) the Court's pre-trial rulings excluding certain lost profits damages evidence that LightLab sought to introduce at trial; b) the Court's decisions adverse to LightLab's claims for trade secret misappropriation in items 1-30 of LightLab's alleged list of trade secrets, including various rulings requiring evidence of use or intent to use as a prerequisite for injunctive relief; c) the Court's post-trial decisions denying permanent injunctive relief that LightLab requested as terms of the Final Judgment; and; d) the denial of LightLab's motion to alter or amend the Final Judgment, which motion sought to obtain additional declaratory relief barring Axsun from “supplying” tunable lasers to Volcano. Volcano and Axsun did not cross appeal the Amended Final Judgment in 2011, and Volcano and Axsun satisfied their payment obligations under the Amended Final Judgment by Volcano paying Lightlab approximately $5.4 million. The Massachusetts Supreme Judicial Court heard LightLab's appeal on December 2, 2013.
	In February 2010, Volcano and Axsun commenced an action in the Delaware Chancery Court, or the Chancery Court Action, against LightLab seeking a declaration of Volcano and Axsun's rights with respect to certain OCT technology, the High Definition Swept Source. LightLab then filed a counter-claim that included a claim against Axsun and Volcano for violations of 93A. This case has been stayed until such time as Volcano has achieved certain development and regulatory milestones.
	Additionally, on May 24, 2011, LightLab commenced a separate action in Delaware Chancery Court, or the Second Chancery Court Action, against Volcano and Axsun alleging that Axsun is inappropriately assisting Volcano in the development of a third-party laser. The complaint seeks injunctive relief and unspecified damages. After Volcano and Axsun moved to dismiss the Second Chancery Court Action, LightLab filed an amended complaint against Volcano and Axsun, adding additional allegations regarding misappropriation of trade secrets. This case has been stayed indefinitely.
	In January 2014, Volcano requested the Chancery Court dismiss the Chancery Court Actions. The Chancery Court has not ruled on this motion.
	Litigation - St. Jude Medical
	On July 27, 2010, St. Jude Medical filed a lawsuit against Volcano in federal district court in Delaware (collectively, with the counterclaims described below, the Delaware Patent Action), alleging that our pressure guide wire products infringe five patents owned by St. Jude Medical. St. Jude Medical is seeking injunctive relief and monetary damages. This action does not involve OCT technology and is separate from the Massachusetts Action.
	On September 20, 2010, Volcano filed its response, in which we denied the allegations that our PrimeWire ® products infringe any valid claim of St. Jude Medical's asserted patents. In addition, Volcano filed a counterclaim in which we alleged that St. Jude Medical's PressureWire ® products and its RadiAnalyzer ® Xpress product infringe three Volcano patents. In our counterclaim, Volcano sought injunctive relief and monetary damages. Trials on the St. Jude Medical patents and Volcano's patents were held in October 2012.
	On October 12, 2012, the court entered summary judgment for Volcano with respect to one of St. Jude Medical's asserted patents. On October 19, 2012, a jury found in favor of Volcano on the remaining four St. Jude Medical patents, finding that two of the patents were invalid and that Volcano did not infringe two of the patents. On October 22, 2012, Volcano voluntarily dismissed its claims against St. Jude Medical with respect to one of Volcano's patents. On October 25, 2012, a jury found in favor of St. Jude Medical with respect to Volcano's asserted patents. In conjunction with the trial, St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano's 6,976,965 patent (a pressure sensing guide wire patent). Post-trial motions are pending or remain available to the parties in the case. Volcano and St. Jude have stipulated to a confidential damages amount.
	On April 9, 2012, St. Jude Medical, Cardiology Division, Inc., St. Jude Medical Systems AB and St. Jude Medical S.C. filed a sealed complaint in the United States District Court for the District of Delaware alleging that Volcano Corporation infringes United States Patent No. 6,565,514. Trial will be in December 2014 in this case.
	On April 16, 2013, Volcano filed suit in Federal District Court in Delaware against St. Jude Medical, Cardiovascular and Ablation Technologies Division, Inc., St. Jude Medical, Cardiology Division, Inc., St. Jude Medical, U.S. Division, St. Jude Medical S.C. Inc., and St. Jude Medical Systems AB, (collectively, “St. Jude”) for infringement of Volcano's recently issued United States Patent Nos. 8,419,647 and 8,419,648 both entitled “Ultra Miniature Pressure Sensor.” Volcano's complaint accuses St. Jude's PressureWire™ Certus and PressureWire™ Aeris cardiac pressure sensing guide wire products (the “Accused Guide Wires”) and St. Jude's RadiAnalyzer™ Xpress Measurement System, Ilumien™ PCI Optimization System and Quantien™ Integrated FFR Platform, which are used with the Accused Guide Wires, of infringing the patented methods of United States Patent No. 8,419,647. Volcano's complaint also accuses the Accused Guide Wires of infringing the patented device claims of United States Patent No. 8,419,648. A claim construction hearing was held in November 2013, and a ruling adverse to Volcano was issued in January 2014. In February 2014, the parties submitted a joint stipulation to the Court agreeing that the Accused Guide Wires do not infringe Volcano’s patents under the Court’s claim construction ruling. Volcano intends to appeal the claim construction ruling.
	Litigation - CardioSpectra
	On March 27, 2012, Christopher E. Banas, et al., filed a lawsuit against Volcano in federal district court in the Northern District of California, alleging claims for breach of contract, breach of fiduciary duty, and breach of the implied covenant of good faith and fair dealing based on Volcano's acquisition of CardioSpectra in 2007. Specifically, plaintiffs assert that Volcano has failed to comply with the terms and the alleged implied obligations of the Merger Agreement relating to potential milestone payments. CardioSpectra was in the business of developing OCT technology; however, this litigation is separate from the Massachusetts Action.
	On May 14, 2012, Volcano moved to dismiss the complaint in its entirety. The motion sought to dismiss the breach of fiduciary duty and implied covenant claims without leave for amendment, and to dismiss the breach of contract claim with leave to amend. By order dated August 6, 2012, the Court granted Volcano's motion as to all issues with leave to amend. The plaintiffs filed a Second Amended Complaint on August 20, 2012, which included a single claim for breach of the Merger Agreement. In addition, the plaintiffs identified in the Second Amended Complaint are listed as Christopher E. Banas and Paul Castella in their respective capacities as Shareholder Representatives under the Merger Agreement. Volcano answered the Second Amended Complaint on September 4, 2012, and in the same document Volcano asserted several affirmative defenses. A trial date has been scheduled for May 27, 2014 for this matter.
	Litigation - Other
	In November 2012, we became aware through newspaper reports in the Italian media that a former employee of ours was under criminal investigation for an alleged violation of Italian anti-bribery laws. We also learned that Volcano Europe B.V.B.A., our wholly-owned subsidiary, had temporarily been prohibited from establishing new contractual relationships with hospitals that are part of the Italian national health system. Following a court hearing, the temporary prohibition was lifted. The Italian public prosecutor's request that such prohibition be reinstituted was denied. The Italian public prosecutor is alleging that the approximately €5,000 that we paid to an Italian state-employed physician for conducting a training session was paid in an effort to influence the outcome of a clinical trial.
	The Company believes the lawsuits and other matter described above are without merit, and intends to vigorously defend against or prosecute, as applicable, the matters described above.
	We may also be a party to various other claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred and were not material in any period reported. Additionally, we assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Any provisions are reviewed at least quarterly and are adjusted to reflect the impact and status of settlements, rulings, advice of counsel and other information and events pertinent to a particular matter. Based on its experience, the Company also believes that the damage amounts claimed in the lawsuits disclosed above are not a meaningful indicator of the Company's potential liability. At this time, we are not able to predict or estimate the ultimate outcome or range of possible losses relating to the lawsuits, claims or counterclaims described above. However, we believe that the ultimate disposition of these matters, individually and in the aggregate, including the matters discussed above, will not have a material impact on our consolidated results of operations, financial position or cash flows. Our evaluation of the likely impact of these matters could change in the future, as litigation is inherently unpredictable, and unfavorable outcomes and/or defense costs, depending upon the amount and timing, could have a material adverse effect on our results of operations, financial position, or cash flows in future periods.
	Licenses
	We entered into various license agreements with third parties whereby we were granted licenses or rights to certain patents and technology. During the years ended December 31, 2013, 2012 and 2011, royalty expense related to the use of these licensed technology of $2.5 million, $1.5 million, and $1.8 million, respectively, was recorded in cost of revenues. None of the agreements are individually material to our consolidated results of operations or financial position.
	Leases
	We lease our domestic and certain foreign facilities and other equipment under non-cancelable capital and operating lease agreements, which expire at various dates through 2023. In addition to the minimum future lease commitments presented below, the leases generally require that we pay property taxes, insurance, maintenance and repair costs. Certain leases also contain escalation clauses and renewal option clauses calling for increased rents. Where a lease contains an escalation clause or a concession such as a rent holiday, rent expense is recognized using the straight-line method over the term of the lease.
	At December 31, 2013, future minimum lease commitments under non-cancelable leases are as follows (in thousands):
	Year Ending December 31,	Capital		Operating
	2014	$	18	$	8,800
	2015	7		5,808
	2016	5		5,766
	2017	—		5,407
	2018	—		5,222
	Thereafter	—		24,449
	Net minimum lease payments	$	30	$	55,452
	Less:
	Amounts representing interest	—
	Current	—
	Long-term	$	30
	Total rental expense was $7.1 million, $7.0 million, and $6.9 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	Commitments and Other Contractual Obligations
	We have obligations under non-cancelable purchase commitments. The majority of these obligations related to inventory, primarily raw materials. At December 31, 2013, the future minimum payments under these non-cancelable purchase commitments totaled $70.1 million. Approximately $65.8 million of these commitments will require payment in 12 months, of which $63.5 million of these commitments will require payment prior to March 31, 2014. The remaining amount will require payments at various dates through 2016.
	We have commitments to provide funding of $4.6 million to a clinical study conducted by a third-party and at December 31, 2013, we have a remaining obligation of up to $2.1 million. We will be billed as services are performed under the agreement. In addition, we have entered into agreements with other third parties to sponsor clinical studies. Generally, we contract with one or more clinical research sites for a single study and no one agreement is material to our consolidated results of operations or financial condition. We are usually billed as services are performed based on enrollment and are required to make payments over periods ranging from less than one year up to three years. Our actual payments under these agreements will vary based on enrollment.
	Indemnification
	Our supplier, distributor and collaboration agreements generally include certain provisions for indemnification against liabilities if our products are recalled, infringe a third party’s intellectual property rights or cause bodily injury due to alleged defects in our products. In addition, we have agreements with our present and former directors and executive officers indemnifying them against liabilities arising from service in their respective capacities to Volcano. We maintain directors’ and officers’ insurance policies that may limit our exposure to such liabilities. To date, we have not incurred any material costs as a result of such indemnifications and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.
	Sole Source Suppliers
	We rely on a number of sole source suppliers to supply transducers, substrates and processing for our scanners used in our catheters. We do not carry significant inventory of transducers, substrates or scanner subassemblies. If we had to change suppliers, we expect that it would take 6 to 24 months to identify appropriate suppliers, complete design work and undertake the necessary inspections and testing before the new transducers and substrates would be available. We are not parties to supply agreements with these suppliers but instead use purchase orders as needed.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Common Stock
	We are authorized to issue 250,000,000 shares of common stock at $0.001 par value per share.
	Stockholders Rights Plan
	In May 2006, our stockholders approved a stockholder rights plan and a classified board of directors with staggered terms of election. Pursuant to the stockholder rights plan, we declared and paid a dividend of one right for each share of common stock. Unless redeemed prior to the time the rights are exercised, upon the occurrence of certain events, the rights will entitle the holders to receive shares of our preferred stock, or shares of an acquiring entity.
	Our increase of the authorized shares to 250,000,000 shares, the stockholder rights plan and the classified board of directors became effective upon the consummation of our initial public offering.
	Warrants
	In connection with our convertible debt offerings discussed in Note 3 “Financial Statement Details — Debt”, at December 31, 2013, we had warrants for approximately 14.0 million shares of common stock that are exercisable at a price of $37.59 per share, subject to certain adjustments, in equal installments for a period of 120 trading days beginning on March 15, 2018, and warrants for approximately 850,000 shares of common stock that are exercisable at a price of $34.875 per share, subject to certain adjustments, in equal installments for a period of 50 trading days beginning on December 1, 2015.
	Preferred Stock
	We are authorized to issue 10,000,000 shares of undesignated preferred stock at $0.001 par value per share. The Board of Directors may determine the rights, preferences, privileges, qualifications, limitations and restrictions granted or imposed upon any series of preferred stock. As of December 31, 2013 and 2012, no preferred stock was outstanding.
	Share Repurchase Program
	On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received 3,557,137 shares of our common stock. The final number of shares to be repurchased by us under this ASR will be determined at the completion of the ASR program and will be based generally on the daily volume-weighted average share price of our common stock during a period of up to approximately four months, less an agreed-to discount. At settlement, we may receive additional shares of common stock from the counterparty, or under certain circumstances, may be required to deliver shares of common stock or remit a settlement amount in cash, at our option. All common shares repurchased under the ASR program were retired in December 2013.
	All of our repurchases were treated as effective retirements of the purchased shares and therefore reduced reported shares issued and outstanding by the number of shares repurchased. In addition, the Company recorded the excess of the purchase price over the par value of the common stock as a reduction to additional paid-in capital.
	Equity Compensation Plans
	In October 2005, our stockholders approved the 2005 Equity Compensation Plan, or the 2005 Plan. Upon adoption of the 2005 Plan, issuance of stock awards under our 2000 Long Term Incentive Plan ceased.
	On July 29, 2009, our stockholders approved an amendment and restatement of our 2005 Plan and the plan was renamed to the Amended and Restated 2005 Equity Compensation Plan, or the 2005 Amended Plan. The 2005 Amended Plan was further amended by our Board of Directors in February 2011, March 2011 and February 2013, which amendments were approved by our shareholders in May 2011 and May 2013. The 2005 Amended Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or RSU, performance stock awards, performance cash awards and other stock awards. The 2005 Amended Plan does not allow repricing of stock options without express approval of the stockholders and clarifies that a change in control must actually occur in order for change in control benefits to be realized. Our 2005 Amended Plan provides for an aggregate of 21,572,558 shares of our common stock that may be issued or transferred to our employees, non-employee directors and consultants, including increases of 2,050,000, 2,500,000 and 5,360,000 shares which were approved by our stockholders on July 29, 2009, May 2, 2011 and May 15, 2013, respectively. Commencing July 29, 2009, the number of shares of common stock available for issuance under the 2005 Amended Plan was reduced by one share for each share of stock issued pursuant to a stock option or a stock appreciation right and one and sixty-three hundredths (1.63) shares for each share of common stock issued pursuant to a restricted stock award, restricted stock unit, or RSU, award, performance stock award or other stock award. On May 2, 2011, the plan was amended again and the number of shares of common stock available for issuance under the 2005 Amended Plan was reduced by one share for each share of stock issued pursuant to a stock option or a stock appreciation right and two and twelve hundredths (2.12) shares for each share of common stock issued pursuant to a restricted stock award, RSU, award, performance stock award or other stock award. Shares net exercised or retained to cover a participant’s minimum tax withholding obligations are not available for issuance under the 2005 Amended Plan.
	At December 31, 2013, we have granted stock options and RSUs under the 2005 Amended Plan. Stock options previously granted under the 2000 Long Term Incentive Plan and the 2005 Plan that are canceled or expired will increase the shares available for grant under the 2005 Amended Plan. At December 31, 2013, 6,793,238 shares remained available to grant under the 2005 Amended Plan.
	Stock Option Activity
	The maximum term of options granted under the 2005 Amended Plan is seven years. For an initial grant to an employee, 25% of the options generally vest on the first anniversary of the original grant date, with the balance vesting monthly over the remaining three years. For subsequent grants to an employee, the options generally vest monthly over a four-year term. We may grant options that are exercisable immediately regardless of the vesting status of the option with us retaining a right to repurchase exercised unvested shares at the original exercise price of the option. Recipients of stock options shall be eligible to purchase shares of our common stock at an exercise price no less than the estimated fair market value of such stock on the date of grant.
	Stock option activity for the year ended December 31, 2013 is as follows:
		Stock			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic Value
					Exercise				Remaining		(in thousands)
					Price				Contractual Life
									(in years)
	Outstanding at December 31, 2012	3,596,135			$	17.82
	Granted	1,009,162			23.11
	Exercised	(574,194	)		11.12
	Forfeited or expired	(265,920	)		21.33
	Outstanding at December 31, 2013	3,765,183			$	20.01			3.43		$	13,734
	Exercisable at December 31, 2013	2,717,951			$	18.27			2.24		$	13,125
	Vested and expected to vest at December 31, 2013	3,663,644			$	19.89			3.36		$	13,689
	Options outstanding at December 31, 2013 are summarized as follows:
		Options Outstanding									Options Vested
		Number			Weighted-		Weighted-				Number		Weighted-
		Outstanding			Average		Average				Vested Outstanding		Average
					Remaining		Exercise Price						Exercise Price
					Contractual Life
					(in years)
	$0.33–$12.63	385,031			1.36		$	8.5			384,907		$	8.51
	$12.96–$13.77	381,232			1.86		13.52				381,232		13.52
	$14.00–$17.27	402,452			2.85		15.6				364,426		15.47
	$17.67–$18.90	129,017			4.72		18.49				41,128		18.4
	$19.07	542,674			3.1		19.07				518,512		19.07
	$19.11-$21.06	384,991			1.06		19.49				345,510		19.35
	$21.07–$25.00	309,224			4.81		22.41				128,311		22.53
	$25.40	484,791			6.15		25.4				88,912		25.4
	$25.57-$28.63	386,569			4.08		27.41				292,373		27.35
	$28.70-$32.52	359,202			5.01		29.43				172,433		29.57
	$0.33–$32.52	3,765,183			3.43		20.01				2,717,744		18.27
	Non-vested stock option activity for the year ended at December 31, 2013 is as follows:
		Non-vested			Weighted-Average
		Stock			Grant Date Fair
		Options			Value
	Outstanding at December 31, 2012	784,820			$	7.63
	Granted	1,009,162			7.37
	Vested	(557,180	)		8.37
	Forfeited or expired	(189,570	)		12.32
	Outstanding at December 31, 2013	1,047,232			6.14
	The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2013, 2012 and 2011 was $7.45, $10.78 and $11.34, respectively.
	Restricted Stock Unit Activity
	The RSU includes time-vested RSU and performance-based RSU. The time-vested RSU entitle the holder to shares of common stock as the units vest in equal annual installments over a four-year period.
	Starting from 2012, we granted performance RSU to officers and key employees under the terms of the 2005 Amended Plan to align key management and senior leadership with stockholders' interests and to retain key employees. The performance RSU granted for years 2012 and 2013 generally vest over three years, with one third vesting on the date of certification of achievement of the pre-determined performance goals, and the remaining two thirds vesting evenly on the following two year-end dates (December 31), contingent upon the recipient’s continued service to the Company on each such date.
On February 19, 2013, the Compensation Committee certified the actual performance achievement of participants in the 2012 Long-Term Incentive Plan, or the 2012 program. Based upon the achievement of specific performance goals outlined in the 2012 Program, participants were granted approximately 58,000 RSUs under the 2012 Program. One third of the RSUs under the 2012 Program vested on the certification date, one third vested on December 31, 2013 and the remaining one third vests on December 31, 2014, contingent upon the recipient's continued service to the Company.
On February 12, 2014, the Compensation Committee certified the actual performance achievement of participants in the 2013 Long-Term Incentive Plan, or the 2013 program. Based upon the achievement of specific performance goals outlined in the 2013 Program, participants were granted approximately 73,000 RSUs under the 2013 Program. One third of the RSUs under the 2013 Program vested on the certification date and the remaining two thirds will vest evenly on each of December 31, 2014 and December 31, 2015, contingent upon the recipient's continued service to the Company.
RSU activity, including time-vested RSU and performance RSU, for the year ended December 31, 2013 is as follows:
	Restricted
	Stock Units
Outstanding at December 31, 2012	918,367
Granted	526,624
Vested	(372,920	)
Forfeited or expired	(69,690	)
Outstanding at December 31, 2013	1,002,381
The weighted-average grant-date fair value of RSU granted, including time-vested RSU and performance RSU, during the years ended December 31, 2013, 2012 and 2011 was $24.30, $27.87 and $26.62, respectively.
During the year ended December 31, 2013, we released 372,920 shares of common stock based on the vesting terms of certain RSU agreements.
There was no common stock held in treasury as of December 31, 2013 and 2012.
Employee Stock Purchase Plan Activity
In June 2007, our stockholders approved the adoption of our 2007 Employee Stock Purchase Plan, or Purchase Plan. The Purchase Plan provides eligible employees the opportunity to purchase shares of our common stock at the lower of up to 85% of the fair market value on the first or last day of the applicable offering period, by having withheld from their salary an amount up to 15% of their compensation, without paying brokerage fees or commissions on purchases. Our Purchase Plan is deemed to be compensatory, and therefore, Purchase Plan expense has been included in our consolidated statements of operations for the years ended December 31, 2013, 2012 and 2011. We pay for the administrative expenses of the Purchase Plan. No employee may purchase more than $25,000 worth of common stock (calculated at the time the purchase right is granted) in any calendar year, nor may purchase more than 750 shares in any six-month purchase period.
Commencing January 1, 2008, common stock reserved for issuance under the Purchase Plan automatically increases by the lower of 1/2% of our outstanding common stock or 600,000 shares on the first day of January of each year. In November 2012 and 2011, the Board of Directors exercised its right not to increase the number of shares of common stock available for issuance under the Purchase Plan that was scheduled to occur on January 1, 2013 and January 1, 2012, respectively. As a result, at December 31, 2013, the number of shares of common stock reserved for issuance under the Purchase Plan remained at 1,100,000 shares and 55,911 shares of common stock were available for issuance under the Purchase Plan. According to the terms of the Purchase Plan, the number of shares of common stock available for issuance under the Purchase Plan was automatically increased by 600,000 shares on January 1, 2014.
During the years ended December 31, 2013, 2012 and 2011, 195,469, 163,818, and 171,251 shares, respectively, were purchased at an average per share price of $18.30, $23.69, and $20.75, respectively.
Fair Value Assumptions
The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
	2013				2012				2011
Risk-free interest rate	0.7		%		0.8		%		1.9		%
Expected life (years)	4.2				4.1				4.4
Estimated volatility	39.2		%		46.9		%		47.4		%
Expected dividends	None				None				None
Weighted-average grant date fair value	$	7.45			$	10.78			$	11.34
The risk-free interest rate for periods within the contractual life of the stock option is based on the implied yield available on U.S. Treasury constant maturity securities with the same or substantially equivalent remaining terms at the time of grant. We use our historical stock option exercise experience to estimate the expected term of our stock options. We use volatility of our own common stock in determining the grant date fair value. We use a zero value of the expected dividend value factor since we have not declared any dividends in the past and we do not anticipate declaring any dividends in the foreseeable future.
The first offering period under the Purchase Plan commenced in September 2007. The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
	Years Ended December 31,
	2013				2012				2011
Risk-free interest rate	0.1		%		0.1		%		0.1		%
Expected life (years)	0.5				0.5				0.5
Estimated volatility	29.6		%		38.2		%		36.4		%
Expected dividends	None				None				None
Fair value of purchase right	$	5.3			$	7.31			$	6.76
The computation of the expected volatility assumption used in the Black-Scholes model for purchase rights is based on the trading history of our common stock. The expected life assumption is based on the six-month term of each offering period. The risk-free interest rate is based on the U.S. Treasury constant maturity securities with the same or substantially equivalent remaining term in effect at the beginning of the offering period. We use a zero value for the expected dividend value factor since we have not declared any dividends in the past and we do not anticipate declaring any dividends in the foreseeable future.
Stock-Based Compensation Expense
With the exception of performance-based RSUs, stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the entire award, which is generally the vesting period.
We recognize the estimated compensation cost of performance-based RSUs, net of estimated forfeitures. The performance-based RSUs are earned upon attainment of identified performance goals, some of which contain discretionary metrics. As such, these award are re-valued based on our traded stock price at the end of each reporting period. If the discretion is removed, the award will be classified as a fixed equity award. The fair value of the awards will be based on the measurement date, which is the date the award becomes fixed. Expense is recognized on a straight-line basis over the requisite service period for each vesting tranche of the award.
The following table sets forth stock-based compensation expense included in our consolidated statements of operations (in thousands):
	Years Ended December 31,
	2013				2012				2011
Cost of revenues	$	748			$	715			$	459
Selling, general and administrative	13,608				12,666				10,850
Research and development	1,728				1,698				1,682
	$	16,084			$	15,079			$	12,991
Included in our stock-based compensation expense is $0, $0 and $115,000 of stock-based compensation expense related to non-employees in the years ended December 31, 2013, 2012 and 2011, respectively. In the years ended December 31, 2013, 2012 and 2011, we recorded $1.0 million, $1.2 million and $1.0 million, respectively, of stock-based compensation expense related to the Purchase Plan. At December 31, 2013 and 2012, there was $219,000 and $258,000, respectively, of total stock-based compensation cost capitalized in inventories.
We estimate forfeitures and only recognize expense for those shares expected to vest. Our estimated forfeiture rates in the years ended December 31, 2013, 2012 and 2011 are based on our historical forfeiture experience.
Stock option excess tax benefits of $0, $35,000 and $165,000 were credited to additional paid-in-capital during the year ended December 31, 2013, 2012 and 2011.
The total intrinsic value of stock options exercised during the year ended December 31, 2013, 2012 and 2011 was $6.3 million, $12.2 million and $14.7 million, respectively, and represents the difference between the exercise price of the option and the fair value of our common stock on the dates exercised. The total grant-date fair value of stock options vested during the year ended December 31, 2013, 2012 and 2011 was $4.7 million, $5.4 million and $5.6 million, respectively.
At December 31, 2013, there was $8.3 million, $16.5 million, and $182,000 of total unrecognized employee compensation cost related to stock options, RSUs and the Purchase Plan, respectively, which is expected to be recognized over a weighted average of 2.60 years, 2.38 years, and 0.20 years, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The income tax expense (benefit) is as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	—		$	—		$	—
	State	224			207			498
	Foreign	2,004			2,469			2,283
		2,228			2,676			2,781
	Deferred:
	Federal	(20,903		)	3,940			(19,739		)
	State	1,878			182			(2,248		)
	Foreign	467			(5,131		)	(784		)
		(18,558		)	(1,009		)	(22,771		)
	Income tax expense (benefit)	$	(16,330	)	$	1,667		$	(19,990	)
	Losses before income taxes relating to non-U.S. operations were $794,000, $43,000 and $133,000 in the years ended December 31, 2013, 2012 and 2011, respectively.
	The income tax expense (benefit) in the accompanying consolidated statements of operations differ from the expense (benefit) calculated by applying the U.S. federal statutory income tax rate of 35% to income (loss) before income taxes expense (benefit) due to the following (in thousands):
		Years Ended December 31,
		2013			2012			2011
	U.S. federal statutory income tax expense (benefit)	$	(17,791	)	$	3,391		$	6,339
	State income tax expense (benefit), net of federal income tax expense	(1,470		)	296			(1,800		)
	Valuation allowance	3,777			(4,917		)	(25,840		)
	Foreign tax rate differential	(2,997		)	(342		)	156
	Credits	(1,935		)	—			(1,405		)
	Acquisition-related items	1,409			559			—
	Other	2,677			2,680			2,560
	Income tax expense (benefit)	$	(16,330	)	$	1,667		$	(19,990	)
	The components of our deferred tax assets are as follows (in thousands):
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryovers	$	40,071		$	28,431
	Tax credit carryovers	12,343			9,704
	Accruals and deferred revenue	12,979			7,355
	Stock based compensation	10,310			9,021
	Original issue discount	—			379
	Total deferred tax assets	75,703			54,890
	Deferred tax liabilities:
	Depreciation and amortization	(18,361		)	(20,557		)
	Deferred tax assets:	57,342			34,333
	Valuation allowance	(12,601		)	(6,309		)
	Net deferred tax assets (liabilities)	$	44,741		$	28,024
	The net change in the total valuation allowance was an increase of $6.3 million in 2013. Of this amount, $3.8 million was recorded as reduction in the income tax benefit and $2.5 million was recorded as a reduction to goodwill.
	In February 2009, the California 2009-2010 budget was enacted into law, allowing companies to elect, for income tax purposes, to apply a single sales factor apportionment for years beginning after January 1, 2011. Further, Proposition 39 was passed on November 6, 2012, requiring multi-state business to apportion income to California using a single-sales factor method of apportionment for taxable years beginning on or after January 1, 2013. Based upon our election in 2011 and change in law in 2012, we were maintaining a valuation allowance to offset a portion of our California deferred tax assets as realization of such assets did not meet the more-likely-than-not threshold required under accounting guidelines. During 2013, we reevaluated our California deferred tax asset, and other state deferred tax assets, in light of our current and forecasted operations, and we concluded that it was more likely than not that we would not be able to realize the remaining California deferred tax assets. Therefore, during 2013, we recognized an additional $3.8 million of valuation allowance against our state deferred tax assets as discussed above.
	In the case of an acquired entity, we record a valuation allowance through purchase accounting as an adjustment to goodwill at the acquisition date if it is more likely than not that all or a portion of the acquired deferred tax assets will not be realized in the future. To the extent there is a change in the valuation allowance in the case of an acquired entity during the measurement period, adjustments were recorded through goodwill provided that such change relates to new information about the facts and circumstances that existed on the acquisition date. In 2013, we completed our purchase accounting analysis regarding two 2012 acquisitions, and concluded that it was more likely than not that an additional $1.4 million of foreign deferred tax assets related to the Sync-Rx, Ltd. acquisition and $1.1 million of acquired state deferred tax assets related to Crux Biomedical, Inc. acquisition are not realizable. This resulted in an increase in valuation allowance against these deferred tax assets, which was recorded as a reduction to goodwill as discussed above.
	In 2013, the Company incurred a net loss, and is not projecting a return to profitability in 2014. As of December 31, 2013, management has evaluated the recoverability of its Federal deferred tax assets, including factors such as a consideration of forecasted operating results, in-process changes in its manufacturing processes, potential tax planning strategies, as well as the period of time that will transpire before the underlying deferred tax assets will expire. Based on this evaluation, management has concluded that it is more likely than not that the underlying deferred tax assets will be utilized prior to their expiration, and therefore continues to believe that the Federal deferred tax assets will be recovered.
	The net change in the total valuation allowance was a decrease of $3.1 million in 2012. At December 31, 2012 , we concluded that it is more likely than not that the benefits of a portion of our foreign deferred income tax assets will be realized. We expect that our foreign operations in the respective jurisdictions will generate sufficient taxable income in future periods to realize the tax benefit associated with the related deferred tax asset. Accordingly,we reversed the valuation allowance on the foreign gross deferred income tax assets.
	At December 31, 2013 and 2012, valuation allowances remained within certain U.S. state jurisdictions and selected international jurisdictions to offset deferred tax assets, as realization of such assets is not more likely than not.
	During 2012, we also acquired Sync-Rx, an Israeli corporation. Total pre-acquisition net operating loss carryforwards were approximately $8.4 million. It is expected that the net operating loss carryforward recorded as a deferred tax asset will not be utilized.
	Internal Revenue Code Section 382 places a limitation on the utilization of U.S. and state net operating losses and credit carryforwards when an ownership change, as defined by the tax law occurs. Generally, this occurs when a greater than 50% change in ownership occurs. During 2012, we acquired a greater than 50% ownership in Crux Biomedical, a U.S. corporation. We analyzed our ability to use the NOL's acquired from Crux under Section 382 limitations and concluded that federal and state net operating losses of $30.6 million and $30.8 million were not limited.
	Pursuant to Internal Revenue Code Section 382, use of net operating loss carry forwards related to prior acquisitions of approximately $20.1 million may be limited. These carry forwards will expire if we are unable to generate sufficient taxable income within the carry forward period. The Company is assessing whether any additional limitations are required.
	At December 31, 2013, we have federal and state net operating loss carry forwards of approximately $133.6 million and $80.4 million, respectively. The federal and state net operating loss carry forwards begin to expire in 2021 and 2014, respectively, unless previously utilized. In addition, we have federal and state research and experimentation tax credit carry forwards of approximately $8.7 million and $10.2 million, respectively. The federal credits begin to expire in 2023. The California state credits carry forward indefinitely. The Massachusetts state credit carry forwards begin to expire in 2019. Foreign net operating losses are approximately $20.9 million and carry forward indefinitely.
	U.S. income and foreign withholding taxes have not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The Company has no intent to repatriate such earnings. The amount of the temporary difference is approximately $16.7 million as of December 31, 2013. The amount of unrecognized deferred tax liability related to the temporary difference is estimated to be no more than $5.9 million as of December 31, 2013.
	As a result of certain realization requirements of ASC 718, the table of deferred tax assets shown above does not include certain deferred tax assets at December 31, 2013 and 2012 that arose directly from tax deductions related to equity compensation in excess of compensation recognized for financial reporting. Equity will be increased by approximately $20.1 million if and when such deferred tax assets are ultimately realized. We use the with-and-without approach ignoring indirect effects for purposes of determining when excess tax benefits have been realized. Stock option excess tax benefits of $0 and $35,000 were credited to additional paid-in-capital during the years ended December 31, 2013 and 2012.
	During the year ended December 31, 2012, we repurchased $90.0 million of our 2.875% convertible notes due 2015 and recognized a loss for tax purposes, which is the difference between the carrying value of the liability for tax purposes compared to the repurchase price. In addition, the deferred tax asset related to the repurchased call option and deferred tax liability related to the warrant sold were recognized. The recognition of the loss for tax purposes (to the extent it related to equity transactions) and the related deferred tax asset and liability totaling $2.5 million was credited to additional paid in capital during the year ended December 31, 2012. The reversal of the valuation allowance related to our convertible senior notes of $1.7 million was credited to additional paid in capital during the year ended December 31, 2012.
	At December 31, 2013, the total amount of gross unrecognized tax benefits, including interest and penalties, was approximately $1.1 million. If recognized, these benefits would affect our effective tax rate. The aggregate change in the balances of these benefits is as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	1,071		$	1,065		$	878
	Increases related to tax positions taken during the current year	53			46			205
	Increases (decreases) related to tax positions taken during a prior period	(42		)	(40		)	(18		)
	Balance at end of year	$	1,082		$	1,071		$	1,065
	We accrue interest and penalties on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in our consolidated statements of operations. The amounts recognized for interest and penalties during the years ended December 31, 2013, 2012 and 2011 were $53,000, $46,000, and $34,000, respectively.
We are open for audit by the U.S. Internal Revenue Service and state tax jurisdictions from our inception in 2000 through 2013. We were audited by the Belgian tax authorities for the 2005 and 2006 years. There were no significant adjustments as a result of this audit. We continue to be open for audit by Belgium and various European tax jurisdictions from the inception of Volcano Europe in 2003 through 2013, and by South Africa from the inception of Volcano South Africa in 2008 through 2013. We were audited by the Japanese tax authorities for the 2005 through 2007 years. There were no significant adjustments as a result of this audit. We continue to be open for audit by the Japanese tax authorities from the inception of Volcano Japan in 2004 through 2013. We continue to be open for audit by the Israeli tax authorities from the inception of Sync-Rx in 2005 through 2013.

Segment_And_Geographic_Informa

Segment And Geographic Information	12 Months Ended
	Dec. 31, 2013
Segment And Geographic Information [Abstract]	'
Segment And Geographic Information	'
	Segment and Geographic Information
	Our chief operating decision-maker reviews financial information presented on a consolidated basis, accompanied by disaggregated information about segment revenues by product and geographic region for purposes of making operating decisions and assessing financial performance. We have two reporting segments, the first being the medical segment which include the manufacture, sale, discovery, development and commercialization of products for the diagnosis of atherosclerosis in the coronary arteries and peripheral vascular system. In addition we have an industrial segment which includes the discovery, development, manufacture and sale of micro-optical spectrometers and optical channel monitors to telecommunications and other industrial companies.
	We do not assess the performance of our segments on other measures of income or expense, such as depreciation and amortization, operating income or net income (loss). We do not produce reports for, or measure the performance of, our segments on any asset-based metrics. Therefore, segment information is presented only for revenues by product.
	The following table sets forth our revenues by segment and product (in thousands):
			Years Ended December 31,						Percentage Change
			2013		2012		2011		2012 to 2013		2011 to 2012
	Medical segment:
	Consoles		$	43,602	$	40,687	$	40,954	7.2	%	(0.7	)%
	Single-procedure disposables:
	IVUS		194,225		205,843		200,970		(5.6	)%	2.4	%
	FM		112,643		94,885		67,082		18.7	%	41.4	%
	Other		34,775		29,716		23,530		17	%	26.3	%
	Sub-total medical segment		385,245		371,131		332,536		3.8	%	11.6	%
	Industrial segment		8,433		10,735		11,010		(21.4	)%	(2.5	)%
			$	393,678	$	381,866	$	343,546	3.1	%	11.2	%
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands) and the changes in revenues in the specified periods expressed as percentages:
			Years Ended December 31,						Percentage Change
			2013		2012		2011		2012 to 2013		2011 to 2012
	Revenues (1):
	United States		$	189,748	$	177,992	$	157,412	6.6	%	13.1	%
	Japan		109,492		123,558		105,892		(11.4	)%	16.7	%
	Europe, the Middle East and Africa		71,018		57,913		60,249		22.6	%	(3.9	)%
	Rest of world		23,420		22,403		19,993		4.5	%	12.1	%
			$	393,678	$	381,866	$	343,546	3.1	%	11.2	%
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.
	At December 31, 2013, approximately 49% of our long-lived assets, excluding financial assets, are located in the U.S., approximately 39% are located in Costa Rica, 8% are located in Japan, and approximately 4% are located in our remaining geographies. At December 31, 2012, approximately 42% of our long-lived assets, excluding financial assets, were located in the U.S., approximately 42% were located in Costa Rica, approximately 12% were located in Japan, and approximately 4% were located in our remaining geographies.
	At December 31, 2013 and 2012, goodwill of $55.1 million and $51.6 million, respectively, has been allocated entirely to our medical segment.

Related_Party

Related Party	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party	'
	Related Party
	In November 2013, we purchased shares of preferred stock of a private company, for an aggregate purchase price of approximately $15.0 million in a preferred stock financing transaction pursuant to which the private company raised an aggregate of $20.0 million. The investment was accounted for under the cost method of accounting and is recorded as other non-current assets in our consolidated balance sheets.
	John Onopchenko, our Executive Vice President of Strategy, Business Development and Integration, owns 33.33% of Synergy Life Science Partners, L.P., or Synergy, which, immediately prior to the financing transaction, held approximately 14% of the private company's outstanding capital stock on a fully-diluted basis. In addition, Synergy invested approximately $884,000 in the financing transaction. Immediately following the financing transaction, we held approximately 13% of the private company's outstanding capital stock on a fully-diluted basis and Synergy held approximately 12% of the private company's outstanding capital stock on a fully-diluted basis.

Employee_Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2013
Employee Benefits and Share-based Compensation [Abstract]	'
Employee Benefits	'
	Employee Benefits
	Defined Contribution Plans
	We have a defined contribution 401(k) plan for our U.S. employees who are at least 21 years of age. Employees are eligible to participate in the plan beginning on the first day of the month following their first date of hire. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation or as a fixed amount per pay period. During the years ended December 31, 2013, 2012 and 2011, we have made discretionary contributions equal to 25% of participant contributions up to a maximum of 6% of the participant’s annual salary totaling $1.1 million, $1.0 million, and $928,000, respectively.
	We also sponsor additional defined contribution plans for most of our European employees. Contributions under all such plans were $707,000, $481,000 and $412,000 in the years ended December 31, 2013, 2012 and 2011, respectively.

Quarterly_Information_Unaudite

Quarterly Information (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Information (Unaudited)	'
	Quarterly Information (Unaudited)
	The following table sets forth our unaudited quarterly summary consolidated statements of operations in each of the quarters for the years ended December 31, 2013 and 2012. The information for each of these quarters is unaudited and has been prepared on the same basis as our consolidated financial statements. This data should be read in conjunction with our consolidated financial statements and related notes. These operating results may not be indicative of results to be expected for any future period (amounts in thousands, except per share data).
			Quarter Ended (unaudited)												Year ended
	2013		March 31			June 30			September 30			December 31 (2)			December 31 (1)
	Revenue		$	93,231		$	101,344		$	95,809		$	103,294		$	393,678
	Gross profit		60,104			65,305			62,351			62,616			250,376
	Operating loss		(1,788		)	(114		)	(6,440		)	(21,561		)	(29,903		)
	Net loss		(3,161		)	(2,388		)	(8,456		)	(20,489		)	(34,494		)
	Net loss per share:
	Basic		$	(0.06	)	$	(0.04	)	$	(0.15	)	$	(0.38	)	$	(0.63	)
	Diluted		$	(0.06	)	$	(0.04	)	$	(0.15	)	$	(0.38	)	$	(0.63	)
	Includes the following stock-based compensation expense:
	Cost of revenues		$	192		194			196			$	166		$	748
	Selling, general and administrative		2,981			3,579			3,592			3,456			13,608
	Research and development		425			476			462			365			1,728
			Quarter Ended (unaudited)												Year ended
	2012		March 31			June 30			September 30			December 31 (3)			December 31
	Revenue		$	90,360		$	95,373		$	93,656		$	102,477		$	381,866
	Gross profit		60,787			63,397			60,408			68,359			252,951
	Operating income		1,921			6,639			5,967			5,063			19,590
	Net income		271			3,299			1,975			2,477			8,022
	Net income per share:
	Basic		$	0.01		$	0.06		$	0.04		$	0.05		$	0.15
	Diluted		$	—		$	0.06		$	0.04		$	0.04		$	0.15
	Includes the following stock-based compensation expense:
	Cost of revenues		$	152		162			202			$	199		$	715
	Selling, general and administrative		2,996			3,278			3,331			3,061			12,666
	Research and development		469			435			403			391			1,698
	-1	During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter.
	-2	During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million.
	In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.
	-3	During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses.
	In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

Organization_And_Summary_Of_Si1

Organization And Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Our Company	'
	Our Company
	We design, develop, manufacture and commercialize a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. We believe that these products enhance the diagnosis and treatment of coronary and peripheral vascular disease by improving the efficiency and efficacy of existing diagnostic angiograms and percutaneous coronary interventional, or PCI, and endovascular procedures in the coronary arteries or peripheral arteries and veins. We are facilitating the adoption of functional PCI, in which our FFR technology is used to help determine whether or not a stent is necessary, and IVUS is used as an adjunct to angiography to guide stent placement and optimization. We market our products to physicians, nurses and technicians who perform a variety of endovascular based coronary and peripheral interventional procedures in hospitals and to other personnel who make purchasing decisions on behalf of hospitals.
	Our products consist of consoles that are marketed as stand-alone units or as units that can be integrated into a variety of hospital-based interventional surgical suites called catheterization laboratories, or cath labs. We have developed customized cath lab versions of these consoles and are developing additional functionality options as part of our cath lab integration initiative. Our consoles have been designed to serve as a multi-modality platform for our phased array and rotational IVUS catheters, FFR pressure and flow wires and image-guided therapy catheters, such as the Pioneer Plus reentry device acquired from Medtronic, Inc., or Medtronic, on August 30, 2013.
	Our IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters, and additional functionality options such as ChromaFlo® stent apposition analysis. Our FFR offerings can be accessed through our multi-modality platforms, and we also provide FFR-only consoles. Our FFR disposables are single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque's physiological impact on blood flow and pressure. We have developed additional offerings for integration into the platform, including adenosine-free Instant Wave-Free Ratio FFR, or iFR®. We are currently developing high resolution Focal Acoustic Computed Tomography, or FACT, catheters, co-registration with IVUS and an IVUS-guided Crux VCF system featuring our inferior vena cava, or IVC, filter. Our Valet microcatheter, Visions® PV .035 catheter and Eagle Eye® Platinum ST short tip catheter, or EEP, products received 510(k) clearance and CE Mark approval in 2012 and their commercial launch occurred in 2013. In addition, we initiated the commercial launch of our Verrata pressure guide wire, our fifth new pressure wire in five years, during 2013.
	Through Axsun Technologies, Inc., or Axsun, one of our wholly-owned subsidiaries, we also develop and manufacture optical monitors for the telecommunications industry, laser and non-laser light sources, optical engines used in medical optical coherence topography, or OCT, imaging systems and advanced photonic components and sub-systems used in spectroscopy and other industrial applications. We believe Axsun's proprietary OCT technology will provide us competitive advantages in the invasive imaging sector, as well as for applications in ophthalmology and dental.
Basis of Presentation and Principles of Consolidation	'
	Basis of Presentation and Principles of Consolidation
	Our consolidated financial statements include the accounts of Volcano Corporation and its wholly–owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Certain amounts have been reclassified to conform to the current year presentation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are used for, but not limited to, the allowance for doubtful accounts, inventory reserves, depreciation and amortization, intangible assets, sales returns, deferred revenues, business combinations, warranty costs, certain accruals, long-lived asset impairment calculations, deferred tax assets and liabilities, contingent consideration and other contingencies. Actual results could differ materially from the estimates and assumptions we use in the preparation of our consolidated financial statements.
Foreign Currency Translation	'
	Foreign Currency Translation
	The Company's reporting currency is the U.S. dollar. The yen and the euro are the functional currencies of our subsidiaries, Volcano Japan and Volcano Europe, respectively, as they are the primary currencies within the economic environments in which Volcano Japan and Volcano Europe operate. Assets and liabilities of their operations are translated into U.S. dollars at period-end exchange rates, and revenues and expenses are translated into U.S. dollars at average exchange rates in effect during each reporting period. Adjustments resulting from the translation are reported in other comprehensive income or loss.
	Exchange rate fluctuations resulting from the remeasurement of the inter-company balances between Volcano Corporation, our U.S. entity, and Volcano Japan, and Volcano Corporation and Volcano Europe, and other non-U.S. dollar denominated balances into U.S. dollars are recorded as foreign currency transaction gains or losses and are included in exchange rate gain (loss) in the consolidated statements of operations.
	The functional currency of our other foreign subsidiaries is the U.S. dollar since they operate as an extension of the Company’s U.S. operations.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash primarily consisted of cash in bank deposits. Cash equivalents consist of money market funds and other highly liquid investments with an original maturity of three months or less on the date of acquisition.
Available-for-Sale Investments	'
	Available-for-Sale Investments
	Our short-term available-for-sale investments consist of highly liquid financial investments with maturities of one year or less that were not previously classified as cash equivalents. Our long-term available-for-sale investments consist of investments with maturities over one year. All investments are classified as available-for-sale and are recorded at market value using the specific identification method. Unrealized gains or losses are reflected in other comprehensive income or loss.
Financial Instruments	'
	Financial Instruments
	Financial instruments included in our financial statements are comprised of cash and cash equivalents, short-term and long-term available-for-sale investments, accounts receivable, derivative financial instruments, accounts payable, certain accrued liabilities, convertible senior notes, contingent consideration and other contingent liabilities. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term nature of those instruments. Our available-for-sale investments are carried at quoted fair market value with unrealized gains and losses reported in stockholders' equity as a component of accumulated other comprehensive income (loss). The fair value of our convertible senior notes is influenced by interest rates, our stock price, and stock price volatility, which is determined by market trading.
	We record derivative financial instruments as either assets or liabilities in our consolidated balance sheets and measure them at fair value in accordance with ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes.
	Certain of the derivative instruments we use to mitigate our exchange rate exposure are not designated for hedge accounting treatment, and as a result, changes in their fair values are recorded in exchange rate gain (loss) in the consolidated statement of operations. Changes in the fair value of cash flow hedges, excluding time value of the hedges which is recorded as interest expense, are reported as a component of accumulated other comprehensive income (loss), or AOCI, within stockholders' equity. Once the underlying hedged transaction occurs, we de-designate the derivative, cease to apply hedge accounting treatment to the transaction, reclassify the gain or loss recorded to date from AOCI into cost of goods sold, and record any further gains or losses to exchange rate gain (loss). We evaluate hedge effectiveness at the inception of the hedge and on an ongoing basis. To the extent we experience ineffectiveness in our hedges, the gains or losses accumulated in other comprehensive income associated with the ineffective portion of the hedge are reclassified immediately into exchange rate gain (loss). We adjust the level and use of derivatives as soon as practicable after learning that an exposure has changed. We review all exposures on derivative positions on a regular basis. See "Note 3 – Financial Statement Details - Derivative Financial Instruments" for additional information.
	We recognize contingent purchase price consideration at fair value at acquisition date. The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period. Therefore, any changes in the fair value will impact our earnings in such reporting period, thereby resulting in potential variability in our earnings until such contingencies are resolved.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments which subject us to potential credit risk consist of our cash and cash equivalents, short-term and long-term available-for-sale investments, derivative financial instruments, and trade accounts receivable.
	We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and holding investments with maturities that maintain safety and liquidity. We place our cash and cash equivalents with high credit quality financial institutions. Deposits with these financial institutions may exceed the amount of insurance provided; however, these deposits typically are redeemable upon demand. Therefore we believe the financial risks associated with these financial instruments are minimal.
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. We consider receivables past due based on the contractual payment terms. We perform ongoing credit evaluations of our customers, and generally we do not require collateral on our accounts receivable. We estimate the need for allowances for potential credit losses based on historical collection activity and the facts and circumstances relevant to specific customers and we record a provision for uncollectible accounts when collection is uncertain. To date, we have not experienced significant credit related losses.
	No single customer accounted for more than 10% of our revenues for 2013, 2012 and 2011. No single customer accounted for more than 10% of our trade receivables at December 31, 2013, 2012 and 2011.
	We are exposed to credit losses in the event of nonperformance by the banks with which we transact foreign currency contracts. We currently hold foreign exchange forward contracts with two counterparties. Our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We manage this credit risk by executing foreign currency contracts with counterparties that meet our minimum requirements, and monitoring the credit ratings of our counterparties on a periodic basis. As of December 31, 2013, we had a total credit exposure of $1.6 million from nonperformance of foreign exchange hedging counterparties.
	In connection with the issuance of our 2.875% Convertible Senior Notes due 2015, or the 2015 Notes, and our 1.75% Convertible Senior Notes due 2017, or the 2017 Notes, or collectively, the Notes, we purchased call options from counterparties. Non-performance by the counterparties under these call options would potentially expose us to dilution of our common stock to the extent our stock price exceeds the conversion price (in the case of the 2015 Notes and the 2017 Notes). See Note 3 “Financial Statement Details—Debt” for additional information.
	We purchase integrated circuits and other key components for use in our products. For certain components, which are currently single sourced, there are relatively few sources of supply. Although we believe that other suppliers could provide similar components on comparable terms, establishment of additional or replacement suppliers cannot be accomplished quickly. Any significant supply interruption could have a material adverse effect on our business, financial condition and results of operations. For further discussion, see “Risk Factors—Our manufacturing operations are dependent upon third party suppliers, some of which are sole-sourced, which makes us vulnerable to supply problems, price fluctuations and manufacturing delays.”
Inventories	'
	Inventories
	Inventories are valued at the lower of first-in, first-out cost or market value. Inventory provisions are recorded for materials that have become obsolete or are no longer used in current production and for inventory that has a market value less than the carrying value in inventory. We regularly monitor potential inventory excess, obsolescence and lower market values compared to standard costs and, when necessary, reduce the carrying amount of our inventory to its market value. Specific reserves are maintained to reduce the carrying value of inventory items on hand that we know may not be used in finished goods. If our estimates for potential inventory losses prove to be too low, then our future earnings will be affected when the related additional inventory losses are recorded.
Long-Lived Assets	'
	Property and Equipment
	Property and equipment are stated at cost, net of accumulated depreciation and amortization. Equipment and capitalized software are depreciated over the estimated useful lives of the assets, which range generally from three to ten years. Leasehold improvements are amortized over the lesser of the lease term including renewal periods that are reasonably assured or the estimated useful lives of the improvements, which are between three and ten years. The straight-line method is used for depreciation and amortization. Land is stated at cost and is not depreciated. Significant improvements which substantially extend the useful lives of assets are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred.
	Assets held under capital leases are recorded at the net present value of the minimum lease payments of the leased asset at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the assets or the period of the related lease and is included in our depreciation expense.
	Our long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. We recorded $2.0 million in long-lived assets impairment charges as part of the restructuring charges during 2013. See Note 3 “Financial Statement Details—Restructuring Activity” for additional information. No significant impairment of long-lived assets was identified or recorded during the years ended December 31, 2012 and 2011.
Goodwill	'
	Goodwill
	We allocate any excess purchase price over the fair value of the net tangible and intangible assets acquired in a business combination to goodwill. The impairment evaluation for goodwill is conducted annually as of October 1, or more frequently if events or changes in circumstances indicate the carrying value of the goodwill may not be recoverable. We test for goodwill impairment at the reporting unit level, which is the same as our operating segment level. Our goodwill at December 31, 2013 and 2012 is allocated entirely to our medical segment.
	We first assess qualitative factors to determine whether it is necessary to perform the two-step impairment test. If we believe, as a result of the qualitative assessment, that it is more-likely-than-not that the fair value of our reporting unit is less than its carrying amount, the quantitative two-step impairment test is required; otherwise, no further testing is required. In the first step, we compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of our reporting unit's goodwill. If the carrying value of our reporting unit's goodwill exceeds its implied fair value, then we record an impairment loss equal to the difference. There was no impairment of goodwill during the years ended December 31, 2013, 2012 and 2011.
Intangible Assets	'
	Intangible Assets
	Intangible assets are recorded at historical cost and amortized over their estimated useful lives. Intangible assets consist of acquired developed technology, licenses, customer relationships, patents and trademarks and covenants-not-to-compete as well as acquired in-process research and development technology. Intangible assets with a definite life are amortized using the straight-line method over their estimated useful lives of up to 20 years.
	When we acquire another entity, the purchase price is allocated, as applicable, between acquired in-process research and development, or IPR&D, other identifiable intangible assets, and net tangible assets, with the remainder recognized as goodwill. IPR&D has an indefinite life and is not amortized until completion and development of the project, at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner or the project is terminated or abandoned, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. Determining the allocation of the purchase price, including the portion of the purchase price allocated to IPR&D requires us to make significant estimates. The amount of the purchase price allocated to IPR&D is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. These methodologies include consideration of the risk of the project not achieving commercial feasibility.
	Intangible assets with definite lives are tested for impairment annually or whenever events or circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Impairment is calculated as the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted future cash flow analysis. We recorded $6.3 million in intangible asset impairment charges, including $4.1 million of IPR&D impairment, as part of our restructuring charges during 2013. See Note 3 “Financial Statement Details—Restructuring Activity” for additional information. No impairment of intangible assets was identified or recorded during the years ended December 31, 2012 and 2011.
Other Non-Current Assets	'
	Other Non-Current Assets
	At December 31, 2013 and 2012, other non-current assets include $18.4 million and $2.0 million, respectively, of investments we have made in various privately held entities engaged in emerging product development activities.
	We account for our investments in privately held entities, for which fair value is not readily determinable, in accordance with ASC Topic 323, Investments – Equity Method and Joint Ventures. For all of our investments in privately held entities, we do not have the ability to exercise significant influence over the investee, thus we accounted for these investments under the cost method of accounting.
	Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. If the fair value of the investment is less than its carrying value, the investment is impaired and we make a determination as to whether the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless we have the ability and intent to hold an investment for a period sufficient for a market recovery up to the carrying value of the investment. Further, evidence must indicate that the carrying value of the investment is recoverable within a reasonable period. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. There was no impairment of investment in privately held entities during the years ended December 31, 2013, 2012 and 2011.
	At December 31, 2013 and 2012, other non-current assets include $749,000 and $711,000, respectively, of restricted cash, which was restricted as collateral for our performance obligations to customers in foreign jurisdictions. The certificates of deposit and cash in the bank will remain restricted until such time as the current obligation is terminated.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue from the sale of our products is generally recognized when title and risk of loss transfer to the customer. We recognize revenue from consignment arrangements based on product usage, which indicates that the sale is complete. Installation and training are generally not required elements of our sales transactions as most of our products do not require these services. In instances where installation and training are required elements of the sales transaction, revenue is recognized upon completion.
	For an arrangement containing multiple deliverables that are considered separate units of accounting, we allocate arrangement consideration based on the relative selling prices of the separate units of accounting. Selling prices are determined using fair value, when available, or our estimate of selling price when fair value is not available.
	We evaluate lease agreements entered into with customers to determine whether they are sales-type leases or operating leases. Agreements classified as operating leases result in rental revenue reported on a straight-line basis as income over the lease term as it becomes receivable according to the provisions of the lease. For leases qualifying as sales-type leases, we recognize the present value of the lease payments as revenue at the time the lease is recorded and the associated unearned interest is amortized over the term of the lease. Our sales-type lease and operating lease revenue and receivables relating to sales-type leases are not significant for the years ended 2013, 2012 and 2011.
	All costs associated with the provision of service are recognized in cost of revenues as incurred. Amounts billed in excess of revenue recognized are included as deferred revenue in the consolidated balance sheets.
	We sell our products through direct sales representatives in the U.S. and a combination of direct sales representatives and independent distributors in international markets. Sales to distributors are recorded when title and risk of loss transfer upon shipment (generally FOB shipping point). No direct sales customers or distributors have price protection. Estimated returns, which are historically nominal, are recorded as an allowance for sales return and as a reduction in revenues.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	Shipping and handling costs billed to customers are included in revenues. Shipping and handling costs we incur associated with shipping products to our customers are included in cost of revenues.
Product Warranty Costs	'
	Product Warranty Costs
	We typically offer a one-year warranty for parts and labor on our products commencing upon the transfer of title and risk of loss to the customer. We accrue the estimated cost of product warranties when we invoice our customers, based on historical results. The warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from these estimates, revisions to the estimated warranty liability would be required. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.
Research and Development	'
	Research and Development
	Company-sponsored research and development expenses include the costs of technical activities that are useful in developing new products, services, processes or techniques, as well as expenses for technical activities that may significantly improve existing products or processes, and are expensed as incurred.
Clinical Studies	'
	Clinical Studies
	We recognize research and development costs for activities associated with clinical studies performed by third parties as incurred. All other costs relative to setting up clinical study sites are recognized as research and development expense as incurred. Clinical study site costs related to patient enrollment are accrued as patients are entered into the studies. Equipment that has alternative future use and is used at clinical study sites for participation in the studies is capitalized and expensed over the estimated life of the equipment.
Acquisition-related Items	'
	Acquisition-related Items
	Acquisition-related items include acquisition transaction costs, subsequent accretion of and revision, if any, to the fair value of the contingent consideration related to acquisitions and other expenses directly associated with acquisitions.
Restructuring Charges	'
	Restructuring Charges
	Restructuring charges include employee termination benefits, contract termination costs, asset impairments and other related charges associated with restructuring activities.
Stock-Based Compensation	'
	Stock-Based Compensation
	We account for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, or ASC 718, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes-Merton option pricing model, or Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. We estimate forfeitures at the time of grant and revise our estimate in subsequent periods if actual forfeitures differ from those estimates. See Note 5 “Stockholders’ Equity” for a complete discussion of our equity compensation programs and the fair value assumptions used to determine our stock-based compensation expense.
	We account for stock-based compensation awards and warrants granted to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees, or ASC 505-50. Under ASC 505-50, we determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.
Income Taxes	'
	Income Taxes
	We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent a deferred tax asset cannot be recognized under the preceding criteria, allowances are established.
	In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.
	In 2013, the Company incurred a net loss, and is not projecting a return to profitability in 2014. As of December 31, 2013, management has evaluated the recoverability of its Federal deferred tax assets, including factors such as a consideration of forecasted operating results, in-process changes in its manufacturing processes, potential tax planning strategies, as well as the period of time that will transpire before the underlying deferred tax assets will expire. Based on this evaluation, management has concluded that it is more likely than not that the underlying deferred tax assets will be utilized prior to their expiration, and therefore continues to believe that the Federal deferred tax assets will be recovered.
	During the fourth quarter of 2013, we concluded that it was more likely than not that we would not be able to realize a $3.8 million benefit related to our state and select foreign deferred tax assets. Further, in 2013, we completed our purchase accounting analysis and concluded that it was more likely than not that $1.4 million of foreign deferred tax assets related to the Sync-Rx, Ltd. acquisition and $1.1 million of state deferred tax assets related to the Crux Biomedical, Inc. acquisition are not realizable. This resulted in an increase in valuation allowance against these deferred tax assets, which was recorded as a reduction to goodwill.
	During the fourth quarter of 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. We released $4.9 million of the valuation allowance on our foreign deferred tax assets as we expect our foreign operations in the respective jurisdictions will generate sufficient taxable income in future periods to realize the tax benefit associated with the related deferred tax assets. We believe that it was more likely than not that the benefit from certain international net operating losses and a portion of our state deferred tax assets will not be realized. In recognition of this risk, we will continue to provide a valuation allowance on the deferred tax assets relating to these items.
	We will continue to assess the need for a valuation allowance on the deferred tax assets by evaluating both positive and negative evidence that may exist. To the extent we establish or change the valuation allowance in a period, the tax effect will generally flow through the statement of operations. In the case of an acquired or merged entity, we will record valuation allowance on a deferred tax asset through purchase accounting procedures as an adjustment to goodwill at the acquisition date, if it is more likely than not that all or a portion of the acquired deferred tax assets will not be realized in the future. Any subsequent change to a valuation allowance established during purchase accounting within the measurement period of the acquisition (not to exceed twelve months) will also be recorded as an adjustment to goodwill, provided that such change relates to new information about the facts and circumstances that existed on the acquisition date.
	FASB ASC Topic 740, Income Taxes, or ASC 740, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	We accrue interest and penalties on underpayment of income taxes related to unrecognized tax benefits as a component of income tax expense in our consolidated statements of operations. The amounts recognized for interest and penalties during the years ended December 31, 2013, 2012 and 2011 were $53,000, $46,000, and $34,000, respectively.
Net Income (Loss) Per Share	'
	Net Income (Loss) Per Share
	Basic and diluted net income (loss) per share is presented in accordance with FASB ASC Topic 260, Earnings per Share. Basic net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing consolidated net income (loss) by the weighted-average number of common shares outstanding and dilutive common stock equivalent shares outstanding during the period.
	On December 2, 2013, our board of directors authorized a $200 million share repurchase program. Pursuant to this approval, we entered into a $100 million accelerated share repurchase, or ASR, program with a counterparty, and received 3,557,137 shares of our common stock (See Note 5 “Stockholders' Equity”). The annual weighted average number of the initial delivered shares was removed from the denominator of the basic and diluted net income (loss) per share calculation at the share delivery date.
	Our potentially dilutive shares include outstanding common stock options, restricted stock units, including those with performance conditions, incremental shares issuable upon the conversion of the Notes or exercise of the warrants relating to the Notes (See Note 3 “Financial Statement Details — Debt”) and the incremental shares receivable under the forward contract portion of the ASR. Such potentially dilutive shares are excluded when the effect would be to reduce net loss per share or increase net income (loss) per share as discussed in the following paragraph. For the years ended December 31, 2013, 2012 and 2011, potentially dilutive shares totaling 20.8 million, 9.0 million, and 1.7 million, respectively, have not been included in the computation of diluted net income (loss) per share, as the result would be anti-dilutive.
	Diluted net income (loss) per common share includes zero, zero and 12,000 incremental shares related to the Notes for the years ended December 31, 2013, 2012 and 2011, respectively. Because the principal amount of the Notes will be settled in cash upon conversion, only the conversion spread relating to the Notes may be included in our calculation of diluted net income (loss) per common share. As such, the Notes have no impact on diluted net income (loss) per common share until the price of our common stock exceeds the conversion price (initially $29.64 for the 2015 Notes and $32.83 for the 2017 Notes, subject to adjustments) of the Notes. During the year ended December 31, 2011, 12,000 shares related to the 2015 Notes were included in the computation of the diluted net income (loss) per common share because the average market price of our common stock during the three months ended September 30, 2011 exceeded the conversion price of the 2015 Notes. The average price of our common stock did not exceed the conversion price of the Notes during any quarter of the years ended December 31, 2013 and 2012 or the other three quarters of 2011.
	The diluted net income (loss) per common share does not include any incremental shares related to the exercise of the warrants for the years ended December 31, 2013, 2012 and 2011. The warrants will not have an impact on diluted net income (loss) per common share until the price of our common stock exceeds the strike price of the warrants (initially $34.875 for the 2015 Notes offering and $37.59 for the warrants issued in connection with the 2017 Notes offering, subject to adjustments). When the market price of our stock exceeds the strike price, as applicable, we will include, in the diluted net income (loss) per common share calculation, the effect of the additional shares that may be issued upon exercise of the warrants using the treasury stock method to the extent the effect is not anti-dilutive.
	The call options to purchase our common stock, which we purchased to hedge against potential dilution upon conversion of the Notes (see Note 3 “Financial Statement Details — Debt”), are not considered for purposes of calculating the total dilutive weighted average shares outstanding, as their effect would be anti-dilutive. Upon exercise, the call options will mitigate the dilutive effect of the Notes.
	The basic and diluted net income (loss) per common share calculations for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands, except per share data):
		Years Ended December 31,
		2013			2012		2011
	Net (loss) income	$	(34,494	)	$	8,022	$	38,093
	Weighted average common shares outstanding for basic	54,341			53,475		52,300
	Dilutive potential common stock outstanding:
	Stock options	—			1,404		1,896
	Restricted stock units	—			309		377
	Employee stock purchase plan	—			7		11
	Convertible senior notes	—			—		12
	Weighted average common shares outstanding for diluted	54,341			55,195		54,596
	Net (loss) income per share:
	Basic	$	(0.63	)	$	0.15	$	0.73
	Diluted	$	(0.63	)	$	0.15	$	0.7
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) represents the net income (loss) for the period plus the results of certain changes to stockholders’ equity that are not reflected in the consolidated statements of operations. Our comprehensive income (loss) consists of net income (loss), foreign currency translation adjustments, and changes in unrealized net gains and losses on available-for-sale investments and foreign currency forward exchange contracts, net of income taxes. Foreign currency translation adjustments were not adjusted for income taxes as they relate to cumulative losses in foreign subsidiaries which provide no corresponding tax benefit or investments in foreign subsidiaries with earnings which the foreign subsidiaries does not plan on remitting to the parent company.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In December 2011, the FASB amended the accounting standards to increase the prominence of other comprehensive income (“OCI”) by eliminating the option to present components of OCI as part of the statement of changes in shareholders’ equity and requiring the components of OCI to be presented either in a single continuous statement of comprehensive income or in two consecutive statements. We adopted the amended accounting standards in 2013 by electing to present consolidated statements of comprehensive income separate from the consolidated statements of income.
	In February 2013, the FASB further amended the above accounting standards to improve the presentation of amounts reclassified out of accumulated other comprehensive income in its entirety and by component by presenting the reclassification adjustments on either the face of the statement where net income is presented or in a separate disclosure in the notes to the financial statements. Amounts that are not required to be reclassified in their entirety to net income are required to be cross referenced to related footnote disclosures that provide additional detail. The amended accounting standards only impact the financial statement presentation of OCI and do not change the components that are recognized in net income or OCI. The adoption had no impact on the Company’s financial position or results of operations.

Organization_And_Summary_Of_Si2

Organization And Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations	'
	The basic and diluted net income (loss) per common share calculations for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands, except per share data):
		Years Ended December 31,
		2013			2012		2011
	Net (loss) income	$	(34,494	)	$	8,022	$	38,093
	Weighted average common shares outstanding for basic	54,341			53,475		52,300
	Dilutive potential common stock outstanding:
	Stock options	—			1,404		1,896
	Restricted stock units	—			309		377
	Employee stock purchase plan	—			7		11
	Convertible senior notes	—			—		12
	Weighted average common shares outstanding for diluted	54,341			55,195		54,596
	Net (loss) income per share:
	Basic	$	(0.63	)	$	0.15	$	0.73
	Diluted	$	(0.63	)	$	0.15	$	0.7

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Crux Acquisition [Member]	'
Business Acquisition [Line Items]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	'
	The following table sets forth the changes in the estimated fair value of the Company’s contingent liabilities (net with working capital receivable adjustment) measured on a recurring basis using significant unobservable inputs (Level 3) (in thousands):
	Fair value measurement at acquisition December 12, 2012	$	30,000
	Change in fair value measurement included in operating expenses	231
	Contingent consideration settled	—
	Fair value measurement at December 31, 2012	30,231
	Change in fair value measurement included in operating expenses	3,607
	Working capital adjustment	(200		)
	Contingent consideration settled	—
	Fair value measurement at December 31, 2013	$	33,638
Business Acquisition, Reconciliation Of Upfront Payments	'
	A reconciliation of upfront payments in accordance with the Merger Agreement to the total purchase price is presented below (in thousands):
	Base payment per agreement	$	36,000
	Reimbursement of transaction expenses incurred by Crux	3,100
	Total up-front payments	39,100
	Estimated fair value of receivable for working capital adjustment	(1,100		)
	Estimated fair value of contingent consideration at acquisition	30,900
	Total purchase price	$	68,900
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	We recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
		12-Dec-12
	Current assets:
	Cash and cash equivalents	$	1,474
	Deferred tax asset - current	108
	Other current assets	253
	Property and equipment	39
	In-process research and development	28,400
	Covenants-not-to-compete	200
	Deferred tax asset	11,861
	Total assets acquired	42,335
	Current liabilities:
	Accounts payable	(223		)
	Accrued expenses	(302		)
	Other long term payable	(97		)
	Deferred tax liability	(10,307		)
	Total liabilities assumed	(10,929		)
	Goodwill	37,494
	Net assets acquired	$	68,900
Business Acquisition, Pro Forma Information	'
	The following unaudited pro forma information presents the combined results of operations for the years ended December 31, 2012 and 2011 as if the acquisition of Crux had been completed as of the beginning of 2011 (in thousands, except per share data):
		Years Ended December 31,
		2012			2011
	Revenues	$	381,866		$	343,546
	Net (loss) income	$	(515	)	$	31,035
	Net (loss) income per share, basic and diluted:
	Basic	$	(0.01	)	$	0.59
	Diluted	$	(0.01	)	$	0.57
	Shares used in computing basic and diluted net (loss) income per share:
	Basic	53,475			52,300
	Diluted	53,475			54,596
Synch-Rx Acquisition [Member]	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	We recorded the identifiable assets acquired and liabilities assumed at fair value as follows (in thousands):
		26-Nov-12
	Current assets:
	Cash and cash equivalents	$	423
	Receivable and other current assets	72
	Property and equipment	37
	Developed technology	3,200
	In-process research and development	1,300
	Covenants not-to-compete	100
	Other non-current assets	8
	Total assets acquired	5,140
	Current liabilities:
	Accounts payable	(56		)
	Accrued expenses	(375		)
	Other long-term debt	(1,100		)
	Total liabilities acquired	(1,531		)
	Goodwill	13,650
	Net assets acquired	$	17,259

Financial_Statement_Details_Ta

Financial Statement Details (Tables)	12 Months Ended
	Dec. 31, 2013
Financial Statement Details [Abstract]	'
Available-For-Sale Investments	'
	At December 31, 2013 and 2012, available-for-sale investments are detailed as follows (in thousands):
	At December 31, 2013
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	165,598			$	72			$	4			$	165,666
	U.S. Treasury and agency debt securities		66,214				2				18				66,198
	Short-term available-for-sale investments		$	231,812			$	74			$	22			$	231,864
	Long-term:
	Corporate debt securities		$	11,814			$	30			$	—			$	11,844
	U.S. Treasury and agency debt securities		23,028				15				—				23,043
	Long-term available for sale investments		$	34,842			$	45			$	—			$	34,887
	At December 31, 2012
			Amortized				Gross Unrealized				Gross Unrealized				Estimated
			Cost				Gains				Losses				Fair Value
	Short-term:
	Corporate debt securities		$	121,883			$	52			$	5			$	121,930
	U.S. Treasury and agency debt securities		19,020				10				—				19,030
	Short-term available-for-sale investments		$	140,903			$	62			$	5			$	140,960
	Long-term:
	Corporate debt securities		$	33,384			$	6			$	17			$	33,373
	U.S. Treasury and agency debt securities		11,010				2				—				11,012
	Long-term available for sale investments		$	44,394			$	8			$	17			$	44,385
Available-For-Sale Investments That Are In An Unrealized Loss Position	'
	Available-for-sale investments that are in an unrealized loss position at December 31, 2013 and 2012 are detailed as follows (in thousands):
			At December 31, 2013
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	21,464			$	4
	U.S. Treasury and agency debt securities		41,034				18
			$	62,498			$	22
			At December 31, 2012
			Estimated				Gross Unrealized
			Fair Value				Losses
	Corporate debt securities		$	46,987			$	22
	U.S. Treasury and agency debt securities		—				—
			$	46,987			$	22
Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis	'
	Financial assets and liabilities measured at fair value on a recurring basis are summarized below at December 31, 2013 and 2012 (in thousands):
			Fair Value Measurements at December 31, 2013
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	98,436			$	98,436			$	—			$	—
	Money market funds		8,723				8,723				—				—
	Corporate debt securities		165,666				—				165,666				—
	U.S. Treasury and agency debt securities		66,198				66,198				—				—
	Foreign currency forward contracts		2,907				—				2,907				—
	Non-current:
	Corporate debt securities		11,844				—				11,844				—
	U.S. Treasury and agency debt securities		23,043				23,043				—				—
	Foreign currency forward contracts		81				—				81				—
	Total assets measured at fair value		$	376,898			$	196,400			$	180,498			$	—
	Liabilities:
	Current:
	Foreign currency forward contracts		$	1,415			$	—			$	1,415			$	—
	Contingent consideration, current portion (1)		3,750				—				—				3,750
	Non-current:
	Other long-term debt		1,268				—				—				1,268
	Contingent consideration		29,888				—				—				29,888
	Total liabilities measured at fair value		$	36,321			$	—			$	1,415			$	34,906
	(1) This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.
			Fair Value Measurements at December 31, 2012
			Total				Level 1				Level 2				Level 3
	Assets:
	Current:
	Cash		$	41,636			$	41,636			$	—			$	—
	Money market funds		288,999				288,999				—				—
	Corporate debt securities		121,930				—				121,930				—
	U.S. Treasury and agency debt securities		19,030				19,030				—				—
	Foreign currency forward contracts		3,886				—				3,886				—
	Non-current:
	Corporate debt securities		33,373				—				33,373				—
	U.S. Treasury and agency debt securities		11,012				11,012				—				—
	Total assets measured at fair value		$	519,866			$	360,677			$	159,189			$	—
	Liabilities:
	Current:
	Foreign currency forward contracts		$	425			$	—			$	425			$	—
	Contingent consideration, current portion		2,908				—				—				2,908
	Non-current:
	Other long-term debt		1,088				—				—				1,088
	Contingent consideration (1)		27,323				—				—				27,323
	Total liabilities measured at fair value		$	31,319			$	—			$	—			$	31,319
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	'
	The following tables summarize the location and fair values of derivative instruments on our consolidated balance sheets (in thousands) at December 31, 2013 and December 31, 2012. The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not.
		As of December 31, 2013
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	954			Other current liabilities		$	251
	Foreign exchange forward contracts	Other long-term assets		81				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			1,035						251
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		1,953				Other current liabilities		1,164
	Total Derivatives Not Designated as Hedging Instruments			1,953						1,164
	Total Derivatives			$	2,988					$	1,415
		As of December 31, 2012
		Asset Derivatives						Liability Derivatives
		Balance sheet location		Fair Value				Balance sheet location		Fair Value
	Derivatives Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		$	—			Other current liabilities		$	—
	Foreign exchange forward contracts	Other long-term assets		—				Other long-term liabilities		—
	Total Derivatives Designated as Hedging Instruments			—						—
	Derivatives Not Designated as Hedging Instruments
	Foreign exchange forward contracts	Other current assets		3,886				Other current liabilities		425
	Total Derivatives Not Designated as Hedging Instruments			3,886						425
	Total Derivatives			$	3,886					$	425
Offsetting Assets and Liabilities	'
		As of December 31, 2013
						Gross Amount Not Offset on the Balance Sheet
		Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged				Net Amount
	Derivative Assets
	Foreign exchange forward contracts	$	2,988			$	(1,415	)		$	—			$	1,573
	Derivative Liabilities
	Foreign exchange forward contracts	(1,415		)		1,415				—				—
	Total	$	1,573			$	—			$	—			$	1,573
		As of December 31, 2012
						Gross Amount Not Offset on the Balance Sheet
		Gross Amount of Recognized Assets (Liabilities)				Financial Instruments				Cash Collateral (Received) or Pledged				Net Amount
	Derivative Assets
	Foreign exchange forward contracts	$	3,886			$	—			$	—			$	3,886
	Derivative Liabilities
	Foreign exchange forward contracts	(425		)		—				—				(425		)
	Total	$	3,461			$	—			$	—			$	3,461
Derivative Instruments, Gain (Loss)	'
	The following table summarizes the effect of our foreign exchange forward contracts on our consolidated statements of operations (in thousands).
			Year Ended
			December 31,
			2013				2012			2011
	Derivatives Designated as Hedging Instruments
	Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)		$	449			$	—		$	—
	Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)		(319		)		—			—
	Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)		49				—			—
	Derivatives Not Designated as Hedging Instruments
	Gain (loss) recognized in exchange rate gain (loss), net		$	6,413			$	4,786		$	(2,772	)
Schedule of Accounts Receivables	'
	Accounts receivable, net consists of the following (in thousands):
			December 31,
			2013				2012
	Trade accounts receivable		$	82,409			$	76,717
	Less: allowance for doubtful accounts		447				369
			$	81,962			$	76,348
Schedule Of Change In Allowance For Doubtful Accounts	'
	The change in the allowance for doubtful accounts for the years ended December 31, 2013, 2012 and 2011 is summarized in the following table (in thousands):
			Years Ended December 31,
			2013				2012				2011
	Balance at beginning of year		$	369			$	84			$	29
	Additions charged to selling, general and administrative expense		78				285				55
	Balance at end of year		$	447			$	369			$	84
Inventories	'
	Inventories consist of the following (in thousands):
			December 31,
			2013				2012
	Finished goods (1)		$	27,237			$	19,002
	Work-in-process		12,051				15,780
	Raw materials		21,682				18,029
			$	60,970			$	52,811
	(1) Finished goods inventory includes consigned inventory of $5.6 million and $5.3 million at December 31, 2013 and 2012, respectively.
Property And Equipment	'
	Property and equipment consists of the following (in thousands):
			December 31,
			2013				2012
	Medical diagnostic equipment		$	68,923			$	65,548
	Other equipment		52,523				44,879
	Leasehold improvements		12,641				9,289
	Software		34,392				5,447
	Land		3,046				3,046
	Building		33,245				29,098
	Construction-in-progress (1)		9,975				27,730
			214,745				185,037
	Less: Accumulated depreciation and amortization		(96,651		)		(80,652		)
			$	118,094			$	104,385
	-1	At December 31, 2012, construction-in-process includes $1.0 million of capitalized interest related to the implementation of ERP systems worldwide. The implementation was completed during 2013.
Intangible Assets By Major Class	'
	Intangible assets subject to amortization, by major class, consist of the following (in thousands):
			December 31, 2013
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	57,507			$	16,393			$	41,114			8.6
	Licenses		7,441				7,102				339				8.8
	Customer relationships		4,441				4,312				129				6.1
	Patents and trademarks		13,668				2,894				10,774				13.2
	Covenants-not-to-compete		300				108				192				3
			83,357				30,809				52,548				9.2
	Intangible assets not yet subject to amortization
	In-process research and development		5,560				—				5,560				n/a
			$	88,917			$	30,809			$	58,108
			December 31, 2012
	Intangible assets subject to amortization		Cost				Accumulated				Net				Weighted-
							Amortization								Average Life
															(in years) (1)
	Developed technology		$	27,051			$	17,408			$	9,643			8.8
	Licenses		7,345				6,709				636				10
	Customer relationships		4,177				3,756				421				6
	Patents and trademarks		8,029				2,114				5,915				13.2
	Covenants-not-to-compete		300				8				292				3
			46,902				29,995				16,907				9.4
	Intangible assets not yet subject to amortization
	In-process research and development		33,750				—				33,750				n/a
			$	80,652			$	29,995			$	50,657
	-1	Weighted average life of intangible assets is presented excluding fully amortized assets.
Future Amortization Expense Of Intangible Assets	'
	At December 31, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
	2014	$	7,187
	2015	7,027
	2016	6,821
	2017	6,309
	2018	6,182
	Thereafter	19,022
		$	52,548
Schedule of Goodwill	'
	The change in goodwill for the years ended December 31, 2013 and 2012 is summarized in the following table (in thousands):
			Years Ended December 31,
			2013				2012
	Balance at beginning of year		$	51,577			$	2,487
	Additions		3,510				49,090
	Balance at end of year		$	55,087			$	51,577
Change In The Accrued Warranty Liability	'
	Accrued warranty liability is included in accrued expenses and other current liabilities in the consolidated balance sheets. The change in the accrued warranty liability for the years ended December 31, 2013, 2012 and 2011 is summarized in the following table (in thousands):
			Years Ended December 31,
			2013				2012				2011
	Balance at beginning of year		$	1,176			$	1,077			$	852
	Warranties issued		2,135				1,898				1,864
	Settlements		(2,159		)		(1,799		)		(1,639		)
	Balance at end of year		$	1,152			$	1,176			$	1,077
Schedule of Restructuring Reserve by Type of Cost	'
	A summary of the restructuring charges related to this initiative during 2013 is presented below (in thousands):
			Employee Termination Cost				Asset Write-Off				Other Associated Cost				Total
	Balance at beginning of year		$	—			$	—			$	—			$	—
	Restructuring charges		2,867				11,402				4,772				19,041
	Payments/write-off		(797		)		(11,402		)		—				(12,199		)
	Balance at end of year		$	2,070			$	—			$	4,772			$	6,842
	A summary of the activities related to this initiative during 2013 is presented below (in thousands):
			Employee Termination Cost
	Balance at beginning of year		$	—
	Restructuring charges		333
	Payments		(333		)
	Balance at end of year		$	—
Restructuring and Related Costs	'
	The following provides a summary of our expected total costs associated with the plan by major type of costs (in thousands):
	Type of Cost		Total Estimated Amount
	Employee termination cost		$	2,812
	Asset write-off		11,402
	Other associated cost		4,983
	Total		$	19,197
Carrying Values Of The Liability And Equity Components Of The Notes	'
	The carrying values of the liability and equity components of both the 2017 Notes and the 2015 Notes, together the "Notes", are reflected in our consolidated balance sheets as follows (in thousands):
			As of December 31,
			2013				2012
	Long-term debt:
	2.875% Convertible Senior Notes due 2015:
	Principal amount		$	25,000			$	25,000
	Unamortized discount of liability component		(1,818		)		(2,830		)
	Unamortized debt issuance costs		(204		)		(326		)
	Carrying value of liability component		$	22,978			$	21,844
	1.75% Convertible Senior Notes due 2017:
	Principal amount		$	460,000			$	460,000
	Unamortized discount of liability component		(72,902		)		(88,536		)
	Unamortized debt issuance costs		(9,064		)		(11,008		)
	Carrying value of liability component		$	378,034			$	360,456
	Total long-term debt		$	401,012			$	382,300
	Equity—net carrying value
	2.875% Convertible Senior Notes due 2015		$	452			$	452
	1.75% Convertible Senior Notes due 2017		$	89,415			$	89,415
Schedule of Fair Value Of Notes	'
	The fair values of the Notes, which are all Level 2 measurements, are summarized as follows (in thousands):
		As of December 31,
		2013				2012
	2.875% Convertible Senior Notes due 2015	$	25,950			$	26,950
	1.75% Convertible Senior Notes due 2017	456,320				462,850
	Total	$	482,270			$	489,800
Schedule Of Interest Expense Related To Notes	'
	Interest expense related to the Notes was included in interest expense on the consolidated statements of operations as follows (in thousands):
		Year Ended December 31,
		2013				2012
	Contractual coupon interest	$	8,769			$	3,625
	Amortization of debt issuance costs	2,217				811
	Accretion of debt discount	16,646				4,932
	Capitalized interest	(939		)		(1,638		)
		$	26,693			$	7,730

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Loss Contingency [Abstract]	'
Schedule Of Future Minimum Lease Commitments Under Non-Cancelable Leases	'
	Year Ending December 31,	Capital		Operating
	2014	$	18	$	8,800
	2015	7		5,808
	2016	5		5,766
	2017	—		5,407
	2018	—		5,222
	Thereafter	—		24,449
	Net minimum lease payments	$	30	$	55,452
	Less:
	Amounts representing interest	—
	Current	—
	Long-term	$	30

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule Of Stock Option Activity	'
	Stock option activity for the year ended December 31, 2013 is as follows:
		Stock			Weighted-				Weighted-		Aggregate
		Options			Average				Average		Intrinsic Value
					Exercise				Remaining		(in thousands)
					Price				Contractual Life
									(in years)
	Outstanding at December 31, 2012	3,596,135			$	17.82
	Granted	1,009,162			23.11
	Exercised	(574,194	)		11.12
	Forfeited or expired	(265,920	)		21.33
	Outstanding at December 31, 2013	3,765,183			$	20.01			3.43		$	13,734
	Exercisable at December 31, 2013	2,717,951			$	18.27			2.24		$	13,125
	Vested and expected to vest at December 31, 2013	3,663,644			$	19.89			3.36		$	13,689
Schedule Of Options Outstanding	'
	Options outstanding at December 31, 2013 are summarized as follows:
		Options Outstanding									Options Vested
		Number			Weighted-		Weighted-				Number		Weighted-
		Outstanding			Average		Average				Vested Outstanding		Average
					Remaining		Exercise Price						Exercise Price
					Contractual Life
					(in years)
	$0.33–$12.63	385,031			1.36		$	8.5			384,907		$	8.51
	$12.96–$13.77	381,232			1.86		13.52				381,232		13.52
	$14.00–$17.27	402,452			2.85		15.6				364,426		15.47
	$17.67–$18.90	129,017			4.72		18.49				41,128		18.4
	$19.07	542,674			3.1		19.07				518,512		19.07
	$19.11-$21.06	384,991			1.06		19.49				345,510		19.35
	$21.07–$25.00	309,224			4.81		22.41				128,311		22.53
	$25.40	484,791			6.15		25.4				88,912		25.4
	$25.57-$28.63	386,569			4.08		27.41				292,373		27.35
	$28.70-$32.52	359,202			5.01		29.43				172,433		29.57
	$0.33–$32.52	3,765,183			3.43		20.01				2,717,744		18.27
Schedule Of Non-Vested Stock Option Activity	'
	Non-vested stock option activity for the year ended at December 31, 2013 is as follows:
		Non-vested			Weighted-Average
		Stock			Grant Date Fair
		Options			Value
	Outstanding at December 31, 2012	784,820			$	7.63
	Granted	1,009,162			7.37
	Vested	(557,180	)		8.37
	Forfeited or expired	(189,570	)		12.32
	Outstanding at December 31, 2013	1,047,232			6.14
Schedule Of Restricted Stock Unit	'
	RSU activity, including time-vested RSU and performance RSU, for the year ended December 31, 2013 is as follows:
		Restricted
		Stock Units
	Outstanding at December 31, 2012	918,367
	Granted	526,624
	Vested	(372,920	)
	Forfeited or expired	(69,690	)
	Outstanding at December 31, 2013	1,002,381
Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions	'
	The fair value of each stock option is estimated on the date of grant using the Black-Scholes model utilizing the following weighted-average assumptions:
		2013				2012				2011
	Risk-free interest rate	0.7		%		0.8		%		1.9		%
	Expected life (years)	4.2				4.1				4.4
	Estimated volatility	39.2		%		46.9		%		47.4		%
	Expected dividends	None				None				None
	Weighted-average grant date fair value	$	7.45			$	10.78			$	11.34
Fair Value Of Stock Option Under The Purchase Plan, Weighted-Average Assumptions	'
	The fair value of each purchase option under the Purchase Plan is estimated at the beginning of each purchase period using the Black-Scholes model utilizing the following weighted-average assumptions:
		Years Ended December 31,
		2013				2012				2011
	Risk-free interest rate	0.1		%		0.1		%		0.1		%
	Expected life (years)	0.5				0.5				0.5
	Estimated volatility	29.6		%		38.2		%		36.4		%
	Expected dividends	None				None				None
	Fair value of purchase right	$	5.3			$	7.31			$	6.76
Table Of Stock-Based Compensation Expense	'
	The following table sets forth stock-based compensation expense included in our consolidated statements of operations (in thousands):
		Years Ended December 31,
		2013				2012				2011
	Cost of revenues	$	748			$	715			$	459
	Selling, general and administrative	13,608				12,666				10,850
	Research and development	1,728				1,698				1,682
		$	16,084			$	15,079			$	12,991

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Components Of Provision For Income Tax Expense	'
	The income tax expense (benefit) is as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	—		$	—		$	—
	State	224			207			498
	Foreign	2,004			2,469			2,283
		2,228			2,676			2,781
	Deferred:
	Federal	(20,903		)	3,940			(19,739		)
	State	1,878			182			(2,248		)
	Foreign	467			(5,131		)	(784		)
		(18,558		)	(1,009		)	(22,771		)
	Income tax expense (benefit)	$	(16,330	)	$	1,667		$	(19,990	)
Income Tax Expenses Differ From The Calculated By Applying U.S. Federal Statutory Income Tax Rate To Loss Before Provision For Income Tax	'
	The income tax expense (benefit) in the accompanying consolidated statements of operations differ from the expense (benefit) calculated by applying the U.S. federal statutory income tax rate of 35% to income (loss) before income taxes expense (benefit) due to the following (in thousands):
		Years Ended December 31,
		2013			2012			2011
	U.S. federal statutory income tax expense (benefit)	$	(17,791	)	$	3,391		$	6,339
	State income tax expense (benefit), net of federal income tax expense	(1,470		)	296			(1,800		)
	Valuation allowance	3,777			(4,917		)	(25,840		)
	Foreign tax rate differential	(2,997		)	(342		)	156
	Credits	(1,935		)	—			(1,405		)
	Acquisition-related items	1,409			559			—
	Other	2,677			2,680			2,560
	Income tax expense (benefit)	$	(16,330	)	$	1,667		$	(19,990	)
Components Of Deferred Tax Assets	'
	The components of our deferred tax assets are as follows (in thousands):
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryovers	$	40,071		$	28,431
	Tax credit carryovers	12,343			9,704
	Accruals and deferred revenue	12,979			7,355
	Stock based compensation	10,310			9,021
	Original issue discount	—			379
	Total deferred tax assets	75,703			54,890
	Deferred tax liabilities:
	Depreciation and amortization	(18,361		)	(20,557		)
	Deferred tax assets:	57,342			34,333
	Valuation allowance	(12,601		)	(6,309		)
	Net deferred tax assets (liabilities)	$	44,741		$	28,024
Aggregate Change In The Balance Of Unrecognized Tax Benefits	'
	The aggregate change in the balances of these benefits is as follows (in thousands):
		Years Ended December 31,
		2013			2012			2011
	Balance at beginning of year	$	1,071		$	1,065		$	878
	Increases related to tax positions taken during the current year	53			46			205
	Increases (decreases) related to tax positions taken during a prior period	(42		)	(40		)	(18		)
	Balance at end of year	$	1,082		$	1,071		$	1,065

Segment_And_Geographic_Informa1

Segment And Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment And Geographic Information [Abstract]	'
Schedule Of Revenues By Segment And Product	'
	The following table sets forth our revenues by segment and product (in thousands):
			Years Ended December 31,						Percentage Change
			2013		2012		2011		2012 to 2013		2011 to 2012
	Medical segment:
	Consoles		$	43,602	$	40,687	$	40,954	7.2	%	(0.7	)%
	Single-procedure disposables:
	IVUS		194,225		205,843		200,970		(5.6	)%	2.4	%
	FM		112,643		94,885		67,082		18.7	%	41.4	%
	Other		34,775		29,716		23,530		17	%	26.3	%
	Sub-total medical segment		385,245		371,131		332,536		3.8	%	11.6	%
	Industrial segment		8,433		10,735		11,010		(21.4	)%	(2.5	)%
			$	393,678	$	381,866	$	343,546	3.1	%	11.2	%
Schedule Of Revenues By Geography	'
	The following table sets forth our revenues by geography expressed as dollar amounts (in thousands) and the changes in revenues in the specified periods expressed as percentages:
			Years Ended December 31,						Percentage Change
			2013		2012		2011		2012 to 2013		2011 to 2012
	Revenues (1):
	United States		$	189,748	$	177,992	$	157,412	6.6	%	13.1	%
	Japan		109,492		123,558		105,892		(11.4	)%	16.7	%
	Europe, the Middle East and Africa		71,018		57,913		60,249		22.6	%	(3.9	)%
	Rest of world		23,420		22,403		19,993		4.5	%	12.1	%
			$	393,678	$	381,866	$	343,546	3.1	%	11.2	%
	-1	Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Quarterly_Information_Unaudite1

Quarterly Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Information	'
	These operating results may not be indicative of results to be expected for any future period (amounts in thousands, except per share data).
			Quarter Ended (unaudited)												Year ended
	2013		March 31			June 30			September 30			December 31 (2)			December 31 (1)
	Revenue		$	93,231		$	101,344		$	95,809		$	103,294		$	393,678
	Gross profit		60,104			65,305			62,351			62,616			250,376
	Operating loss		(1,788		)	(114		)	(6,440		)	(21,561		)	(29,903		)
	Net loss		(3,161		)	(2,388		)	(8,456		)	(20,489		)	(34,494		)
	Net loss per share:
	Basic		$	(0.06	)	$	(0.04	)	$	(0.15	)	$	(0.38	)	$	(0.63	)
	Diluted		$	(0.06	)	$	(0.04	)	$	(0.15	)	$	(0.38	)	$	(0.63	)
	Includes the following stock-based compensation expense:
	Cost of revenues		$	192		194			196			$	166		$	748
	Selling, general and administrative		2,981			3,579			3,592			3,456			13,608
	Research and development		425			476			462			365			1,728
			Quarter Ended (unaudited)												Year ended
	2012		March 31			June 30			September 30			December 31 (3)			December 31
	Revenue		$	90,360		$	95,373		$	93,656		$	102,477		$	381,866
	Gross profit		60,787			63,397			60,408			68,359			252,951
	Operating income		1,921			6,639			5,967			5,063			19,590
	Net income		271			3,299			1,975			2,477			8,022
	Net income per share:
	Basic		$	0.01		$	0.06		$	0.04		$	0.05		$	0.15
	Diluted		$	—		$	0.06		$	0.04		$	0.04		$	0.15
	Includes the following stock-based compensation expense:
	Cost of revenues		$	152		162			202			$	199		$	715
	Selling, general and administrative		2,996			3,278			3,331			3,061			12,666
	Research and development		469			435			403			391			1,698
	-1	During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter.
	-2	During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million.
	In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.
	-3	During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses.
	In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

Organization_And_Summary_Of_Si3

Organization And Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 02, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Convertible Debt [Member]

Convertible Debt [Member]

Convertible Debt [Member]

Accelerated Share Repurchase Program [Member]

Foreign Tax Authority [Member]

State [Member]

Synch-Rx Acquisition [Member]

Crux Acquisition [Member]

Other Noncurrent Assets [Member]

Other Noncurrent Assets [Member]

Restructuring Plans, 2013 [Member]

In Process Research And Development [Member]

Other Machinery and Equipment [Member]

Other Machinery and Equipment [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Foreign Exchange Contract [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Trade Accounts Receivable [Member]

Trade Accounts Receivable [Member]

Trade Accounts Receivable [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

Foreign Tax Authority [Member]

State [Member]

Restructuring Plans, 2013 [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Warrant [Member]

Options Held [Member]

Warrant [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration risk, percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

10.00%

10.00%

'

'

'

'

'

'

Concentration risk, credit risk, financial instrument, maximum exposure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

Convertible senior notes, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.88%

'

1.75%

'

'

Estimated useful lives of the assets, years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'10 years

'3 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment charges

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful lives of intangible assets, years

'20 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of intangible assets, finite-lived

'

'

'

'

'

'

'

'

'

'

'

'

'

6,300,000

4,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other non-current assets

18,400,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash and cash equivalents

'

'

'

'

'

'

'

'

'

'

'

749,000

711,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net change in the total valuation allowance

6,300,000

-3,100,000

'

'

'

'

'

-4,900,000

3,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

Unrecognized tax benefits, increase resulting from acquisition

'

'

'

'

'

'

'

'

'

1,400,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amounts recognized for interest and penalties for income taxes

53,000

46,000

34,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program, authorized amount

'

'

'

'

'

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accelerated share repurchases, settlement (payment) or receipt

'

'

'

'

'

'

$100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchased and retired during period, shares

'

'

'

'

'

'

3,557,137

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potentially dilutive shares not included in the computation of diluted net income (loss) per share

20,800,000

9,000,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares included in diluted earnings per share, convertible senior notes

'

'

'

0

0

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial effective conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$29.64

'

'

$32.83

'

Investment warrants, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$34.88

'

'

$37.59

Organization_And_Summary_Of_Si4

Organization And Summary Of Significant Accounting Policies (Schedule Of Basic And Diluted Net Income (Loss) Per Common Share Calculations) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net (loss) income

($20,489)

[1]

($8,456)

($2,388)

($3,161)

$2,477

[2]

$1,975

$3,299

$271

($34,494)

[3]

$8,022

$38,093

Weighted average common shares outstanding for basic

'

'

'

'

'

'

'

'

54,341

53,475

52,300

Weighted average common shares outstanding for diluted

'

'

'

'

'

'

'

'

54,341

55,195

54,596

Net (loss) income per share:

'

'

'

'

'

'

'

'

'

'

'

Basic (dollars per share)

($0.38)

[1]

($0.15)

($0.04)

($0.06)

$0.05

[2]

$0.04

$0.06

$0.01

($0.63)

[3]

$0.15

$0.73

Diluted (dollars per share)

($0.38)

[1]

($0.15)

($0.04)

($0.06)

$0.04

[2]

$0.04

$0.06

$0

($0.63)

[3]

$0.15

$0.70

Stock Options [Member]

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Dilutive potential common stock outstanding

'

'

'

'

'

'

'

'

0

1,404

1,896

Restricted Stock Units (RSUs) [Member]

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Dilutive potential common stock outstanding

'

'

'

'

'

'

'

'

0

309

377

Employee Stock Purchase Plan [Member]

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Dilutive potential common stock outstanding

'

'

'

'

'

'

'

'

0

7

11

Convertible Debt [Member]

'

'

'

'

'

'

'

'

'

'

'

Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Convertable senior notes

'

'

'

'

'

'

'

'

0

0

12

[1]

During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million. In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.

[2]

During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses. In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

[3]

)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

Acquisitions_Pioneer_Acquisiti

Acquisitions (Pioneer Acquisition - Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 30, 2013
				Pioneer [Member]
Business Acquisition [Line Items]	'	'	'	'
Aggregate purchase price of acquisition	'	'	'	$15,000,000
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill	'	'	'	12,700,000
Goodwill	$55,087,000	$51,577,000	$2,487,000	'

Acquisitions_Crux_Acquisition_

Acquisitions (Crux Acquisition - Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 12, 2012

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 12, 2012

Dec. 31, 2013

Dec. 12, 2012

Dec. 31, 2013

Dec. 31, 2013

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Appropriate and Timely Filing of 510(k) [Member]

Appropriate and Timely Filing of 510(k) [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Various Sales Milestones [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Up-front cash payments

'

'

'

'

$39,100,000

'

'

'

'

'

'

'

'

'

'

Business acquisition, percentage of voting interests acquired

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

Business combination, consideration transferred, working capital adjustment

'

'

'

'

1,200,000

'

1,400,000

'

'

'

'

'

'

'

'

Business combination, consideration transferred, working capital adjustment fair value

'

'

'

'

900,000

'

1,100,000

1,200,000

'

'

'

'

'

'

'

Working capital adjustment

'

'

'

'

'

'

200,000

200,000

'

'

'

'

'

'

'

Contingent consideration settled

'

'

'

'

'

0

'

0

'

3,000,000

'

'

'

'

'

Business combination, contingent consideration, liability

'

'

'

'

30,000,000

30,231,000

'

33,638,000

30,231,000

'

2,900,000

'

28,000,000

'

'

Business acquisition, contingent consideration, potential cash payment current

'

'

'

'

'

'

'

'

'

'

'

48,600,000

46,600,000

'

'

Contingent consideration, fair value

'

'

'

'

'

'

'

'

'

'

'

31,900,000

'

'

'

Fair value inputs, discount rate

'

'

'

'

'

'

'

'

'

'

'

14.00%

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, low

'

'

'

'

'

'

'

'

'

'

'

32,800,000

'

'

'

Business combination, contingent consideration arrangements, range of outcomes, value, high

'

'

'

'

'

'

'

'

'

'

'

70,100,000

'

'

'

Business combination, contingent consideration, fair value input, commercial sales

'

'

'

'

'

'

'

'

'

'

'

'

'

124,900,000

279,800,000

Change in fair value measurement included in operating expenses

'

'

'

'

'

'

'

3,607,000

231,000

'

'

'

'

'

'

Goodwill

51,577,000

55,087,000

51,577,000

2,487,000

37,494,000

36,677,000

'

817,000

36,677,000

'

'

'

'

'

'

In-process research and development

'

'

'

'

28,400,000

'

'

'

'

'

'

'

'

'

'

Deferred tax assets, valuation allowance

6,309,000

12,601,000

6,309,000

'

'

'

'

1,000,000

'

'

'

'

'

'

'

Acquisition-related items

$1,900,000

$4,964,000

$1,858,000

$0

'

'

'

'

$943,000

'

'

'

'

'

'

Acquisitions_Crux_Acquisition_1

Acquisitions (Crux Acquisition - Contingent Consideration Rollforward) (Details) (Crux Acquisition [Member], USD $)	1 Months Ended	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]	'	'	'	'
Fair value measurement, contingent consideration, beginning balance	$30,000	$30,231	$30,231	'
Change in fair value measurement included in operating expenses	'	'	3,607	231
Contingent consideration settled	0	'	0	'
Working capital adjustment	'	-200	-200	'
Fair value measurement, contingent consideration, ending balance	30,231	'	33,638	30,231
Operating Expense [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Change in fair value measurement included in operating expenses	$231	'	$3,607	'

Acquisitions_Crux_Acquisition_2

Acquisitions (Crux Acquisition - Reconciliation of Upfront Payments) (Details) (Crux Acquisition [Member], USD $)	0 Months Ended	12 Months Ended
	Dec. 12, 2012	Dec. 31, 2013	Jun. 30, 2013
Crux Acquisition [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Base payment per agreement	$36,000,000	'	'
Reimbursement of transaction expenses incurred by Crux	3,100,000	'	'
Total up-front payments	39,100,000	'	'
Business combination, consideration transferred, working capital adjustment fair value	900,000	1,200,000	1,100,000
Estimated fair value of contingent consideration at acquisition	'	30,900,000	'
Total purchase price	'	$68,900,000	'

Acquisitions_Crux_Acquisition_3

Acquisitions (Crux Acquisition - Purchase Price Allocation as of Acquisition Date) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 12, 2012
In Thousands, unless otherwise specified				Crux Acquisition [Member]	Crux Acquisition [Member]	Crux Acquisition [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	'	'	$1,474
Deferred tax asset - current	'	'	'	'	'	108
Other current assets	'	'	'	'	'	253
Property and equipment	'	'	'	'	'	39
In-process research and development	'	'	'	'	'	28,400
Covenants-not-to-compete	'	'	'	'	'	200
Deferred tax asset	'	'	'	'	'	11,861
Total assets acquired	'	'	'	'	'	42,335
Accounts payable	'	'	'	'	'	-223
Accrued expenses	'	'	'	'	'	-302
Other long term payable	'	'	'	'	'	-97
Deferred tax liability	'	'	'	'	'	-10,307
Total liabilities acquired	'	'	'	'	'	-10,929
Goodwill	55,087	51,577	2,487	817	36,677	37,494
Net assets acquired	'	'	'	'	'	$68,900

Acquisitions_Crux_Acquisition_4

Acquisitions (Crux Acquisition - Pro Forma Information Date) (Details) (Crux Acquisition [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Crux Acquisition [Member]	'	'
Business Acquisition [Line Items]	'	'
Revenues	$381,866	$343,546
Net (loss) income	($515)	$31,035
Net (loss) income per share, basic and diluted:	'	'
Basic (dollars per share)	($0.01)	$0.59
Diluted (dollars per share)	($0.01)	$0.57
Shares used in computing basic and diluted net (loss) income per share:	'	'
Basic (shares)	53,475	52,300
Diluted (shares)	53,475	54,596

Acquisitions_SyncRx_Acquisitio

Acquisitions (Sync-Rx Acquisition - Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 26, 2012

Dec. 31, 2013

Dec. 31, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Nov. 26, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 12, 2012

Dec. 31, 2013

Dec. 31, 2012

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Pioneer, Crux and Sync-Rx Acquisition [Member]

Crux and Sync-Rx Acquisition [Member]

Developed Technology [Member]

In Process Research And Development [Member]

Minimum [Member]

Maximum [Member]

Government Grant to Develop Underlying Technology [Member]

Government Grant to Develop Underlying Technology [Member]

Government Grant to Develop Underlying Technology [Member]

Minimum [Member]

Maximum [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price of acquisition

'

'

'

'

$17,300,000

'

'

'

'

'

'

'

'

'

$68,900,000

'

'

'

'

Business acquisition hold-back liability retained

'

'

'

'

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Time frame for claims, months

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other long-term debt

'

'

'

'

1,100,000

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

Fair value inputs, discount rate

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business combination, estimated commercial sales

'

'

'

'

'

'

'

'

'

256,100,000

298,300,000

'

'

'

'

'

'

'

'

Business combination, development grant, liability, repayment period

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'16 years

'

'

'

'

'

Business acquisition, contingent consideration, potential cash payment current

'

'

'

'

'

'

'

'

'

'

'

1,900,000

'

'

'

'

'

'

'

Deferred tax assets, valuation allowance

6,309,000

12,601,000

6,309,000

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

Developed technology

'

'

'

'

3,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, estimated useful life intangible

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

In-process research and development

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

28,400,000

'

'

Discount rate, after-tax cash flows present value

'

'

'

'

'

'

'

19.00%

20.00%

'

'

'

'

'

'

'

'

'

'

Goodwill

51,577,000

55,087,000

51,577,000

2,487,000

13,650,000

1,200,000

12,409,000

'

'

'

'

'

'

'

817,000

36,677,000

37,494,000

'

'

Acquisition-related items

1,900,000

4,964,000

1,858,000

0

'

'

'

'

'

'

'

'

'

'

'

943,000

'

860,000

1,600,000

Change in fair value measurement included in operating expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,607,000

$231,000

'

'

'

Acquisitions_SyncRx_Acquisitio1

Acquisitions (Sync-Rx Acquisition - Purchase Price Allocation as of Acquisition Date) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Nov. 26, 2012
In Thousands, unless otherwise specified				Synch-Rx Acquisition [Member]	Synch-Rx Acquisition [Member]	Synch-Rx Acquisition [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'
Cash and cash equivalents	'	'	'	'	'	$423
Receivable and other current assets	'	'	'	'	'	72
Property and equipment	'	'	'	'	'	37
Developed technology	'	'	'	'	'	3,200
In-process research and development	'	'	'	'	'	1,300
Covenants-not-to-compete	'	'	'	'	'	100
Other non-current assets	'	'	'	'	'	8
Total assets acquired	'	'	'	'	'	5,140
Accounts payable	'	'	'	'	'	-56
Accrued expenses	'	'	'	'	'	-375
Other long-term debt	'	'	'	'	'	-1,100
Total liabilities acquired	'	'	'	'	'	-1,531
Goodwill	55,087	51,577	2,487	1,200	12,409	13,650
Net assets acquired	'	'	'	'	'	$17,259

Financial_Statement_Details_Na

Financial Statement Details (Narrative) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 26, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 12, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

1.75% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Debt [Member]

Debt [Member]

Debt [Member]

Equity [Member]

Equity [Member]

Equity [Member]

Observation Period [Member]

Scenario One [Member]

Scenario One [Member]

Scenario One [Member]

Scenario One [Member]

Scenario One [Member]

Scenario Two [Member]

Scenario Two [Member]

Scenario Two [Member]

Scenario Two [Member]

Scenario Two [Member]

Scenario Two [Member]

Restructuring Plans, 2013 [Member]

Disposables Manufacturing Transition to Costa Rica Initiative [Member]

Strategic Reorganization Initiative [Member]

Strategic Reorganization Initiative [Member]

Pioneer [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Synch-Rx Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

Developed Technology [Member]

In Process Research And Development [Member]

In Process Research And Development [Member]

In Process Research And Development [Member]

In Process Research And Development [Member]

Licensing Agreements [Member]

Licensing Agreements [Member]

Patents And Trademarks [Member]

Patents And Trademarks [Member]

Internally Developed Patents And Trademarks [Member]

Trademarks and Trade Names [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Licensed Technology [Member]

Medical Diagnostic Equipment - Customer Location [Member]

Medical Diagnostic Equipment - Customer Location [Member]

Medical Diagnostic Equipment - Customer Location [Member]

Medical Diagnostic Equipment - Demostration Equipment [Member]

Medical Diagnostic Equipment - Demostration Equipment [Member]

Medical Diagnostic Equipment - Demostration Equipment [Member]

Call Option [Member]

Call Option [Member]

Call Option [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Options Held [Member]

Corporate Debt Securities [Member]

U.S. Treasury And Agency Debt Securities [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Observation Period [Member]

Observation Period [Member]

Measurement Period [Member]

Measurement Period [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Observation Period [Member]

Observation Period [Member]

Measurement Period [Member]

Measurement Period [Member]

Employee Termination Costs [Member]

Employee Termination Costs [Member]

Optical Coherence Tomography [Member]

ReFlow Technology [Member]

Pioneer [Member]

Restructuring Plans, 2013 [Member]

Crux Acquisition [Member]

Pioneer [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

debt_securities

debt_securities

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Restructuring Plans, 2013 [Member]

Restructuring Plans, 2013 [Member]

Derivatives, Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period for investments, months

'18 months

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available-for-Sale Securities in Unrealized Loss Position

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8

2

Derivative, notional amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$97,300,000

$64,400,000

$40,300,000

$0

'

'

'

'

'

'

Changes in unrealized gains on foreign currency forward exchange contracts, net of tax

'

'

'

501,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Right to purchase common stock, number of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000,000

850,000

3,900,000

'

'

'

'

14,000,000

850,000

3,900,000

'

'

'

Purchase price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32.8286

'

29.64

'

'

'

'

'

'

'

'

'

'

Investment warrants, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$37.59

'

$34.88

'

'

'

Debt instrument, repurchase amount

'

'

'

'

'

'

'

'

'

'

'

90,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

460,000,000

460,000,000

'

'

'

115,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of working capital receivable

1,200,000

'

'

1,200,000

907,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation expense

'

'

'

22,000,000

19,900,000

19,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,300,000

9,600,000

10,900,000

416,000

816,000

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net book value of equipment

118,094,000

'

'

118,094,000

104,385,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,500,000

21,700,000

'

939,000

869,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible asset, useful life, years

'

'

'

'20 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years 7 months 6 days

[1]

'8 years 9 months 18 days

[1]

'

'

'

'

'

'

'

'8 years 9 months 18 days

[1]

'10 years

[1]

'13 years 2 months 12 days

[1]

'13 years 2 months 12 days

[1]

'

'

'3 years

[1]

'3 years

[1]

'6 years 1 month

[1]

'6 years

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets additions during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,700,000

4,400,000

'

'

11,600,000

29,700,000

'

'

24,100,000

'

'

5,600,000

4,000,000

4,700,000

900,000

'

300,000

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of intangible assets, finite-lived

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,300,000

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

566,000

'

'

'

4,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, gross

88,917,000

'

'

88,917,000

80,652,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

57,507,000

27,051,000

3,200,000

2,100,000

'

33,750,000

5,560,000

'

'

7,441,000

7,345,000

13,668,000

8,029,000

'

'

300,000

300,000

4,441,000

4,177,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-lived intangible assets, accumulated amortization

30,809,000

'

'

30,809,000

29,995,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,393,000

17,408,000

1,600,000

1,500,000

'

0

0

'

'

7,102,000

6,709,000

2,894,000

2,114,000

'

'

108,000

8,000

4,312,000

3,756,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of intangibles

'

'

'

3,832,000

3,240,000

3,447,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

55,087,000

'

'

55,087,000

51,577,000

2,487,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

1,200,000

12,409,000

13,650,000

817,000

36,677,000

37,494,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total expected restructuring costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

19,197,000

2,812,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

14,500,000

4,600,000

258,000

19,374,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

333,000

19,041,000

2,867,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Related Cost, Expected Cost, Cash Outlay

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,795,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset impairment charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of long-lived assets held-for-use

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible senior notes, interest rate

'

'

'

'

'

'

1.75%

1.75%

'

2.88%

2.88%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial conversion rate, number of shares

'

'

'

'

'

'

'

30.4612

'

'

33.7339

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial conversion rate, principal amount

'

'

'

'

'

'

1,000

1,000

'

1,000

1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial effective conversion price

'

'

'

'

'

'

'

'

'

$29.64

$29.64

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$32.83

'

'

Proceeds from issuance of the notes

'

'

'

'

'

'

409,300,000

'

'

100,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs (including broker fees)

'

'

'

'

'

'

14,600,000

'

'

4,400,000

'

'

11,800,000

3,500,000

'

2,800,000

866,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net payments related to hedge transactions

'

'

'

'

'

'

36,100,000

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Years on which debt issuance cost accreted to interest expense

'

'

'

'

'

'

'5 years

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percent of principal repaid on repurchase of notes

'

'

'

'

'

'

'

100.00%

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'25 days

'

'20 days

'20 days

'30 days

'30 days

'

'

'5 days

'5 days

'10 days

'10 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Threshold of conversion price to last reported sales price

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

'

'

'

'

'

'

130.00%

'

'

'

'

98.00%

98.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum amount of principal to be converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective interest rate

'

'

'

'

'

'

7.00%

7.00%

'

7.65%

7.65%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining term of the notes years

'

'

'

'

'

'

'

'3 years 11 months 1 day

'

'

'1 year 8 months 1 day

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for purchase of call options from JPMorgan Chase

'

'

'

'

'

'

89,800,000

'

'

27,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date of call options

'

'

'

'

'

'

'

1-Dec-17

'

'

1-Sep-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of trading days over which warrants expire

'

'

'

'

'

'

'

'120 days

'

'

'50 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment warrants expiration date

'

'

'

'

'

'

15-Mar-18

'

'

1-Dec-15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the issuance of warrants

'

'

'

0

53,686,000

0

53,700,000

'

'

17,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction to additional paid-in capital

'

'

'

'

89,415,000

'

36,100,000

'

'

10,000,000

3,600,000

'

'

'

'

'

'

21,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase of a portion of 2.875% convertible senior notes due 2015

'

'

'

'

'

'

'

'

'

'

104,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest paid, repurchase long term debt

'

'

'

'

'

'

'

'

'

'

711,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on debt extinguishment

'

'

'

0

-4,969,000

0

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liability component of convertible debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Retirement of call options senior convertable notes 2015

'

'

'

0

15,156,000

0

'

'

'

'

15,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Retirement of warrants senior convertable notes 2015

'

'

'

$0

($11,603,000)

$0

'

'

'

'

$11,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Weighted average life of intangible assets is presented excluding fully amortized assets.

Financial_Statement_Details_Av

Financial Statement Details (Available-For-Sale Investments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	$22	$22
Available-for-sale Securities, Fair Value Disclosure	62,498	46,987
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	4	22
Available-for-sale Securities, Fair Value Disclosure	21,464	46,987
U.S. Treasury And Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Gross Unrealized Losses	18	0
Available-for-sale Securities, Fair Value Disclosure	41,034	0
Short-Term Available-For-Sale Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	231,812	140,903
Available-for-sale securities, Gross Unrealized Gains	74	62
Available-for-sale securities, Gross Unrealized Losses	22	5
Available-for-sale Securities, Fair Value Disclosure	231,864	140,960
Short-Term Available-For-Sale Investments [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	165,598	121,883
Available-for-sale securities, Gross Unrealized Gains	72	52
Available-for-sale securities, Gross Unrealized Losses	4	5
Available-for-sale Securities, Fair Value Disclosure	165,666	121,930
Short-Term Available-For-Sale Investments [Member] | U.S. Treasury And Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	66,214	19,020
Available-for-sale securities, Gross Unrealized Gains	2	10
Available-for-sale securities, Gross Unrealized Losses	18	0
Available-for-sale Securities, Fair Value Disclosure	66,198	19,030
Long-Term Available For Sale Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	34,842	44,394
Available-for-sale securities, Gross Unrealized Gains	45	8
Available-for-sale securities, Gross Unrealized Losses	0	17
Available-for-sale Securities, Fair Value Disclosure	34,887	44,385
Long-Term Available For Sale Investments [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	11,814	33,384
Available-for-sale securities, Gross Unrealized Gains	30	6
Available-for-sale securities, Gross Unrealized Losses	0	17
Available-for-sale Securities, Fair Value Disclosure	11,844	33,373
Long-Term Available For Sale Investments [Member] | U.S. Treasury And Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Amortized Cost	23,028	11,010
Available-for-sale securities, Gross Unrealized Gains	15	2
Available-for-sale securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Fair Value Disclosure	$23,043	$11,012

Financial_Statement_Details_Av1

Financial Statement Details (Available-For-Sale Investments That Are In An Unrealized Loss Position) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	$62,498	$46,987
Available-for-sale Securities, Gross Unrealized Losses	22	22
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	21,464	46,987
Available-for-sale Securities, Gross Unrealized Losses	4	22
U.S. Treasury And Agency Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Estimated Fair Value	41,034	0
Available-for-sale Securities, Gross Unrealized Losses	$18	$0

Financial_Statement_Details_Fo

Financial Statement Details (Foreign Currency Forward Contract) (Details) (Foreign Exchange Forward [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	$2,988	$3,886
Derivative liability, notional amount	1,415	425
Derivative asset, gross amount of recognized assets (liabilities)	2,988	3,886
Derivative assets, gross amount not offset on the balance sheet, financial instruments	-1,415	0
Derivative assets, gross amount not offset on the balance sheet, cash collateral (received) or pledged	0	0
Derivative asset, net amount	1,573	3,886
Derivative liabilities, gross amount of recognized assets (liabilities)	-1,415	-425
Derivative liabilities, gross amount not offset on the balance sheet, financial instruments	1,415	0
Derivative liabilities, gross amount not offset on the balance sheet, cash collateral (received) or pledged	0	0
Derivative liabilities, net amount	0	-425
Total, gross amount of recognized assets (liabilities)	1,573	3,461
Total, gross amount not offset on the balance sheet, financial instruments	0	0
Total, gross amount not offset on the balance sheet, cash collateral (received) or pledged	0	0
Total, net amount	1,573	3,461
Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	1,035	0
Derivative liability, notional amount	251	0
Designated as Hedging Instrument [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	954	0
Designated as Hedging Instrument [Member] | Other Current Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, notional amount	251	0
Designated as Hedging Instrument [Member] | Other Noncurrent Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	81	0
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, notional amount	0	0
Not Designated as Hedging Instrument [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	1,953	3,886
Derivative liability, notional amount	1,164	425
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, notional amount	1,953	3,886
Not Designated as Hedging Instrument [Member] | Other Current Liabilities [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, notional amount	$1,164	$425

Financial_Statement_Details_Ef

Financial Statement Details (Effect Of Foreign Exchange Forward Contracts On Consolidated Statements Of Income) (Details) (Foreign Exchange Forward [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Designated as Hedging Instrument [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in other comprehensive income on foreign currency forward contracts (effective portion)	$449	$0	$0
Gain (loss) reclassified from accumulated other comprehensive income into cost of revenue (effective portion)	-319	0	0
Gain (loss) recognized in income (ineffective portion and amount excluded from effectiveness testing)	49	0	0
Not Designated as Hedging Instrument [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in exchange rate gain (loss), net	$6,413	$4,786	($2,772)

Financial_Statement_Details_Fi

Financial Statement Details (Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	$231,864		$140,960
Available-for-sale Securities, Noncurrent	34,887		44,385
Assets, fair value disclosure	376,898		519,866
Total long-term liabilities measured at fair value	36,321		31,319
Fair value of working capital receivable	-1,200		-907
Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	196,400		360,677
Total long-term liabilities measured at fair value	0		0
Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	180,498		159,189
Total long-term liabilities measured at fair value	1,415		0
Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Assets, fair value disclosure	0		0
Total long-term liabilities measured at fair value	34,906		31,319
Cash [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	98,436		41,636
Cash [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	98,436		41,636
Cash [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Cash [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Money Market Funds [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	8,723		288,999
Money Market Funds [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	8,723		288,999
Money Market Funds [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Money Market Funds [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Cash and cash equivalents	0		0
Corporate Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	165,666		121,930
Available-for-sale Securities, Noncurrent	11,844		33,373
Corporate Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
Corporate Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	165,666		121,930
Available-for-sale Securities, Noncurrent	11,844		33,373
Corporate Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Available-for-sale Securities, Noncurrent	0		0
U.S. Treasury And Agency Short Term Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	66,198		19,030
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	66,198		19,030
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
U.S. Treasury And Agency Short Term Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Current	0		0
Foreign Currency Forward Contracts [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	2,907		3,886
Foreign Currency Contract, Non-current Asset, Fair Value Disclosure	81		'
Fair value of foreign currency forward contracts included in accrued expense and other current liabilities	1,415		425
Long-term Debt, Fair Value	1,268		'
Foreign Currency Forward Contracts [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	0		0
Foreign Currency Contract, Non-current Asset, Fair Value Disclosure	0		'
Fair value of foreign currency forward contracts included in accrued expense and other current liabilities	0		0
Long-term Debt, Fair Value	0		'
Foreign Currency Forward Contracts [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	2,907		3,886
Foreign Currency Contract, Non-current Asset, Fair Value Disclosure	81		'
Fair value of foreign currency forward contracts included in accrued expense and other current liabilities	1,415		425
Long-term Debt, Fair Value	0		'
Foreign Currency Forward Contracts [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Foreign currency forward contracts	0		0
Foreign Currency Contract, Non-current Asset, Fair Value Disclosure	0		'
Fair value of foreign currency forward contracts included in accrued expense and other current liabilities	0		0
Long-term Debt, Fair Value	1,268		'
US Government Agencies Debt Securities [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	23,043		11,012
US Government Agencies Debt Securities [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	23,043		11,012
US Government Agencies Debt Securities [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	0		0
US Government Agencies Debt Securities [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Available-for-sale Securities, Noncurrent	0		0
Commitments [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	3,750	[1]	'
Contigent considerations	29,888		'
Commitments [Member] | Level 1 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	0	[1]	0
Long-term Debt, Fair Value	'		0
Contigent considerations	0		0	[2]
Commitments [Member] | Level 2 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	0	[1]	0
Long-term Debt, Fair Value	'		0
Contigent considerations	0		0	[2]
Commitments [Member] | Level 3 [Member]	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Commitments, current, fair value	3,750	[1]	2,908
Long-term Debt, Fair Value	'		1,088
Contigent considerations	$29,888		$27,323	[2]
[1]	This amount is reflected net of the fair value of the working capital receivable in the amount of $1.2 million at December 31, 2013.
[2]	This amount is reflected net of the fair value of the working capital receivable in the amount of $907,000 at December 31, 2012.

Financial_Statement_Details_Sc

Financial Statement Details (Schedule Of Accounts Receivable) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Financial Statement Details [Abstract]	'	'
Trade accounts receivable	$82,409	$76,717
Less: allowance for doubtful accounts	447	369
Accounts Receivable, Net, Current	$81,962	$76,348

Financial_Statement_Details_Sc1

Financial Statement Details (Schedule Of Change In Allowance For Doubtful Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts Receivable [Roll Forward]	'	'	'
Balance at beginning of year	$369	$84	$29
Additions charged to selling, general and administrative expense	78	285	55
Balance at end of year	$447	$369	$84

Financial_Statement_Details_In

Financial Statement Details (Inventories) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
Financial Statement Details [Abstract]	'		'
Finished goods	$27,237,000	[1]	$19,002,000	[1]
Work-in-process	12,051,000		15,780,000
Raw materials	21,682,000		18,029,000
Inventories	60,970,000		52,811,000
Consigned inventory	$5,600,000		$5,300,000
[1]	Finished goods inventory includes consigned inventory of $5.6 million and $5.3 million at December 31, 2013 and 2012, respectively.

Financial_Statement_Details_Pr

Financial Statement Details (Property And Equipment) (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Medical Diagnostic Equipment [Member]

Medical Diagnostic Equipment [Member]

Other Equipment [Member]

Other Equipment [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Purchased Software [Member]

Purchased Software [Member]

Land [Member]

Land [Member]

Building and Building Improvements [Member]

Building and Building Improvements [Member]

Construction-In-Progress [Member]

Construction-In-Progress [Member]

Implementation Of Enterprise Resource Planning System [Member]

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and Equipment, Gross

$214,745,000

$185,037,000

$68,923,000

$65,548,000

$52,523,000

$44,879,000

$12,641,000

$9,289,000

$34,392,000

$5,447,000

$3,046,000

$3,046,000

$33,245,000

$29,098,000

$9,975,000

[1]

$27,730,000

[1]

'

Less: Accumulated depreciation and amortization

-96,651,000

-80,652,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and Equipment, Net

118,094,000

104,385,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capitalized interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

[1]

At December 31, 2012, construction-in-process includes $1.0 million of capitalized interest related to the implementation of ERP systems worldwide. The implementation was completed during 2013.

Financial_Statement_Details_In1

Financial Statement Details (Intangible Assets By Major Class) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	$88,917		$80,652
Accumulated Amortization	30,809		29,995
Net	58,108		50,657
Finite-lived intangible asset, useful life, years	'20 years		'
Developed Technology [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	57,507		27,051
Accumulated Amortization	16,393		17,408
Net	41,114		9,643
Finite-lived intangible asset, useful life, years	'8 years 7 months 6 days	[1]	'8 years 9 months 18 days	[1]
Licensing Agreements [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	7,441		7,345
Accumulated Amortization	7,102		6,709
Net	339		636
Finite-lived intangible asset, useful life, years	'8 years 9 months 18 days	[1]	'10 years	[1]
Customer Relationships [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	4,441		4,177
Accumulated Amortization	4,312		3,756
Net	129		421
Finite-lived intangible asset, useful life, years	'6 years 1 month	[1]	'6 years	[1]
Patents And Trademarks [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	13,668		8,029
Accumulated Amortization	2,894		2,114
Net	10,774		5,915
Finite-lived intangible asset, useful life, years	'13 years 2 months 12 days	[1]	'13 years 2 months 12 days	[1]
Noncompete Agreements [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	300		300
Accumulated Amortization	108		8
Net	192		292
Finite-lived intangible asset, useful life, years	'3 years	[1]	'3 years	[1]
Intangible Assets Subject To Amortization [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	83,357		46,902
Accumulated Amortization	30,809		29,995
Net	52,548		16,907
Finite-lived intangible asset, useful life, years	'9 years 2 months 12 days	[1]	'9 years 4 months 24 days	[1]
In Process Research And Development [Member]	'		'
Finite-Lived Intangible Assets [Line Items]	'		'
Cost	5,560		33,750
Accumulated Amortization	0		0
Net	$5,560		$33,750
[1]	Weighted average life of intangible assets is presented excluding fully amortized assets.

Financial_Statement_Details_Fu

Financial Statement Details (Future Amortization Expense Of Intangible Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Net	$58,108	$50,657
Intangible Assets Subject To Amortization [Member]	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
2014	7,187	'
2015	7,027	'
2016	6,821	'
2017	6,309	'
2018	6,182	'
Thereafter	19,022	'
Net	$52,548	$16,907

Financial_Statement_Details_Sc2

Financial Statement Details (Schedule Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Roll Forward]	'	'
Balance at beginning of year	$51,577	$2,487
Additions	3,510	49,090
Balance at end of year	$55,087	$51,577

Financial_Statement_Details_Ch

Financial Statement Details (Change In The Accrued Warranty Liability) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]	'	'	'
Balance at beginning of year	$1,176	$1,077	$852
Warranties issued	2,135	1,898	1,864
Settlements	-2,159	-1,799	-1,639
Balance at end of year	$1,152	$1,176	$1,077

Financial_Statement_Details_Re

Financial Statement Details (Restructuring Rollforward) (Details) (USD $)	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Restructuring charges	$14,500	$4,600	$258	$19,374	$0	$0
Strategic Reorganization Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	'	0	'	'
Restructuring charges	'	'	'	19,041	'	'
Payments/write-off	'	'	'	-12,199	'	'
Balance at end of year	6,842	'	'	6,842	'	'
Employee Termination Costs [Member] | Disposables Manufacturing Transition to Costa Rica Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	'	0	'	'
Restructuring charges	'	'	'	333	'	'
Payments/write-off	'	'	'	-333	'	'
Balance at end of year	0	'	'	0	'	'
Employee Termination Costs [Member] | Strategic Reorganization Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	'	0	'	'
Restructuring charges	'	'	'	2,867	'	'
Payments/write-off	'	'	'	-797	'	'
Balance at end of year	2,070	'	'	2,070	'	'
Asset Write-Off [Member] | Strategic Reorganization Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	'	0	'	'
Restructuring charges	'	'	'	11,402	'	'
Payments/write-off	'	'	'	-11,402	'	'
Balance at end of year	0	'	'	0	'	'
Other Associated Costs [Member] | Strategic Reorganization Initiative [Member]	'	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'	'
Balance at beginning of year	'	'	'	0	'	'
Restructuring charges	'	'	'	4,772	'	'
Payments/write-off	'	'	'	0	'	'
Balance at end of year	$4,772	'	'	$4,772	'	'

Financial_Statement_Details_To

Financial Statement Details (Total Estimated Restructuring) (Details) (Strategic Reorganization Initiative [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	$19,197
Employee Termination Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	2,812
Asset Write-Off [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	11,402
Other Associated Costs [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Total expected restructuring costs	$4,983

Financial_Statement_Details_Ca

Financial Statement Details (Carrying Values Of The Liability And Equity Components Of The Notes) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Carrying value of liability component	$401,012	$382,300
2.8575% Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount	25,000	25,000
Unamortized discount of liability component	-1,818	-2,830
Unamortized debt issuance costs	-204	-326
Carrying value of liability component	22,978	21,844
Equity - net carrying value	452	452
1.75% Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal amount	460,000	460,000
Unamortized discount of liability component	-72,902	-88,536
Unamortized debt issuance costs	-9,064	-11,008
Carrying value of liability component	378,034	360,456
Equity - net carrying value	$89,415	$89,415

Financial_Statement_Details_Li

Financial Statement Details (Liability and Equity Component Of Notes Measured At Fair Value) (Details) (Level 2 [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	$482,270	$489,800
2.8575% Convertible Senior Notes [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	25,950	26,950
1.75% Convertible Senior Notes [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Convertible Senior Notes	$456,320	$462,850

Financial_Statement_Details_Sc3

Financial Statement Details (Schedule Of Interest Expense Related To Notes) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Financial Statement Details [Abstract]	'	'
Contractual coupon interest	$8,769	$3,625
Amortization of debt issuance costs	2,217	811
Accretion of debt discount	16,646	4,932
Less: capitalized interest	-939	-1,638
Interest expense related to the Notes	$26,693	$7,730

Commitments_And_Contingencies_1

Commitments And Contingencies (Narrative) (Details)	0 Months Ended	1 Months Ended	12 Months Ended				12 Months Ended
	Apr. 07, 2011	Nov. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 31, 2007	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)	USD ($)	USD ($)	Patents And Technology [Member]	Patents And Technology [Member]	Patents And Technology [Member]	Minimum [Member]	Maximum [Member]
							USD ($)	USD ($)	USD ($)
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Loss contingency, damages awarded, value	$600,000	'	'	'	'	'	'	'	'	'	'
Attorney's fees	4,500,000	'	'	'	'	'	'	'	'	'	'
Settlement payment obligation to third party	'	'	5,400,000	'	'	'	'	'	'	'	'
Alleged payment to influence outcome of clinical trial	'	5,000	'	'	'	'	'	'	'	'	'
Royalty expense related to use of licensed technology	'	'	'	'	'	'	2,500,000	1,500,000	1,800,000	'	'
Total rental expense	'	'	7,100,000	7,000,000	6,900,000	'	'	'	'	'	'
Purchase commitments	'	'	70,100,000	'	'	'	'	'	'	'	'
Purchase commitments that require payments in 12 months	'	'	65,800,000	'	'	'	'	'	'	'	'
Commitments will require payments, in months	'	'	'12 months	'	'	'	'	'	'	'	'
Purchase commitments that require payments in 3 months	'	'	63,500,000	'	'	'	'	'	'	'	'
Agreement to fund clinical study activities	'	'	$2,100,000	'	'	$4,600,000	'	'	'	'	'
Contractual payments due, in years	'	'	'	'	'	'	'	'	'	'1 year	'3 years
Number of months needed replace sole source suppliers	'	'	'	'	'	'	'	'	'	'6 months	'24 months

Commitments_And_Contingencies_2

Commitments And Contingencies (Schedule Of Future Minimum Lease Commitments Under Non-Cancelable Leases) (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Loss Contingency [Abstract]	'
Capital lease, 2014	$18
Capital lease, 2015	7
Capital lease, 2016	5
Capital lease, 2017	0
Capital lease, 2018	0
Thereafter	0
Net minimum lease payments	30
Capital lease, Amounts representing interest	0
Capital lease, Current	0
Long-term	30
Operating lease, 2014	8,800
Operating lease, 2015	5,808
Operating lease, 2016	5,766
Operating lease, 2017	5,407
Operating lease, 2018	5,222
Operating lease, Thereafter	24,449
Operating lease, Net minimum lease payments	$55,452

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

0 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Jul. 29, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

15-May-13

2-May-11

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

2-May-11

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 02, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

2007 Employee Stock Purchase Plan [Member]

Non-Employees [Member]

Non-Employees [Member]

Non-Employees [Member]

Amended Plan [Member]

Purchase Plan [Member]

Purchase Plan [Member]

Purchase Plan [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Accelerated Share Repurchase Program [Member]

1.75% Convertible Senior Notes [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

2012 Program [Member]

2013 Program [Member]

1.75% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

250,000,000

250,000,000

'

'

'

'

'

'

'

'

21,572,558

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt conversion, converted instrument, warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,000,000

850,000

3,900,000

Investment warrants, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$37.59

'

$34.88

Number of trading days over which warrants expire

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'120 days

'

'50 days

'

'

'

Investment warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15-Mar-18

'

1-Dec-15

'

'

'

'

Preferred stock, shares authorized

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock par value per share

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program, authorized amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$200,000,000

'

'

'

'

'

'

'

Accelerated share repurchases, settlement (payment) or receipt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

Stock repurchased and retired during period, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,557,137

'

'

'

'

'

'

'

Increase in common stock shares issued in equity compensation plan

2,050,000

'

'

'

5,360,000

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in number of shares available for issuance under amendment plan pursuant to stock option

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction in number of shares available for issuance under amendment plan pursuant to restricted stock award

$1.63

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in equity compensation plan

'

'

'

'

'

'

'

'

'

'

'

6,793,238

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting rights percentage

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining monthly vesting period of stock options, in years

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of options granted and units, in years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average grant date fair value of stock options granted

'

$7.45

$10.78

$11.34

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Stock Units, Granted

'

526,624

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

58,000

73,000

'

'

'

'

'

'

'

'

Weightred-average grant date fair value of restricted stock units granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$24.30

$27.87

$26.62

'

'

'

'

'

'

'

'

'

'

Common stock released based on vesting terms of restricted stock units

'

372,920

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan activity discount from market price offering date

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan activity maximum employee subscription rate

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum stock purchased during period value employee stock purchase plan

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum stock purchased during period shares employee stock purchase plan

'

750

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserve increased on outstanding common stock percentage

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserve increased on outstanding common stock shares

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock available for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

55,911

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan activity shares purchased

'

195,469

163,818

171,251

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan activity shares purchased, price per share

'

$18.30

$23.69

$20.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

'

16,084,000

15,079,000

12,991,000

'

'

'

'

0

0

115,000

'

1,000,000

1,200,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation cost capitalized inventories

'

219,000

258,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option excess tax benefits

'

0

35,000

165,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of stock option exercised

'

6,300,000

12,200,000

14,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total grant-date fair value of stock options vested

'

4,700,000

5,400,000

5,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized employee compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

$182,000

'

'

'

$8,300,000

$16,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized employee compensation cost recognized over weighted average period, in years

'

'

'

'

'

'

'

'

'

'

'

'

'2 months 12 days

'

'

'

'2 years 7 months 6 days

'2 years 4 months 17 days

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Schedule_o

Stockholders' Equity (Schedule of Stock Option Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options, Outstanding, Beginning Balance	3,596,135,000
Stock Options, Granted	1,009,162,000
Stock Options, Exercised	-574,194,000
Stock Options, Forfeited or expired	-265,920,000
Stock Options, Outstanding, Ending Balance	3,765,183,000
Stock Options, Exercisable, Ending Balance	2,717,951,000
Stock Options, Vested and expected to vest, Ending Balance	3,663,644,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'
Weighted-Average Exercise Price, Outstanding, Beginning Balance	$17.82
Weighted-Average Exercise Price, Granted	$23.11
Weighted-Average Exercise Price, Exercised	$11.12
Weighted-Average Exercise Price, Forfeited or expired	$21.33
Weighted-Average Exercise Price, Outstanding, Ending Balance	$20.01
Weighted-Average Exercise Price, Exercisable, Ending Balance	$18.27
Weighted-Average Exercise Price, Vested and expected to vest, Ending Balance	$19.89
Weighted-Average Remaining Contractual Life, Outstanding, Ending Balance	'3 years 5 months 5 days
Weighted-Average Remaining Contractual Life, Exercisable, Ending Balance	'2 years 2 months 26 days
Weighted-Average Remaining Contractual Life Vested and expected to vest, Ending Balance	'3 years 4 months 10 days
Aggregate Intrinsic Value, Outstanding, Ending Balance	$13,734
Aggregate Intrinsic Value, Exercisable, Ending Balance	13,125
Aggregate Intrinsic Value, Vested and expected to vest, Ending Balance	$13,689

Recovered_Sheet1

Stockholders' Equity (Schedule Of Options Outstanding) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	3,765,183,000	3,596,135,000
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'3 years 5 months 5 days	'
Options Outstanding, Weighted-Average Exercise Price	$20.01	$17.82
Options Vested, Number Outstanding	3,663,644,000	'
Options Vested, Weighted-Average Exercise Price	$19.89	'
$0.33–$12.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	385,031	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'1 year 4 months 10 days	'
Options Outstanding, Weighted-Average Exercise Price	$8.50	'
Options Vested, Number Outstanding	384,907	'
Options Vested, Weighted-Average Exercise Price	$8.51	'
$12.96–$13.77 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	381,232	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'1 year 10 months 10 days	'
Options Outstanding, Weighted-Average Exercise Price	$13.52	'
Options Vested, Number Outstanding	381,232	'
Options Vested, Weighted-Average Exercise Price	$13.52	'
$14.00–$17.27 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	402,452	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'2 years 10 months 6 days	'
Options Outstanding, Weighted-Average Exercise Price	$15.60	'
Options Vested, Number Outstanding	364,426	'
Options Vested, Weighted-Average Exercise Price	$15.47	'
$17.67–$18.90 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	129,017	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'4 years 8 months 19 days	'
Options Outstanding, Weighted-Average Exercise Price	$18.49	'
Options Vested, Number Outstanding	41,128	'
Options Vested, Weighted-Average Exercise Price	$18.40	'
$19.07 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$19.07	'
Options Outstanding, Number Outstanding	542,674	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'3 years 1 month 6 days	'
Options Outstanding, Weighted-Average Exercise Price	$19.07	'
Options Vested, Number Outstanding	518,512	'
Options Vested, Weighted-Average Exercise Price	$19.07	'
$19.11-$21.06 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	384,991	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'1 year 0 months 22 days	'
Options Outstanding, Weighted-Average Exercise Price	$19.49	'
Options Vested, Number Outstanding	345,510	'
Options Vested, Weighted-Average Exercise Price	$19.35	'
$21.07–$25.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	309,224	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'4 years 9 months 22 days	'
Options Outstanding, Weighted-Average Exercise Price	$22.41	'
Options Vested, Number Outstanding	128,311	'
Options Vested, Weighted-Average Exercise Price	$22.53	'
$25.40 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$25.04	'
Options Outstanding, Number Outstanding	484,791	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'6 years 1 month 24 days	'
Options Outstanding, Weighted-Average Exercise Price	$25.40	'
Options Vested, Number Outstanding	88,912	'
Options Vested, Weighted-Average Exercise Price	$25.40	'
$25.57-$28.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	386,569	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'4 years 0 months 29 days	'
Options Outstanding, Weighted-Average Exercise Price	$27.41	'
Options Vested, Number Outstanding	292,373	'
Options Vested, Weighted-Average Exercise Price	$27.35	'
$28.70-$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	359,202	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'5 years 0 months 4 days	'
Options Outstanding, Weighted-Average Exercise Price	$29.43	'
Options Vested, Number Outstanding	172,433	'
Options Vested, Weighted-Average Exercise Price	$29.57	'
$0.33–$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Options Outstanding, Number Outstanding	3,765,183	'
Options Outstanding, Weighted-Average Remaining Contractual Life, in years	'3 years 5 months 5 days	'
Options Outstanding, Weighted-Average Exercise Price	$20.01	'
Options Vested, Number Outstanding	2,717,744	'
Options Vested, Weighted-Average Exercise Price	$18.27	'
Minimum [Member] | $0.33–$12.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$0.33	'
Minimum [Member] | $12.96–$13.77 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$12.96	'
Minimum [Member] | $14.00–$17.27 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$14	'
Minimum [Member] | $17.67–$18.90 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$17.67	'
Minimum [Member] | $19.11-$21.06 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$19.11	'
Minimum [Member] | $21.07–$25.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$21.07	'
Minimum [Member] | $25.57-$28.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$25.57	'
Minimum [Member] | $28.70-$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$28.70	'
Minimum [Member] | $0.33–$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$0.33	'
Maximum [Member] | $0.33–$12.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$12.63	'
Maximum [Member] | $12.96–$13.77 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$13.77	'
Maximum [Member] | $14.00–$17.27 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$17.27	'
Maximum [Member] | $17.67–$18.90 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$18.90	'
Maximum [Member] | $19.11-$21.06 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$21.06	'
Maximum [Member] | $21.07–$25.00 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$25	'
Maximum [Member] | $25.57-$28.63 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$28.63	'
Maximum [Member] | $28.70-$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$32.52	'
Maximum [Member] | $0.33–$32.52 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Range Of Options Outstanding And Exercisable Price	$32.52	'

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Non-Vested Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Non-vested Stock Options, Outstanding beginning balance	784,820
Non-vested stock options, granted	1,009,162
Non-vested Stock Options, Vested	-557,180
Non-vested Stock Options, Forfeited or expired	-189,570
Non-vested Stock Options, Outstanding ending balance	1,047,232
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]	'
Weighted-Average Grant Date Fair Value, Outstanding beginning balance	$7.63
Weighted-Average Grant Date Fair Value, Granted	$7.37
Weighted-Average Grant Date Fair Value, Vested	$8.37
Weighted-Average Grant Date Fair Value, Forfeited or Expired	$12.32
Weighted-Average Grant Date Fair Value, Outstanding ending balance	$6.14

Stockholders_Equity_Schedule_O2

Stockholders' Equity (Schedule Of Restricted Stock Unit) (Details)	12 Months Ended
	Dec. 31, 2013
Restricted Stock Unit Activity [Roll Forward]	'
Restricted Stock Units Outstanding, Beginning Balance	918,367
Restricted Stock Units, Granted	526,624
Restricted Stock Units, Vested	-372,920
Restricted Stock Units, Forfeited or expired	-69,690
Restricted Stock Units Outstanding, Ending Balance	1,002,381

Stockholders_Equity_Fair_Value

Stockholders' Equity (Fair Value Of Stock Option On Grant Date Using Weighted-Average Assumptions) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted-average grant date fair value	$7.45	$10.78	$11.34
Stock Option [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	0.70%	0.80%	1.90%
Expected life (years)	'4 years 2 months 26 days	'4 years 1 month 6 days	'4 years 4 months 24 days
Estimated volatility	39.20%	46.90%	47.40%
Weighted-average grant date fair value	$7.45	$10.78	$11.34

Stockholders_Equity_Fair_Value1

Stockholders' Equity (Fair Value Of Stock Option Under The Purchase Plan Weighted-Average Assumptions) (Details) (Purchase Option Under Purchase Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Purchase Option Under Purchase Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate	0.10%	0.10%	0.10%
Expected life (years)	'6 months	'6 months	'6 months
Estimated volatility	29.60%	38.20%	36.40%
Fair value of purchase right	$5.30	$7.31	$6.76

Stockholders_Equity_Table_Of_S

Stockholders' Equity (Table Of Stock-Based Compensation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	$16,084	$15,079	$12,991
Cost Of Revenues [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	748	715	459
Selling, General And Administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	13,608	12,666	10,850
Research And Development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Stock-based compensation expense	$1,728	$1,698	$1,682

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 12, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 12, 2012

Dec. 31, 2012

Dec. 31, 2013

Maximum [Member]

Additional Paid-In Capital [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

2.8575% Convertible Senior Notes [Member]

Goodwill [Member]

Federal [Member]

Federal [Member]

State [Member]

State [Member]

State [Member]

Foreign Tax Authority [Member]

Foreign Tax Authority [Member]

Additional Paid-In Capital [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Crux Acquisition [Member]

Synch-Rx Acquisition [Member]

Valuation Allowance [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Losses before income taxes relating to non-U.S. operations

$794,000

$43,000

$133,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

U.S. federal statutory income tax rate

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net change in the total valuation allowance

6,300,000

-3,100,000

'

'

'

'

1,700,000

'

'

2,500,000

'

'

3,800,000

'

'

-4,900,000

'

Unrecognized tax benefits, increase resulting from acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

1,400,000

Operating loss carryforwards

'

'

'

'

'

'

'

'

'

'

133,600,000

30,600,000

80,400,000

'

30,800,000

'

8,400,000

Operating loss carryforward related to acquisitions

20,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Federal and state research and experimentation tax credit carryforwards

'

'

'

'

'

'

'

'

'

'

8,700,000

'

10,200,000

'

'

'

'

Foreign net operating losses

20,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liability not recognized, temporary difference to be taxable, undistributed earnings of foreign subsidiaries

16,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries

'

'

'

'

5,900,000

'

'

'

'

'

'

'

'

'

'

'

'

Increase in equity

20,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustment to additional paid in capital, income tax effect from share-based compensation, net

0

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, repurchase amount

'

'

'

'

'

'

90,000,000

'

'

'

'

'

'

'

'

'

'

Convertible senior notes, interest rate

'

'

'

'

'

'

'

2.88%

'

'

'

'

'

'

'

'

'

Net deferred tax recognized in connection with issuance of convertible senior notes

'

2,599,000

'

'

'

2,599,000

'

'

2,500,000

'

'

'

'

'

'

'

'

Unrecognized tax benefits

1,082,000

1,071,000

1,065,000

878,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amounts recognized for interest and penalties for income taxes

$53,000

$46,000

$34,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Components_Of_Pro

Income Taxes (Components Of Provision For Income Tax Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Current income tax, Federal	$0	$0	$0
Current income tax, State	224	207	498
Current income tax, Foreign	2,004	2,469	2,283
Total current	2,228	2,676	2,781
Deferred income tax, Federal	-20,903	3,940	-19,739
Deferred income tax, State	1,878	182	-2,248
Deferred income tax, Foreign	467	-5,131	-784
Total deferred	-18,558	-1,009	-22,771
Income tax expense (benefit)	($16,330)	$1,667	($19,990)

Income_Taxes_Income_Tax_Expens

Income Taxes (Income Tax Expenses Differ From The Calculated By Applying U.S. Federal Statutory Income Tax Rate To Loss Before Provision For Income Tax) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
U.S. federal statutory income tax expense (benefit)	($17,791)	$3,391	$6,339
State income tax expense (benefit), net of federal income tax expense	-1,470	296	-1,800
Valuation allowance	-3,777	4,917	25,840
Foreign tax rate differential	-2,997	-342	156
Credits	-1,935	0	-1,405
Acquisition-related items	1,409	559	0
Other	2,677	2,680	2,560
Income tax expense (benefit)	($16,330)	$1,667	($19,990)

Income_Taxes_Components_Of_Def

Income Taxes (Components Of Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryovers	$40,071	$28,431
Tax credit carryovers	12,343	9,704
Accruals and deferred revenue	12,979	7,355
Stock based compensation	10,310	9,021
Original issue discount	0	379
Total deferred tax assets	75,703	54,890
Depreciation and amortization	-18,361	-20,557
Deferred tax assets:	57,342	34,333
Valuation allowance	-12,601	-6,309
Net deferred tax assets (liabilities)	$44,741	$28,024

Income_Taxes_Aggregate_Change_

Income Taxes (Aggregate Change In The Balance Of Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Balance at beginning of year	$1,071	$1,065	$878
Increases related to tax positions taken during the current year	53	46	205
Increases (decreases) related to tax positions taken during a prior period	-42	-40	-18
Balance at end of year	$1,082	$1,071	$1,065

Segment_And_Geographic_Informa2

Segment And Geographic Information (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'	'	'
Goodwill	$55,087	$51,577	$2,487
United States [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Percentage of long-lived assets excluding financial assets	49.00%	42.00%	'
Costa Rica [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Percentage of long-lived assets excluding financial assets	39.00%	42.00%	'
Japan [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Percentage of long-lived assets excluding financial assets	8.00%	12.00%	'
Rest Of World [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Percentage of long-lived assets excluding financial assets	4.00%	4.00%	'

Segment_And_Geographic_Informa3

Segment And Geographic Information (Schedule Of Revenues By Segment And Product) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

$103,294

[1]

$95,809

$101,344

$93,231

$102,477

[2]

$93,656

$95,373

$90,360

$393,678

[3]

$381,866

$343,546

Percentage Change

'

'

'

'

'

'

'

'

3.10%

[4]

11.20%

[4]

'

Medical Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

385,245

371,131

332,536

Percentage Change

'

'

'

'

'

'

'

'

3.80%

11.60%

'

Industrial Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

8,433

10,735

11,010

Percentage Change

'

'

'

'

'

'

'

'

-21.40%

-2.50%

'

Consoles [Member] | Medical Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

43,602

40,687

40,954

Percentage Change

'

'

'

'

'

'

'

'

7.20%

-0.70%

'

IVUS [Member] | Medical Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

194,225

205,843

200,970

Percentage Change

'

'

'

'

'

'

'

'

-5.60%

2.40%

'

FFR [Member] | Medical Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

112,643

94,885

67,082

Percentage Change

'

'

'

'

'

'

'

'

18.70%

41.40%

'

Other [Member] | Medical Segment [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

$34,775

$29,716

$23,530

Percentage Change

'

'

'

'

'

'

'

'

17.00%

26.30%

'

[1]

During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million. In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.

[2]

During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses. In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

[3]

)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

[4]

Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Segment_And_Geographic_Informa4

Segment And Geographic Information (Schedule Of Revenues By Geography) (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

$103,294

[1]

$95,809

$101,344

$93,231

$102,477

[2]

$93,656

$95,373

$90,360

$393,678

[3]

$381,866

$343,546

Percentage Change

'

'

'

'

'

'

'

'

3.10%

[4]

11.20%

[4]

'

United States [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

189,748

[4]

177,992

[4]

157,412

[4]

Percentage Change

'

'

'

'

'

'

'

'

6.60%

[4]

13.10%

[4]

'

Japan [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

109,492

[4]

123,558

[4]

105,892

[4]

Percentage Change

'

'

'

'

'

'

'

'

-11.40%

[4]

16.70%

[4]

'

Europe, The Middle East And Africa [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

71,018

[4]

57,913

[4]

60,249

[4]

Percentage Change

'

'

'

'

'

'

'

'

22.60%

[4]

-3.90%

[4]

'

Rest Of World [Member]

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

$23,420

[4]

$22,403

[4]

$19,993

[4]

Percentage Change

'

'

'

'

'

'

'

'

4.50%

[4]

12.10%

[4]

'

[1]

During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million. In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.

[2]

During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses. In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

[3]

)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter

[4]

Revenues are attributed to geographies based on the location of the customer, except for shipments to original equipment manufacturers, which are attributed to the country of origin of the equipment distributed.

Related_Party_Details

Related Party (Details) (Private Company [Member], USD $)	1 Months Ended
	Nov. 30, 2013
Synergy [Member]	'
Related Party Transaction [Line Items]	'
Related party transaction, executive's ownership percentage in third party company	33.33%
Related party transaction, related party's ownership percentage in third party company	14.00%
Related party transaction, related party's cost Method Investment, Ownership Percentage	12.00%
Preferred Stock [Member]	'
Related Party Transaction [Line Items]	'
Payments to acquire cost method investments	15,000,000
Related party transaction, capital raised by third party	20,000,000
Cost method investment, ownership percentage	13.00%
Preferred Stock [Member] | Synergy [Member]	'
Related Party Transaction [Line Items]	'
Related party transaction, related party payments to acquire investments	884,000

Employee_Benefits_Details

Employee Benefits (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Benefits and Share-based Compensation [Abstract]	'	'	'
Minimum age require for an employee's under defined contribution plan	'21 years	'	'
Defined contribution plan participant contributes percentage	25.00%	25.00%	25.00%
Defined contribution plan maximum salary contribution percentage	6.00%	6.00%	6.00%
Defined contributions matching contribution	$1,100	$1,000	$928
Contributions under all plans	$707	$481	$412

Quarterly_Information_Unaudite2

Quarterly Information (Unaudited) (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Valuation Allowance [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Revenues

$103,294,000

[1]

$95,809,000

$101,344,000

$93,231,000

$102,477,000

[2]

$93,656,000

$95,373,000

$90,360,000

$393,678,000

[3]

$381,866,000

$343,546,000

Gross profit

62,616,000

[1]

62,351,000

65,305,000

60,104,000

68,359,000

[2]

60,408,000

63,397,000

60,787,000

250,376,000

[3]

252,951,000

229,013,000

Operating (loss) income

-21,561,000

[1]

-6,440,000

-114,000

-1,788,000

5,063,000

[2]

5,967,000

6,639,000

1,921,000

-29,903,000

[3]

19,590,000

25,411,000

Net (loss) income

-20,489,000

[1]

-8,456,000

-2,388,000

-3,161,000

2,477,000

[2]

1,975,000

3,299,000

271,000

-34,494,000

[3]

8,022,000

38,093,000

Basic (dollars per share)

($0.38)

[1]

($0.15)

($0.04)

($0.06)

$0.05

[2]

$0.04

$0.06

$0.01

($0.63)

[3]

$0.15

$0.73

Diluted (dollars per share)

($0.38)

[1]

($0.15)

($0.04)

($0.06)

$0.04

[2]

$0.04

$0.06

$0

($0.63)

[3]

$0.15

$0.70

Cost of revenues

166,000

[1]

196,000

194,000

192,000

199,000

[2]

202,000

162,000

152,000

748,000

[3]

715,000

'

Selling, general and administrative

3,456,000

[1]

3,592,000

3,579,000

2,981,000

3,061,000

[2]

3,331,000

3,278,000

2,996,000

13,608,000

[3]

12,666,000

'

Research and development

365,000

[1]

462,000

476,000

425,000

391,000

[2]

403,000

435,000

469,000

1,728,000

[3]

1,698,000

'

Restructuring charges

14,500,000

4,600,000

258,000

'

'

'

'

'

19,374,000

0

0

Valuation allowance

'

'

'

'

'

'

'

'

3,777,000

-4,917,000

-25,840,000

Increase (Decrease) in Bonus Accrual

2,300,000

'

'

'

'

'

'

'

'

'

'

Acquisition-related items

'

'

'

'

1,900,000

'

'

'

4,964,000

1,858,000

0

Loss on debt extinguishment

'

'

'

'

'

'

'

'

0

-4,969,000

0

Net change in the total valuation allowance

'

'

'

'

'

'

'

'

6,300,000

-3,100,000

'

State [Member]

'

'

'

'

'

'

'

'

'

'

'

Valuation Allowance [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Valuation allowance

'

'

'

'

'

'

'

'

3,800,000

'

'

Net change in the total valuation allowance

'

'

'

'

'

'

'

'

3,800,000

'

'

Foreign Tax Authority [Member]

'

'

'

'

'

'

'

'

'

'

'

Valuation Allowance [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Net change in the total valuation allowance

'

'

'

'

($4,900,000)

'

'

'

'

'

'

[1]

During the quarter ended December 31, 2013, we concluded that it was more likely than not that we would not be able to realize the benefit of our remaining state and select foreign deferred tax assets in the future. Therefore, we increased the valuation allowance on our state and foreign deferred income tax assets by $3.8 million. In addition, during the quarter ended December 31, 2013, we reduced our bonus accrual by $2.3 million as a result of change in the estimate of our bonus payout.

[2]

During the quarter ended December 31, 2012, we recorded $1.9 million in acquisition-related expense within operating expenses and $5.0 million in loss from debt extinguishment within other expenses. In addition, during the quarter ended December 31, 2012, we concluded that it was more likely than not that we would be able to realize the benefit of a significant portion of our foreign deferred tax assets in the future. Therefore, we reversed $4.9 million of the valuation allowance on the Company’s net certain foreign deferred income tax assets.

[3]

)During the year ended December 31, 2013, we recorded $19.4 million in restructuring charges, including $258,000 in the second quarter, $4.6 million in the third quarter and $14.5 million in the fourth quarter